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1 Summary 
 
The incidence of allergy and related diseases such as asthma increased rapidly over the last century, 
especially in western societies. The allergic symptoms impair the quality of life of patients and can even be 
life threatening. The symptoms vary in strength and location, leading to sneezing, allergic sinusitis, itching, 
broncho-constriction, diarrhoea or anaphylaxis. Allergy is an acquired hyperreactivity of the immune system 
towards non-harmful substances, which leads to the activation of mast cells as a central component in the 
disease development and progression. Thus a detailed understanding of how mast cells are activated could 
be beneficial for the development of novel anti-allergic medication. For proper mast cell differentiation, 
proliferation, tissue distribution and their activation the lipid kinase family of Phosphoinositide 3-kinase 
(PI3K) has been proven fundamental, which are thus putative pharmacologic targets.  
Class I PI3K activation by cell surface receptors facilitates the production of the lipid second messenger 
phosphatidylinositol(3,4,5)-trisphosphate (PtdIns(3,4,5)P3) which is central for the integration of effector 
proteins, equipped with PtdIns(3,4,5)P3 binding PH domains. In turn activation of serine/threonine kinases, 
tyrosine kinases, GEFs and GAPs of small GTPases modulate mast cell survival, proliferation, migration 
and degranulation. 
Subclass IA PI3K serves receptor tyrosine kinases (RTK) and non-receptor tyrosine kinase (NRTK) as well 
as immunoglobulin receptors by direct or indirect association, through their p85 family of regulatory subunits.  
In contrast the only class IB member, PI3Kγ, is primarily activated downstream of G-protein coupled 
receptors (GPCR). Thereby PI3Kγ interaction with released Gβγ subunits from heterotrimeric G proteins is 
required to transmit signals from the extracellular milieu.  
PI3Kγ is a heterodimeric complex, consisting of the catalytic subunit (p110γ) and a adapter subunit, either 
p101 or the recently identified p84 (or p87PIKAP). In line with PI3Kγ’s predominant expression in immune 
cells, genetic ablation of the catalytic subunit p110γ causes defects in inflammatory and allergic responses, 
such as leukocyte chemotaxis, mast cell migration, and the synergistic amplification of IgE and antigen 
mediated degranulation.  
While the requirement of class IB PI3K activity in mast cell function was proven in murine disease models, 
there is still a lack of knowledge on the physiologic function of its adapter subunits, dubbed p101 and p84. 
Based on in vitro experiments both adapters support p110γ activity by sensitizing p110γ for the Gβγ- 
mediated activation downstream of GPCRs.  
Expression analysis performed here determined mast cells most appropriate to study the physiologic 
requirement of p84. Mast cells have high abundance of p84 and p110γ protein, while p101 protein was 
undetectable. In particular the observed destabilization of p84 protein in p110γ null mast cells was beneficial 
to conduct elegant complementation experiments. To this end, p84 complexed with the catalytic subunit 
p110γ (p84:p110γ), was essential for all PI3Kγ dependent cell responses, such as adenosine driven 
PtdIns(3,4,5)P3 production, phosphorylation of PKB/Akt, cell migration and the adenosine enforced 
degranulation. Of note, increased abundance of p110γ was ineffective in compensating lack of p84.  
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Moreover, the replacement of p84 by p101 in complex with p110γ (p101:p110γ) unraveled a non-redundant 
function for the two adapter subunits, as p101:p110γ failed to support degranulation, while cell migration and 
phosphorylation of PKB/Akt were intact.  
A possible explanation was provided by adapter dependent spatiotemporal differences of PtdIns(3,4,5)P3 
production. Both PI3Kγ complexes produced PtdIns(3,4,5)P3 at the plasma membrane, which was however 
rapidly endocytosed via microtubule dependent process, when derived from p101:p110γ signaling. 
Especially during co-stimulation with adenosine and IgE and antigen, p84:p110γ derived PtdIns(3,4,5)P3 
significantly prolonged localization to the plasma membrane was observed as compared to PtdIns(3,4,5)P3 
of p101:p110γ origin. Moreover the two PI3Kγ complexes have differential sensitivity to cholesterol depleting 
agents. Altogether this implies adapter dependent production of distinct pools of PtdIns(3,4,5)P3 at the 
plasma membrane, eliciting specific cell responses.  
Thus it is exclusively the p84:p110γ complex, that amplifies mast degranulation and allergic responses. This 
adds an additional pathway for specific treatment of allergic diseases, e.g. by particular disruption of this 
complex. 
                                                                                                                                                         Introduction 
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2 Introduction 
 
The incidence of allergic diseases increased dramatically over the last decades, now reaching one third of 
the german population, thus recognized as the widespread disease. Allergic symptoms have a very broad 
range, which is in particular dependent of the site of the allergic reaction. Thus allergic skin reactions induce 
itching redness, urticaria and edema formation, while inhaled allergens leads to sneezing, rhinitis, the 
swelling of the respiratory tract mucosa, resulting in bronchoconstriction and asthmatic symptoms. Moreover 
diarrhoae or life threatening systemic anaphylaxis can occur.  
The initial trigger for the development of allergy is an imbalanced immune response to non-harmful 
substances, which under healthy condition would induce immune tolerance, but which are misleadingly 
recognized dangerous by the immune system of pre-disposed individuals. 
Although the exact mechanisms of allergy development are unclear, it is certainly connected with a skewed 
ratio of type1 (Th1) and type2 (Th2) T helper cells. In developing allergy, dendritic cells present antigen to 
naïve CD4+ T cells under the influence of interleukins IL-4, IL-5, IL-9, IL-10 and IL-13, which promote 
differentiation of naïve T cells toward Th2 cells. The consequently enhanced Th2 response increases the 
release of IL-4, -5, -9, -10 and -13, and thus favours the isotype switch in B cells, to produce immunoglobulin 
E (IgE), proliferate and differentiate into antibody secreting plasma cells. In parallel differentiation of naïve 
CD4+ T cells to Th1 cells is decreased. This further contributes to the detrimental process, as Th1 derived 
expression of IL-12 and interferon γ (INFγ) is reduced. Under normal conditions these cytokines inhibit Th2 
differentiation (Romagnani, 2000).  
The secreted IgE is captured by the high affinity receptors for IgE, FcεRI, especially on mast cells, but also 
basophils and eosinophils, sensitizing these for the antigen. A subsequent second exposure of IgE 
decorated cells to polyvalent antigens, cross-links IgE-FcεRI complexes leading to mast cell activation and 
consequently to allergic symptoms (Wills-Karp, 1999; Wedemeyer et al., 2000). 
 
 
2.1 Treatment of allergic disease 
 
Currently treatment of allergy is for the most part restricted to symptomatic medication, thereby antagonizing 
the function of released mast cell mediators. In contrast the treatments recognized etiologic by the World 
Health Organization (WHO) is only allergen prevention and allergen desensitizing treatment (personal 
communication with Dr. med. K.-H. Bohnacker, allergologist and pulmonary physician).  
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2.1.1 Symptomatic treatment 
 
Symptomatic treatment of allergies includes the application of second-generation histamine receptor 1 (H1) 
antagonists, such as Loratadin or Cetirizin. These prevent binding of histamine to its cognate receptors. 
Thus they decrease vascular permeability and itching and function antispasmodic. In contrast to first 
generation H1 antagonist adverse effects, such as sedation are reduced, nevertheless they can still cause 
cardiac arrhythmia and cross-react with a variety of other medications. 
Singulair (Montelukast) and Accolate (Zafirlukast) are a second class of receptor antagonists, implicated in 
allergy treatment, targeting leukotriene receptors, e.g. CysLT1 receptor on smooth muscle and endothelial 
cells or B-LT1 receptors on granulocytes. Thereby patients benefit from reduced smooth muscle contraction, 
vascular permeability in the respiratory tract and from their anti-inflammatory capacity reducing the 
chemotactic response of granulocytes, expressing the B-LT1 receptors.  
“Mast cell stabilizers”, derivates of sodium-cromoglycate, such as Tilade (Nedocromil), are commonly used 
relieving patients from allergic symptoms. In contrast to the above, cromoglycate prevents inflammatory 
mediator release from mast cells, by inhibiting the essential Ca2+ mobilization required for mast cell 
exocytosis. Many other symptomatic medications are known, e.g. corticosteroids or antagonists for 
cholinergic receptors (Merk and Ott, 2008). 
Reducing the allergic symptoms is certainly convenient for the patients, while the medications above share 
also unfavourable traits. First, adverse effects, e.g. sleepiness, vomiting, headache and mucosal irritation, to 
name a few, hamper the acceptance of the treatment by the patients. Second the short-term effectiveness 
requires continuous dosage throughout the time of allergen exposure and raises health care cost 
tremendously. In addition cromoglycate derivates and corticosteroids are not implicated in acute reactions 
and thus require the constant intake in advance. 
 
 
2.1.2 Etiologic treatment of allergies: 
 
An etiologic treatment of allergy is the prevention of allergen exposure, which can lead to extended 
asymptomatic periods. Dependent on the allergens nature and distribution prevented allergen exposure can 
however be impossible and it is obviously necessary to know the specific allergen. The second etiologic 
treatment is the specific immunotherapy against a known allergen, dubbed hyposensitization. Thereby a 
solution of the isolated antigen is repeatedly injected subcutaneously or orally (Deutscher Allergie- und 
Asthmabund e.V.; http://www.daab.de/hypo.php). The positive long-term effects, e.g. symptom remission 
and protection from disease progress to more severe pathologies, are the consequence of desensitization of 
mast cells towards the allergen, a reduced IgE production by B-cells, restoration of the Th1/Th2 ratio and 
the activation of regulatory T-cells (James and Durham, 2008). Disadvantageous is that hyposensitization 
does not result in immediate disease improvement and requires symptomatic treatment initially, as well as 
long-term medical attendance, for up to three years, raising the costs for the health care system.  
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Recently a humanized recombinant monoclonal anti-IgE antibody was launched on the market (Xolair 
[Omalizumab]). Administration of this IgG1k prevents the association of free IgE to the high affinity receptor 
for IgE, FcεRI, on mast cell, eosinophils and basophils, as it recognizes and thus shields the epitope for 
FcεRI association. Consequently the reduced number of IgE-bound FcεRI on mast cells reduces exocytosis, 
when exposed to allergen. Moreover the observed down-modulation of FcεRI on immune cells is beneficial 
(Lin et al., 2004; Winchester et al., 2006). Xolair medication is however mostly implicated in individuals with 
increased serum IgE levels, which not all allergic individuals share. Moreover Xolair administration requires, 
as hyposensitzation, long-term medical attendance and its considerably high costs, as compared to the 
other treatments, prevent its comprehensive application (personal communication with Dr. med. K.-H. 
Bohnacker, allergologist and pulmonary physician).   
The positive effects of IgE and FcεRI in the expulsion of parasites (Marshall, 2004) can also be 
contraindicative for an anti-IgE treatment. 
 
Thus there is still a need to investigate for alternative allergy treatments, which requires a detailed 
understanding of mast cell function. To unravel molecular aspects of mast cell activation and of mast cell 
migration to IgE occupied tissues could be fundamental for new therapeutic approaches. 
 
 
2.2 Mast cells 
 
Mast cells are tissue resident immune cells, especially located in the perivascular space in tissues close to 
the host-environment interface, e.g. the connective or mucosal tissues of the skin, the gut, or in the 
respiratory and gastrointestinal tract.  They are characterized by dense cytoplasmic granules, which contain 
neutral proteases, histamine, heparin, carboxy-peptidases and preformed inflammatory mediators, to be 
released upon activation by exogenous stimuli as an immediate response, followed by de novo synthesis 
and release of inflammatory mediators, chemokines and cytokines (Tab.1).  
The vast array of surface receptor types, including Toll-like receptors (TLR-1,-2,-3,-4,-6 and -9), complement 
receptors (CR2, CR4, C3aR and C5aR) and immunoglobulin receptors (FcεRI, FcγRI, FcγRIII) allow mast 
cells to modulate innate and acquired immunity as well as pathologic conditions as allergy, asthma or 
autoimmune diseases, either with initiator or effector function (Marshall, 2004). 
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Table 1: The repertoire of mast cell mediators and their functions 
Mediators Function 
Granule associated 
Histamine (Serotonin in rodents) Modulate vascular permeability; induces adhesion molecule expression 
on endothelial cells; increase migration of DCs (Jawdat et al., 2004) 
and polarizes immune reponse to Th2 responses via DCs (Mazzoni et 
al., 2001)  
Heparin, chondroitin sulphate Improved cytokine and chemokine function 
Tryptase, Chymase, 
Carboxypeptidase, mast cell 
proteases (MCPs) 
Effector cell recruitment, tissue remodeling, cleavage of exogenous and 
endogenous toxins (Schneider et al., 2007)  
Tumor necrosis factor (TNFα)**, 
Vascular endothelial growth factor 
(VEGF) 
Effector cell recruitment, angiogenesis, adhesion molecule expression 
(ICAM-1, VCAM-1) on endothelial cells  
Lipid mediators 
Leukotriene C4, B4,  
Prostaglandin D2, E2 
Recruit effector cells (e.g. LTC4: eosinophils; LTB4: neutrophils, subset 
of CD4+ T cells), regulate immune responses, smooth muscle 
contraction 
Platelet-activating factor (PAF) Effector cell activation 
Cytokines 
TNFα, IL-1α, IL-1β, IL-6, IL-18, 
INFα,β, GM-CSF; LIF 
Inflammatory response  
IL-3, IL-4, IL-5, IL-9, IL-13, IL-15, 
IL-16 
Th2 type cytokines. In allergy with a detrimental feedback to increase 
the Th2 response. Eosinophil recruitment 
IL-12, INFγ Th1 type cytokine 
IL-10, TGF-β, VEGF Regulate inflammation, angiogenesis, but also tissue remodeling (TGF-
β; fibrosis) 
Chemokines 
CCL2, 3, 4, 5, 11 and 20 Effector cell recruitment (including DCs), regulated immune response 
CXCL 1, 2, 8, 9, 10, 11 Recruitment of effector cells, modulation immune response 
Superoxide radicals, nitric 
oxide, antimicrobial peptides 
Antibacterial capacity 
 
Mediators released from mast cells, adapted from (Marshall, 2004), additional functions included here are 
given with references. DCs: dentritic cells; ICAM: intercellular adhesion molecule; VCAM: vascular cell 
adhesion molecule; IL: interleukin; INF: interferon; GM-CSF: granulocyte/macrophage colony stimulating 
factor; CCL: ligand of the chemokine of the CC family, CXCL: ligand of the chemokine of the CXC family; 
TGF: transforming growth factor, ** TNFα is partially stored in granules, but also de novo synthesized after 
mast cell activation 
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2.2.1 Mast cell development and homeostasis 
 
Mast cells originate from c-KIThi FcεRI- Sca I+, Thy1.1+ (human CD34+) bone marrow progenitor cells of the 
haematopoietic lineage (Rottem et al., 1994; Kirshenbaum et al., 1999; Kirshenbaum et al., 1991). The 
differentiation and maturation to FcεRI+ mast cells and their survival are largely dependent on stem cell 
factor (SCF), which activates the proto-oncogenic receptor tyrosine kinase (RTK) c-KIT, and can be 
modulated by the presence of T cell derived cytokines, such as IL-3, -4, -9 and -10. Preceding is the weakly 
characterized, but eventually SCF dependent, distribution of progenitors through the circulation, their 
adhesion (Lorentz et al., 2002), migration (Nilsson et al., 1994) and extravasation mainly to mucosal or 
connective tissues (Boyce, 2003).  
Mast cells are very heterogenous population of cells with different histamine contents and type of secreted 
protease. Dependent on tissue localization mast cells show different surface receptors expression and 
different responsiveness to T cell derived cytokines (Marshall, 2004).  
 
 
2.2.2 Mast cells in immune responses 
 
Mast cells were mainly connected with their harmful effects in allergic disease. The discovery of i) mice 
carrying cKIT mutations or carrying modulations in positive regulating elements of the c-Kit locus (W/Wv or 
Wsh/Wsh mice; (Kitamura et al., 1978; Lyon and Glenister, 1982)), with almost complete lack of mast cells, ii) 
the successful in vitro cultivation of isolated, bone marrow- or embryonic stem cell- derived mast cells, and 
iii) their adoptive transfer to mast cell deficient mice were fundamental for the assignment of physiologic 
responses to mast cells, and the cellular components required (Wedemeyer et al., 2000; Nakano et al., 
1985; Tsai et al., 2000). This elegant in vivo reconstitution approach broadened knowledge on the 
physiologic requirement of mast cells and improved their reputation not only being detrimental, as in allergy, 
but also beneficial. 
 
Innate immunity 
In innate immunity the mast cell’s repertoire of surface receptors, such as TLR, complement receptors and 
immunglobulin-receptors, and their location determines mast cells as very effective sentinels for the 
detection of pathogens, like bacteria, viruses, parasites, helminthes, or their respective components and 
products. Subsequently they promote the clearance of the parasites or their toxic compounds (Marshall, 
2004; Marshall and Jawdat, 2004; Wedemeyer et al., 2000; Dawicki and Marshall, 2007).  
TLR signaling, except for TLR2, does not induce degranulation but TNFα and IL-6 expression and release, 
together with a variable pattern of cyto- and chemokines to especially attract neutrophils. Signaling of LPS 
via TLR4 and peptidoglycan via TLR2 are confirmed in vivo, while other TLRs were only investigated in vitro 
(Supajatura et al., 2002; Marshall, 2004). Indirect pathogen recognition is based on complement receptors 
or immunoglobulin receptors, which either recognize specific antigens, or super-antigens, e.g. gp120 from 
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HIV, the S.aureus protein A, or the Fv protein after hepatitis B viral infection. Interestingly dengue virus 
infected mast cells change pattern of inflammatory mediators, as compared to mast cells exposed to 
bacterial components, resulting in T- and natural killer (NK) cell recruitment instead of neutrophils. A 
fundamental life-saving role was recently ascribed to granule stored mast cell proteases, which degrade and 
thereby detoxify snake and bee venoms, as well as high concentrations of Endothelin-1, during bacterial 
peritonitis and sepsis (Maurer et al., 2004; Metz et al., 2006; Schneider et al., 2007). 
 
Acquired immune responses 
Of course, effector functions of mast cells in allergy and asthma are very well documented and known since 
long. To date their initiating function in acquired immunity is gaining more and more acceptance. Thereby 
the release of IL-4, -6 and -13 activates differentiation and migration of B- cells, with which they can also 
communicate by expression of CD40 ligand. Their effect on T cells is also mediated by released factors, 
such as leukotrienes, prostaglandins, histamine, TNFα and various chemokines and cytokine to modulate 
differentiation into T cell subsets, induce migration proliferation and activation. Moreover mast cells were 
also reported to have antigen presenting capacity by expression of MHC molecules and co-stimulatory 
molecules. Both cells types can also be indirectly affected by mast cell signaling, in that this also modulates 
dentritic cells (DC) migration maturation and differentiation, especially of peripheral DC (Sayed and Brown, 
2007; Galli et al., 2005).  
 
Autoimmunity 
A down side of mast cells is the contribution to the initiator and effector phase of autoimmune diseases. 
Thus mast cells have detrimental effects in multiple sclerosis (MS) or its animal model experimental allergic 
encephalomyelitis (EAE) (Secor et al., 2000; Brown et al., 2002), by a myriad of possible pathways driving 
development and progression of the disease, see (Sayed and Brown, 2007). Murine models for rheumatoid 
arthritis also links to activated mast cells (Lee et al., 2002; Nigrovic et al., 2007), as well as atherosclerosis 
(Sun et al., 2007), chronic urticaria, Bullous pemphingoid and many more (Rottem and Mekori, 2005).  
 
Allergy 
The development of allergic diseases was outlined above. Hereby the enhanced secretion of IgE to specific 
antigens integrates mast cells in disease development and progression. Mast cell capture the IgE by FcεRI 
receptors expressed on the cell surface and are thus sensitized for the antigen. A subsequent second 
exposure of IgE decorated mast cells to polyvalent antigens, cross-links IgE-FcεRI complexes, inducing 
intracellular signal transduction cascade leading to immediate mast cell degranulation and the delayed 
production and release of de novo synthesized inflammatory mediators (Fig.1). Thus mast cell induce the 
immediate type 1 hypersensitivity reaction, in which released histamine causes itching of the skin by binding 
to histamine receptors on nerve cells, bronchospams by inducing smooth muscle contraction and modulates 
endothelium permeability and adhesion molecule expression on the latter. As consequence the blood 
pressure can drop dramatically and effector cells are recruited through the combined action with the 
released TNFα. The release of proteases can further drive immune cell migration to the site of the allergic 
response, but also results in mucus production and tissue remodeling. The subsequent late phase response 
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in allergy can also be linked to mast cells, in that the de novo synthesized compounds further increase 
vascular permeability and smooth muscle contraction. They also recruit and activate an increasing amount 
of neutrophils, eosinophils and T-cells. Consequently inflammation is prolonged and leading to increased 
tissue damage and remodeling, which can promote disease progression, e.g. from rhinitis to asthma. The 
increased production of Th2 polarizing cytokines further enhances IgE production, which exacerbates the 
allergic response in a subsequent allergen exposure (James and Durham, 2008; Wills-Karp, 1999; 
Wedemeyer et al., 2000).  
 
 
 
Fig. 1: Inflammatory mediators of mast cells in allergy and asthma: Activated mast cells, e.g. by FcεRI cross-
linking, release preformed granule stored mediators (left, bluish cloud,) as an immediate response. De novo 
synthesized mediators of the late response are depicted on the right (grayish cloud, only a selection is displayed) 
Both responses affect multiple cell types or tissue components. Thereby mast cells drive typical allergic and 
asthmatic symptoms, such as smooth muscle contraction, increased endothelial permeability, recruitment of 
lymphocytes to inflamed tissues and mucus production, tissue remodeling and fibrosis. ECM: extracellular matrix; * 
Different chemo- and cytokines recruit different effector cells; ** Place restrictions do not allow a complete list of 
effector functions of TNFα. For abbreviations see Tab. 1 
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2.3 The Phosphatidylinositol 3-kinase (PI3K) family  
 
In multi-cellular organisms the extra-cellular milieu is mainly composed of neighboring cells, which need to 
communicate to each other in order to guarantee a well-balanced homeostasis in healthy individuals. This is 
facilitated by direct cell-to-cell contacts using adhesion molecules or indirectly by the release of signaling 
molecules such as hormones, growth factors, cytokines, chemokines or neurotransmitters.  Receptors 
recognizing such molecules link to an intracellular, tightly regulated signaling network, which transduces, 
amplifies and integrates the plurality of inputs to orchestrate a cellular response according to the 
environmental requirements. An imbalanced regulation of extracellular or of its intracellular components is 
however connected to the development and progress of disease. A well-known protein family of intracellular 
signal transducers within these signaling networks is the Phosphatidylinositol 3-kinase (PI3K) family. 
Alterations of PI3K signaling were consequently linked to cancer development, progression and metastasis, 
and immunological disorders, such as autoimmune diseases, chronic inflammation and allergy.  
 
PI3Ks are a protein family of lipid kinases, which catalyze the phosphorylation of the D3 position in the D-
myo-inositol ring of phosphoinositides (PtdIns) and can thus produce key lipid second messenger molecules 
such as PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3 (Fig.2). The PI3-Kinase activity was initially 
connected with oncogenic products (Macara et al., 1984), but then shown to be fundamental in non-
transformed cells, as only activated but not resting neutrophils produced PtdIns(3,4,5)P3 (Traynor-Kaplan et 
al., 1989). Subsequently PI3K and its lipid products have gained much attention in several vital cell 
responses, such as cell survival, cell migration, chemotaxis, glucose metabolism, vesicular trafficking. As 
consequence deregulated PI3K activity supports disease development and progression, such as oncogenic 
transformation, chronic inflammation, allergy or cardiovascular diseases (Wymann and Marone, 2005).  
According to their in vitro substrate specificity, their structural and functional homologies the PI3K family is 
subdivided into three classes (class I, II and III) (Wymann and Pirola, 1998; Vanhaesebroeck et al., 2001) 
(Fig. 3).  
 
 
2.3.1 Class I PI3Ks 
 
Class I PI3Ks are the best characterized members of the PI3K family and are most importantly the only ones 
that phosphorylate phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2) yielding in the second messenger 
phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3), although they also metabolize PI and PI(4)P in 
vitro. PtdIns(3,4,5)P3 production requires extracellular stimuli and is restricted to the plasma membrane.  
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Fig.2 Phosphoinositide metabolism (simplified): Phosphoinositides (PI), components of the inner leaflet 
of lipid bilayers, are phosphorylated by lipid-kinases (green), or dephosphorylated by lipid-phosphatases 
(red) at the 3-, 4- or 5-OH position of the D-myo-inositol ring, regulating the recruitment of phosphoinositide 
interacting proteins. PI3Ks are labeled with filled circles, as well as the major phosphatases, which degrade 
the class I PI3K product (PtdIns(3,4,5)P3; PTEN and SHIP) downstream of cell surface receptors. Known 
components are indicated with names, others indicate the catalytic activity only (PI4K, PI5K). InsPP 4P’tase: 
Inositol-Polyphosphate 4-phosphatse; P’tase: Phosphatase; class I and cI: Class I PI3K; cII: class II PI3K; 
cIII: class III PI3K). Note: PI’s are also converted by other enzymatic activities, e.g. hydrolysis by 
phospholipases to generate the second messenger diacylglycerol (DAG) and soluble inositol-poly-
phosphates (IPx), not depicted here. 
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2.3.1.1 Class IA PI3Ks 
 
Structure: 
Class IA PI3Ks are heterodimeric complexes consisting of a catalytic subunit of about 110 kDa molecular 
mass, dubbed p110α, β  or δ (Fig. 3), which bind to a regulatory subunit of one of the five p85 family 
members (Fig. 4) (Wymann and Pirola, 1998; Vanhaesebroeck et al., 2001; Klippel et al., 1993). Class IA 
catalytic subunits contain all four PI3K homology regions, namely a Ras-binding-, a C2-, the PI3K 
accessory- (PIK) and a C-terminal kinase domain, but are unique for the N-terminal p85-binding domain.  
The members of the regulatory p85 family contain two Src homology 2 (SH2) domains N- and C- terminal 
(nSH2 or cSH2, respectively) of the interSH2 domain (iSH2), which is crucial for binding the catalytic subunit 
p110. In addition proline rich region were mapped for all members and p85α and β have a N-terminal src 
homology 3 (SH3) domain, a second proline rich region and a breakpoint cluster region homology domain 
(BH domain), which allows association with Rho GTPases (Wymann and Pirola, 1998).  
 
Fig. 3: Nomenclature and linear domain organization of PI3K catalytic subunits: The PI3K family 
consists of eight catalytic subunits (all encoded by different genes), which are divided into three classes (cI, 
cII and cIII; according to their homology), of which the first is sub-devided into class IA and IB. They share 
centrally located homologous domains, e.g. the C2 domain, the PIK (also known as accessory or helical) 
domain, as well as a c-terminal kinase domain, but differ in N- and C-terminal extensions. Class I and II have 
an additional Ras binding domain (RBD), and class II is c-terminally extended with a Phox homology domain 
(PX) and a second C2 domain. The N-terminal region of class I PI3K is central for the differential activation, 
as it defines the adapter subunits to associate with: class IA binds p85 family members while class IB 
associates with either p101 or p84 (p85B and adapterB).  
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Fig. 4: Structural organization of class I 
regulatory subunits: The five known class 
IA regulatory subunits are encoded in 3 
genes, as PIK3R1 gene yields 3 different 
gene products. Their common core module 
for receptor association are the two SH2 
domains interlinked through the coiled-
coiled p110-binding domain (p110BD), and 
1-2 proline-rich repeat (Pro). Isoforms of 85 
kDa (p85α,β) contain additionally a n-
terminal SH3 domain and a BH domain 
(Breakpoint cluster [BCR] homology 
domain), which allows association with Rho 
GTPase family members. The class IB sub-  
units p101 and p84 (dubbed after their calculated molecular weight), are encoded by two genes, located in close 
proximity. Domains indicated for p110γ binding (p110γBD) and association to Gβγ subunits are only an approximation 
derived from deletion mutants, as their primary amino acid sequences lack similarity to any known proteins domains. 
NLS: nuclear localization sequences. 
 
 
Class IA PI3K activation 
Class IA PI3K are activated downstream growth factor receptors, cytokine receptors or antigen receptors, 
which are categorized either as receptor- or non-receptor tyrosine kinases (RTK, NRTK respectively). 
Membrane recruitment is mainly driven through the constitutively bound p85 family regulatory subunits due 
to their protein-protein interaction domains, especially their SH2 domains.  
Monomeric RTKs are dimerized through ligand binding. Due to their intrinsic kinase activity, tyrosine 
residues in their cytoplasmic tails or in associated adaptor molecules, such as the insulin receptor substrate-
1 (IRS-1, (Backer et al., 1992)) are auto- or transphosphorylated. In particular the phosphorylated YxxM 
(pYxxM) motif within the receptors or adaptors has been identified as recognition site for the SH2 domains 
of p85 (Fantl et al., 1992). Besides direct association by pYxxM recognition class IA PI3K recruitment is 
facilitated by additional SH2-domain-containing adapter molecules, which associate with phosphorylated 
tyrosines (pY) different from YxxM motifves  (e.g. Shc or Grb2), which is especially important for RTKs not 
harbouring a YxxM motif (Schlessinger, 2000;Wymann et al., 2003)(Fig. 5). 
Here association of the SH2 domains of p85 with pYxxM motifs has a dual function. First class IA PI3K is 
recruited to the plasma membrane, providing lipid substrate availability, second the interaction relieves 
partial inhibition of the p110 activity (Yu et al., 1998), through a conformational change in the linker region of 
the nSH2 and the iSH2 domain (Shekar et al., 2005). 
Receptors, lacking intrinsic kinase activity, are associated with tyrosine kinases, which tyrosyl-phosphorylate 
the receptor, non-covalently associated adaptor proteins or co-receptors.  So are receptors that employ the 
beta-common chain or gp130 for signal transduction associated to Janus kinases (JAK; Fig. 5), while 
antigen receptors, like the B cell receptor (BCR), the T cell receptor (TCR), or the FcεRI in mast cells, 
depend on src kinase activity (Wymann et al., 2003). 
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Fig. 5:Activation of class IA PI3K: 
Agonist binding to recpetor tyrosine 
kinases (RTKs) dimerizes receptors, 
which leads to tyrosine autophos-
phorylation (pY) in their cytoplasmic 
tails.  
Top: pY within YxxM motifs directly 
recruit p85/p110 complexes. via p85’s 
SH2 domain thus activating catalytic 
p110α, β or δ , which then phosp-
horylate PtdIns(4,5)P2. Association of 
GTP loaded Ras enhances activity. 
Examples: cKIT, EGF-R, PDGF-R, 
CSF1-R, VEGF-R.  
Middle: Both, RTKs with or without 
YxxM motif (not shown) recruit adapter 
molecules (e.g. Shc, Grb2 and Gab1,2 ; 
as shown here, or Cbl) to pY other than 
pYxxM. In consequence YxxM on Gab 
or Cbl is phosphorylated and class IA 
PI3K recruited. The adapters also 
provide binding site for various other 
molecules e.g. GEFs, which increases 
RasGTP thus further recruiting and 
activating PI3K. Examples: NGFR, 
CSF1R, HGFR, PDGFR. 
Bottom: Non-receptor tyrosine kinases 
require receptor associated tyrosine 
kinases such as JAK or src, to 
phosphorylate the receptors cytoplasmic 
tails to transduce signaling as described 
in the middle section. 
Examples: Receptors acquiring the β-
common chain or gp130 (IL-3, -5R, 
GMCSF-R or IL-6R respectively). 
Not depicted: RTKs and NRTK signal 
by phosphorylating YxxM on insulin 
receptor substrates (IRS) for recruitment 
of class IA PI3K. Examples: IR, IGFR, 
IL4R, INFα,βR  
Antigen receptor signaling is exemplified 
for the FceRI in Fig. 8 
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The commonalities of BCR, TCR and FcεRI (discussed in more detail for FcεRI in chapter 2.6.6 and Fig. 8) 
are receptor aggregation and a suggested re-localization to lipid rafts (Pierce, 2002; Xavier et al., 1998; 
Holowka and Baird, 2001; Field et al., 1995;Fattakhova et al., 2006) thus inducing close proximity to src 
kinases (Lck, Fyn for T cells; Lyn in B cells; Lyn, and Fyn in mast cells). Subsequently the phosphorylation 
of tyrosines within the cytoplasmic receptor tails increases the recruitment and the activation of more src 
kinases and of other SH2 domain containing kinases, such as Syk in B- and mast cells or Zap70 in T cells 
(Beitz et al., 1999; Benhamou et al., 1993; (Iwashima et al., 1994). In consequence the phosphorylation 
cascade is expanded to co-receptors, like CD19 in B cells or CD28 in T cells, to transmembrane adaptor 
proteins, e.g. LAT in mast cells and T cells or NTAL in mast cells and B cells, which are core to large 
signalosome complexes of cytosolic adapters and enzymatic proteins, providing multiple sites for interaction 
with class IA PI3K (Okkenhaug et al., 2007). A more direct class IA PI3K translocation occurs via pYxxM 
motifs in T-cell interacting molecule (TRIM), the B-cell adaptor protein (BCAP) (Okada et al., 2000) or Gab2 
in mast cells, which phosphorylation via Fyn is required for PI3K activity (Parravicini et al., 2002). Moreover 
phosphorylated Syk or ZAP70 were reported to directly recruit class I PI3K (Yu et al., 2006; Moon et al., 
2005). The clustered protein-protein interaction domains of p85 family members provide a plethora of 
alternative or cooperative modes of class IA PI3K membrane translocation and activation as many of the 
docking/adaptor proteins of RTKs or NRTKs contain the complementary motifs required for binding. 
 
Ras in class IA PI3K activation 
 The catalytic subunits p110α and p110δ  (the latter with weak affinity and restricted to few Ras-proteins) 
contribute to PI3K membrane localization by interacting with GTP-loaded Ras (Rodriguez-Viciana et al., 
1994; Rodriguez-Viciana et al., 1996; Rodriguez-Viciana et al., 1997; Rodriguez-Viciana et al., 2004). Still, 
the p85SH2 - pYxxM interaction precedes Ras-induced PI3K activation, as unbound cSH2 and parts of iSH2 
of p85 sterically hinder the Ras-association to p110 (Jimenez et al., 2002).  
Nevertheless the importance of Ras interaction with class IA PI3Ks was underlined recently in Drosophila 
melanogaster, carrying a Ras binding deficient transgene of Dp110, the sole orthologue of class IA PI3Ks in 
flies, which resulted in decreased insulin signaling, size and egg numbers (Orme et al., 2006).  
Earlier studies however suggested, that only mutated constitutively active Ras was able to augment Dp110 
activity (Prober and Edgar, 2002). Analysis of transgenic mice with a Ras-binding deficient p110α were 
largely protected from Ras-oncogene mediated tumorigenesis, further supporting connection of, at least 
constitutive active Ras with some class IA PI3Ks  (Gupta et al., 2007). 
 
 
2.3.1.2 Class IB PI3K 
 
Class IB PI3K is restricted to vertebrates and consists of the catalytic subunit p110γ (Stoyanov et al., 1995) 
and two regulatory subunits, p101 (Stephens et al., 1997), and the recently identified p84 (Suire et al., 
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2005). In contrast to class IA catalytic subunits, p110γ cannot associate with p85 family members and is 
consequently not activated by RTKs but by GPCRs (Stoyanov et al., 1995).  
 
 
2.3.1.2.1 Class IB structure 
 
The catalytic subunit p110γ  
The p110γ subunit was prototypical for understanding the organization of PI3K catalytic subunits, the mode 
of PI3K inhibitor action, and its association with Ras, as it was the first resolved in its crystal structure 
(Walker et al., 1999), including small molecule inhibitors (Walker et al., 2000), or co-crystalization with H-
Ras (Pacold et al., 2000). The C-terminal catalytic domain, the C2 domain and the Ras-binding domain 
surround the central helical PIK domain. Surface exposure of the catalytic and the C2 domain allow the 
interaction with phospholipids either required as substrate or for protein translocation. The catalytic domain 
shows similarity to protein serine/threonine kinases, in accordance with the dual specificity kinase character 
of p110γ  (Bondeva et al., 1998), composed of a N- and C-terminal lobe, that form the catalytic cleft. Co-
crystals with wortmannin, Ly294002 and protein kinase inhibitors provided insight into their mechanistic 
action, binding into the ATP binding pocket, thus providing invaluable information for the successful design 
of PI3K inhibitors (Walker et al., 2000). The mode of Ras mediated PI3K activation, which is essential for 
PI3Kα (Gupta et al., 2007) and PI3Kγ (Suire et al., 2006) function, was also addressed by co-crystallizing 
p110γ and Ras (Pacold et al., 2000). Binding of GTP-loaded Ras induces a conformational change in the 
catalytic domain of p110γ, thus most likely relieving it from an allosteric inhibition.  
The most profound aberration of p110γ compared to class IA p110 is its N-terminal sequence, which 
excludes the binding of p85 family members, but instead associates the adapters p101 (Stephens et al., 
1997) or p84 (Suire et al., 2005). Krugmann et al. localized the interaction of p101 with p110γ to the N-
terminus of p110γ (Krugmann et al., 1999), while Maier et al. reported the N-terminus dispensable for 
association with p101 (Maier et al., 1999). To date this discrepancy was not re-evaluated. Interaction of 
p110γ with Gβγ subunits of heterotrimeric G-proteins was mapped N- and C-terminal (Leopoldt et al., 1998), 
which could set membrane association into operation.  
 
Structure of the regulatory subunits 
The sound knowledge on the molecular structure and physiologic functions of p110γ contrasts the little 
information on its poorly explored adapter subunits p101 (Stephens et al., 1997), and p84 (Suire et al., 
2005). Structure-wise both adapters do neither share homologies with other proteins, when aligned to the 
known proteome, nor can protein domains be detected by domain knowledge databases. The adapters 
themselves however have similarity especially in N- and C-terminal stretches of about 50%, separated by a 
rather non-homologous intermediate stretch, with three potential nuclear localization signals in p101 (Voigt 
et al., 2005) but not in p84. Thus over-expressed p101, not associated to p110γ, resides nuclear, while its 
interaction with p110γ renders it cytosolic (Brock et al., 2003). 
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 Interestingly, the p110γ binding region in p101 (Krugmann et al., 1999), (Voigt et al., 2005) covers the N-
terminal region homologous to p84 and the Gβγ association localizes to the C-terminal homology region. 
Both, the overlap of functional regions in p101 with regions of high similarity to p84, and the fact that p101 
and p84, associate via their N-terminal regions with the N-terminus of p110γ (Brock et al., 2003), (Voigt et 
al., 2005), (Voigt et al., 2006) indicate equivalent adapter association to overlapping regions of p110γ- and 
indeed their binding is mutually exclusive (Voigt et al., 2006).  
 
 
2.3.1.2.2 Class IB activation  
 
G-protein coupled receptors (GPCR) 
GPCR are seven transmembrane helix receptors, which associate with GDP loaded heterotrimeric G-
proteins in an inactive state. The signal transduction downstream is channeled and diversified by the 
assembly of associated trimeric G-proteins, of which up to 20 Gα-, 5 Gβ- and 12 Gγ- subunits have been 
described. Extracellular ligand binding, including light photons, ions, neurotransmitters, chemokines, 
nucleotides and adenosine, results in a conformational change of the GPCR, thereby decreasing GDP-
affinity of the Gα subunit and favouring GTP-bound state of the associated heterotrimeric G-protein. The 
spatial reorganization of GTP-bound Gα-subunit dissociates Gβγ subunits from the complex, and the Gα-
subunit as well as the Gβγ-complex signal to downstream effectors (Pierce et al., 2002). Four distinct Gα- 
subunit families have been classified, due to their downstream signaling: Simplified, Gαi-subunits couple to 
the inhibition of adenylyl cyclase, thereby reducing cAMP signal transduction, while Gαs proteins stimulate 
adenylyl cyclase. Gαq subunits activate the phospholipase Cβ (PLCβ) branch, signaling through Inositiol-
(1,4,5) trisphosphate (IP3), Diacylglycerol (DAG) and consequently Ca2+, and Gα12 stimulate Rho-GEF 
signaling (Pierce et al., 2002). Gβγ complexes also gained attention to actively transduce signals from 
GPCR (Clapham and Neer, 1993). The multiple combinations of Gβ and Gγ subunits diversify signaling to 
preferential downstream targets. In vitro, the activity of the p101:p110γ  complex is modulated with different 
efficacy by different Gβγ combinations, e.g. Gβ5γ2 fails to activate the complex, is however effective in 
activating PLCβ, while Gβ1γ2 efficiently activates PI3Kγ (Maier et al., 2000; Kerchner et al., 2004).  
Still all Gβγ subunits share essential structural traits: a common β-propeller motive consisting of WD40 
repeats required for effector binding on the Gβ-subunit, and as for the Gα-subunits, a C-terminal prenylation 
of the Gγ-subunits (Clapham and Neer, 1997). Thus interaction of p110γ with Gβγ complexes targets the 
kinase to plasma membrane, where it has access to its substrate PtdIns(4,5)P2.  
 
 
 The function of p101 and p84 in p110γ activation 
Complexes of p110γ in tight association with its adapter p101 were first reported in lysates from pig 
neutrophils (Stephens et al., 1997). In vitro p101 or p84 association increases the affinity of monomeric 
p110γ to recombinant Gβγ, resulting in enhanced PI3Kγ activity (Stephens et al., 1997; Suire et al., 2005). In 
                                                                                                                                                         Introduction 
24 
 
 
contrast, Stoyanov et al. and Leopoldt et al. reported, that already the sole presence of Gβγ readily 
enhances the activity of monomeric p110γ in in vitro kinase assays (Stoyanov et al., 1995; Leopoldt et al., 
1998). The contradiction is most likely due to the substrates used in the studies (PtdIns(4,5)P2 in Stephens 
et al. and PtdIns in the latter ones), thus p101 might define substrate specificity of p110γ (Maier et al., 1999). 
In non-haematopoietic cells over-expression studies on the localization of p110γ with or without p101 
suggested, that p101 is mainly required for p110γ translocation to the membrane, due to its higher affinity for 
co-expressed Gβγ, rather then being activating per se, as constitutively membrane targeted p110γ (p110γ-
CAAX) compensated the lack of p101 (Brock et al., 2003). The interaction of p84 and its requirement in Gβγ 
or GPCR mediated p110γ activation was addressed similarly with identical outcome (Voigt et al., 2006).  
The necessity of the p101 adapter subunit of p110γ was however challenged in the haematopoietic cell line 
U937, in which retinoic acid increased p110γ expression, while p101 levels were unaffected, thus arguing, 
that p110γ could function without p101, dependent on the cellular context (Baier et al., 1999). Moreover 
cytosol depleted neutrophils were fMLP sensitive by the addition of p110γ only (Kular et al., 1997). 
The physiologic requirement of p101 at least in some PI3Kγ mediated cell responses was reported recently, 
as p101-/- neutrophils were defective in migration towards fMLP or C5a (Suire et al., 2006) (Fig.6). The 
oxidative burst induced by the same stimuli was intact, although PI3Kγ dependent (Hirsch et al., 2000). From 
the data presented by Suire et al. (2006) it is however not possible to ascribe the migration of neutrophils 
specifically to the p101:p110γ complex. Certainly low agonist concentrations resulted in severely reduced 
migration capacities, but high concentrations reestablished the migratory capacity to 50% of the wild type 
controls. Thus it could be either monomeric p110γ or the minor portion of p84:p110γ complexes that support 
migration at high agonist concentration. Consequently it needs to be validated whether the overall PI3Kγ 
activity rather than the p101 adapter specific function is the basis of the reported effects. A physiologic role 
p84 is currently not known and it will be highly exciting to know, if both PI3Kγ adapter proteins are mutually 
replaceable in physiologic contexts. The little comparative information of both adapter:p110γ complexes is 
thus far based on in vitro data, which only included the Gβ1γ2  but no other combinations of Gβγ subunits 
(Suire et al., 2005; Voigt et al., 2006), or the over-expressed fMLPreceptor system (Voigt et al., 2006). In 
addition only PtdIns(3,4,5)P3 production was monitored, while physiologic responses were excluded from 
the studies. Thus it is impossible to conclude, whether either of the adapter:p110γ complexes has 
preferential receptor systems, Gβγ complexes or can even promote distinct physiologic responses.  
 
Ras dependent p110γ activation  
Ras association to p110γ was resolved in crystal structure, in which constitutively GTP loaded H-RasG12V 
induced an activating conformational change of p110γ, which was confirmed in cellular over-expression 
systems. Activating effects of Ras were inhibited by multiple amino acids exchanges in the Ras binding 
domain of p110γ (T232D, K251A, K254S, K255A and K256A; dubbed DASAA mutant) (Pacold et al., 2000). 
The physiologic relevance was confirmed in neutrophils derived from transgenic mice (p110γ-DASAA mice), 
in which migration and the oxidative burst was impaired after fMLP or C5a challenge (Suire et al., 2006).  
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Fig.6: Class IB PI3K activation: 
PI3Kγ is activated downstream of 
agonist bound G-protein coupled 
receptors (GPCR). Released βγ 
subunits of trimeric G-proteins 
support p110γ membrane tar-
geting, to access its substrate 
PI(4,5)P2. Top: the adapter sub-
units of p110γ were reported to 
increase the affinity to βγ sub-
units in vitro and within cells to 
mainly support membrane trans-
location of p110γ instead of being 
primarily activating. The physio-
logic requirement is however only 
proven for p101, but not for p84. 
Bottom: the identical receptor 
system, as used to prove p101’s 
requirement, revealed an essen-
tial role of Ras mediated p110γ 
activation. The requirement of the 
PI3Kγ adapter subunits and/or βγ 
subunits was not addressed in 
the context of Ras mediated 
PI3Kγ activation (thus shaded 
here).  
 
 
 
 
 
2.4 Downstream Effectors of Class I PI3K Signaling 
 
Class I PI3K activity results in increased PI(3,4,5)P3 levels, which provide docking sites for the pleckstrin 
homology (PH) domain containing effector molecules. Consequently the effector molecules are recruited to 
PI(3,4,5)P3 rich membrane areas. Thereby a spatial proximity is provided by the concomitant recruitment of 
proteins, with enzymatic activity, and their substrate, thus facilitating signal transduction. In addition binding 
of the PH domain to PtdIns(3,4,5)P3 can, through conformational changes, enhance the enzyme activity, 
substrate affinity or accessibility to the substrate.  
The PH domain is one of several phosphoinositide binding protein domains. Beside FYVE, PX, ENTH [Epsin 
N-terminal Homology] and PROPPINS [β-Propellers that bind phosphoinositdes] domains, which bind 
phosphoinositides of non-class I PI3K activity in vivo, and are thus not discussed here (Lemmon, 2007).  
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PH domains were first described by Haslam et al. (Haslam et al., 1993) and Mayer et al. (Mayer et al., 1993) 
being homologous to sequences to N- and C-terminal regions of the pleckstrin protein. However it is rather 
the overall structure than the primary amino acid sequence, which makes them homologous. They all form a 
β- sandwich in the core and a C-terminal α−helix (Lemmon and Ferguson, 2000). Although PH domains 
were reported to bind all phosphoinositides with variant and weak affinity, strong association requires 
phosphorylation of at least at two adjacent phosphate groups, like PtdIns(3,4,5)P3, PtdIns(4,5)P2, 
PtdIns(3,4)P2.  
The observation that the PH domain containing serine/threonine kinase PKB/Akt recognizes the PI3K lipid 
product finally established PtdIns(3,4,5)P3 as an important second messenger molecule (Franke et al., 
1995). Since then various PI3K effectors were identified, which can be roughly grouped according to their 
relation to protein families, such as serine/threonine- or tyrosine-kinases, regulators of small GTPases 
(GEFs and GAPs) or adapter proteins, providing platforms to transduce, sustain or amplify signals (Fig. 7).  
 
 
 
 
Fig. 7: Protein families downstream of class I PI3K activity: Major protein families, containing a PH domain, are 
given in grey boxes, with typical members listed above. Below major physiologic functions of each familiy are 
indicated. PH domains preferentially bind phosphoinositides with 2-3 adjacent phosphate groups. Still PH domains 
differ in the affinity (size of coloured boxes) and specificity (colour code). 
 
 
Serine/Threonine Kinases:  
PtdIns(3,4,5)P3 dependent effects on cell survival, cell growth, proliferation, metabolism, translation and 
transcription are mainly channeled through the PI3K downstream effectors which have serine/threonine 
kinases. Most importantly the phosphoinositide dependent kinase 1 (PDK1), as master kinase in the PI3K-
PDK1-PKB axis, and its substrates such as PKB/Akt transduce signaling to the above cell responses. The 
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PtdIns(3,4,5)P3 binding dependent spatial proximity of PDK1 and its substrates, thereby facilitates 
phosphorylation of the activation- or T-loop, in case of PKB at position Thr308 (Alessi et al., 1997). 
Conserved for all members of the AGC family of protein kinases (cAMP-dependent kinases, PKAs; cGMP-
dependent kinases, PKGs; PKCs or serum- and glucocorticoid induced kinase SGK) full activity of PKB 
requires a second PDK2 dependent phosphorylation in the regulatory hydrophobic motif, for PKB residue 
Ser473. PDK2 activities are attributed to mTORC2 (summarized in (Polak and Hall, 2006) and DNA-PK 
(Feng et al., 2004). Its vast array of protein substrates, allows activated PKB/Akt to modulate their activity, 
with tremendous effects on the cellular state (Fig. 7).  
 
The Tec family of tyrosine kinases: 
Members of the Tec (tyrosine kinase expressed in hepatocellular carcinoma) family of protein tyrosine 
kinases (Tec, Btk, Itk, Bmx, Txk in mammals) are another prominent example, known to be recruited by 
PtdIns(3,4,5)P3. They are most abundant in, but not restricted to immune cells. Beside the kinase and the 
PH domain, except for Txk, which has a palmitoylated Cys-rich repeat instead, they additionally harbour 
SH3 and SH2 domains, and the family-specific TH domain, which consists of the Btk homology domain (BH) 
and proline rich regions. This gives rise to a variety of possible protein and lipid interactions, which 
synergistically activate Tec kinases and orchestrate activation of multiple effectors. Simplified it is the 
interplay of i) PtdIns(3,4,5)P3 binding, for translocation of Tec-kinases to the plasma membrane and 
positively modulating their activity (for Btk see Saito et al., 2001), ii) the resulting close proximity to 
membrane bound protein tyrosine kinases (PTK) of the src family, which in turn phosphorylate Tec kinases 
in their activation loop, and iii) the subsequent auto-phosphorylation (Park et al., 1996, Wilcox and Berg, 
2003) (Fig.8), which are required for full kinase activity. Tec kinases then phosphorylate and activate their 
substrates, amongst them PLCγ, hydrolyzing PtdIns(4,5)P2 to IP3 and DAG, leading to Ca2+ mobilization, 
and activation of PKC. Aside Ca2+ mobilization, the Tec kinases, as part of a big “signalosome” complex, 
modulate/activate small GTPases, MAPK signaling, leading to actin-reorganization, gene-expression, cell 
growth or proliferation (reviewed in Smith et al., 2001 and Takesono et al., 2002). 
 
Small G-protein signaling: 
Small G-proteins or GTPases, especially of the Rho family, e.g. Rho, Rac, Cdc42, are crucial enzymes for 
cytoskeletal remodeling, during cell migration, chemotaxis, processes essential in development, immunity 
but also metastasis (Sasaki and Firtel, 2006). Alike class IB PI3K were implicated in cell migration (Hirsch et 
al., 2000; Sasaki et al., 2000; Li et al., 2000), indicating a connection of PI3K and Rho GTPases. 
GTPases cycle between an inactive GDP- and an active GTP-loaded state. The exchange of GDP to GTP is 
supported by guanine nucleotide exchange factors (GEFs), while GTP hydrolysis is catalyzed by an intrinsic 
GTPase activity, which is additionally supported by GTPase activating proteins (GAPs, Schmidt and Hall, 
2002). 
Rho family GTPases are by far not only PI3K-dependent, but all GEFs contain a PH domain i) for membrane 
recruitment and ii) for those, binding to PtdIns(3,4,5)P3, to increase activity. For Sos1 and Vav1 association 
with PtdIns(3,4,5)P3 relieves the GEF from an auto-inhibitory state, as PtdIns(3,4,5)P3 binding prevents an 
auto-inhibitory binding of the PH domain to the conserved Dbl homology domain (DH). The autoinhibition 
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prevents phosphorylation by tyrosine kinases (Han et al., 1998) and consequently also the association of the 
GEF with Rac and the exchange of the guanine-nucleotide in Rac (Das et al., 2000).  
 
Adapter proteins: 
Adapter or scaffolding proteins lack enzymatic activity, but possess besides their PH-domain additional 
protein-protein interaction motifs, for association with membrane-localized proteins or for recruitment of 
proteins to assemble large protein platforms, facilitating signal amplification. Although signal initiation can be 
independent of its PH domain, its association to PtdIns(3,4,5)P3 is required for sustained signaling. 
For example the Gab (Grb2-associated binder)/Dos family of adapter proteins, (consisting of Gab1-3 in 
mammals, Dos in flies or Soc-1 in worms), which additionally contain tyrosine or serine/threonine 
phosphorylation motifs and proline rich stretches, are almost exclusively membrane recruited through 
association of its SH3 domain with Grb2, which itself interacts with pY motifs on activated receptors or their 
adapters (e.g. Shc; Gu and Neel, 2003; Lock et al., 2000; Ravichandran, 2001). Gab2, being 
phosphorylated in its YxxM motif (e.g. by Fyn) targets PI3K activity to the plasma membrane. In 
consequence the production of PtdIns(3,4,5)P3 provides additional binding site to retain the Grb2-Gab1 
complex membrane associated and sustains signaling. This applies to EGFR signalling (Rodrigues et al., 
2000), to BCR signal transduction, which is completely compromised with PH-domain deletion mutants of 
Gab1, and to multiple vital receptor systems, reflected by the embryonic lethality of Gab1 gene-targeted 
mice (Itoh et al., 2000). Gab2 deficient mice are viable but are compromised FcεRI and IL-3R signaling in 
mast cells (Gu et al., 2001) 
An essential role of PI3K induced membrane translocation also has been reported for the B-cell specific 
Bam32 (B-lymphocyte adapter molecule of 32 kDa) and its closest homologues TAPP1 and 2 (Tandem PH 
domain-containing protein 1 or 2) (Marshall et al., 2002; Marshall et al., 2000), which PH domains 
preferentially bind to PtdIns(3,4)P2 rather then PtdIns(3,4,5)P3 (Ferguson et al., 2000; Thomas et al., 2001) 
and translocation thus most likely requires PI3K activity followed by activity of the phosphatidylinositol 5-
phosphatase SHIP. 
 
 
 
2.5 Determination of class I PI3K signaling by Phosphatidyl- 
 inositol phosphatases: 
 
Class I PI3K signaling, downstream of many receptor systems modulate cell growth, differentiation, 
proliferation, the migratory capacity. On a systemic level, these cellular features are essential for proper 
tissue homeostasis, development and immune responses. Deregulated PI3K signaling is thus linked to 
autoimmune disease, chronic inflammation, allergy, as well as cancer development, progression and 
metastasis (Wymann and Marone, 2005). A tight regulation of PI3K action is therefore required, realized 
through lipid phosphatases, which degrade PtdIns(3,4,5)P3. Best characterized are PTEN (phosphatase and 
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tensin homologue deleted on chromosome 10), which dephosphorylates the 3’ position (Myers et al., 1998), 
(Stambolic et al., 1998) and SHIP (SH2-containing inositol 5-phosphatase) family members. 
 
Phosphatase and tensin homologue deleted on chromosome 10  
PTEN was identified and dubbed due to its location on chromosome 10 q23 as a tumor suppressor gene, 
which mutations and loss of heterozygocity are strongly abundant in sporadic tumors, like glioblastoma, 
prostate and breast cancer (Li et al., 1997; Steck et al., 1997), but also present in inherited proliferative 
diseases, e. g. the cowden syndrome. Genetic targeting results in embryonic lethality for homozygous mice 
(Di Cristofano et al., 1998; Suzuki et al., 1998), while heterozygous mice or mice with T-cell specific loss of 
PTEN have increased susceptibility for lymphomas and autoimmune disorders, such as glomerulonephritis 
(Di Cristofano et al., 1999 Suzuki et al., 2001). Elevated PtdIns(3,4,5)P3 due to loss of PTEN, with all its 
consequences, is conserved throughout species including D. melanogaster  (Stocker et al., 2002) and 
C.elegans (Rouault et al., 1999). Accessibility of PtdIns(3,4,5)P3 to PTEN is mediated by its C2 domain (Lee 
et al., 1999) or by interaction with membrane associated proteins via its PDZ binding domain, e.g. MAGI 
(Wu et al., 2000) 
 
SH2-containing inositol 5-phosphatases  
The SHIP1 phosphatase was simultaneously identified by three independent research groups. Today two 
mammalian isoforms, SHIP1 and SHIP2, are known, with various splice variants or truncated forms of 
SHIP1 (Rohrschneider et al., 2000). Interestingly non-mammalian orthologues of SHIP proteins are missing. 
SHIP1 expression is restricted to the haematopoietic system and spermatogenic cells, while SHIP2 is 
broadly expressed (Bruyns et al., 1999; Muraille et al., 1999). In contrast to PTEN, SHIP metabolizes 
PtdIns(3,4,5)P3 to PtdIns(3,4)P2 (Damen et al., 1996; Lioubin et al., 1996; Pesesse et al., 1997), which 
allows to modulate PI3K mediated signal transduction, e.g. by recruiting TAPP1 and Bam32. In accordance 
with SHIP1’s haematopoietic expression, SHIP1-/- mice suffer from myeloid infiltration, hyperplasia of 
granulocytes or macrophages (Helgason et al., 1998). On a molecular basis SHIP’s N-terminal SH2 domain 
preferentially binds ITIM (immunreceptor tyrosine-based inhibition motif) based pY on inhibitory receptors 
like in B cells the FcγRIIB or the FcγRIIB and gp49B1 in mast cells (Ono et al., 1996), (Kuroiwa et al., 1998). 
Association with ITAM (immunreceptor tyrosine-based activation motif) based pY of the FcεRI (Osborne et 
al., 1996) or the monocytic FcγRIIa (Maresco et al., 1999) was reported, too. Multiple alternative protein 
interactions, either mediated by the SH2 domain, e.g. with class I PI3K (Gupta et al., 1999), the C-terminal 
NPXY motifs, if tyrosyl-phosphorylated interacting with Shc (Lamkin et al., 1997)), or the proline rich motifs 
(binding to Grb2; Damen et al., 1996), position SHIP1 proximal to activating receptors, to counteract their 
activity.  
Association of SHIP with inhibitory (co-) receptors that co-ligate with BCR or FcεRI after antigen association 
is a critical process for negative signaling in B cells and mast cells. Thus SHIP1-/- B cells and mast cells 
have increased Btk membrane association and Ca2+ fluxes, which in mast cells enhances degranulation  
(Huber et al., 1998) and cytokine production (Kalesnikoff et al., 2002). Thus SHIP1 is a “gatekeeper”, which 
regulates the threshold level of PtdIns(3,4,5)P3 to avoid constitutive degranulation already after sensitization 
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with IgE or weak affinity antigen (Huber et al., 2002).In addition SHIP1 controls proliferation and anti-
apoptotic signaling downstream of the IL-3 or the GM-CSF receptor (Liu et al., 1999) 
 
 
2.6 Class I PI3K signaling in immune cells 
2.6.1 Isoform expression 
 
The two catalytic subunits p110α and β are ubiquitously expressed and homozygous ablation results in early 
embryonic lethality (p110α E9-E10; p110β E3-7) (Bi et al., 1999; Bi et al., 2002). Viable mice can however 
be generated, in case of a combined heterozygous genotype, thus 50% of protein and kinase activity is 
sufficient for viability. Severe impacts on development thus far impaired clear studies of immunologic 
phenotypes of both isoforms. PI3Kδ and PI3Kγ are mainly expressed in leukocytes, and gene targeted mice 
are viable, fertile, with immunological defects only if acutely stressed (Hirsch et al., 2000; Sasaki et al., 
2000; Li et al., 2000; Okkenhaug et al., 2002; Clayton et al., 2002; Jou et al., 2002).  
 
2.6.2 Genetic Targeting of Phosphoinositide 3-Kinases 
 
To define the physiologic functions of class IA PI3K either the regulatory or the catalytic subunits were 
eliminated or inactivated by gene targeting. Elimination of the regulatory subunits by disruption of i) the 
PIK3r1 gene, thus deleting p85α, p55α, p50α or ii) the first exon thus expressing p55α, p50α protein but not 
p85α, or iii) the PI3Kr2 gene (p85β) (Fruman et al., 1999; Suzuki et al., 1999; Ueki et al., 2002) were 
approached to inactivate all class IA catalytic subunits and to define isoform-specific functions of the 
regulatory subunits.  
Attempts for isoform specific targeting of class IA catalytic subunits yielded viable mice only for p110δ 
(PI3Kδ−/−), but not for p110 α and β (Bi et al., 1999; Bi et al., 2002; Clayton et al., 2002; Jou et al., 2002). 
Transgenic mice with kinase inactivated PI3Kβ (PI3KβKR/KR; Ciraolo et al., 2008) and PI3Kδ (PI3KδKD/KD; 
Okkenhaug et al., 2002) are viable, however only the latter were investigated for immunologic phenotypes, 
yet. Except for p85β null and PI3KδKD/KD mice, cell-type specific modulations of non-targeted class IA PI3K 
protein levels hamper data interpretation. Compensatory effects of non-targeted subunits can cover loss of 
protein effects of the targeted one, while down-modulated expression of the remaining subunits can cause 
effects, which are ascribed to the targeted subunit but are primarily independent of the latter one.  
Class IB PI3K activity was genetically engineered by either disrupting the PIK3CG gene, p110γ-/- (Hirsch et 
al., 2000; Sasaki et al., 2000; Li et al., 2000) or by insertion of a catalytic inactive variant, p110γKR/KR (with 
replacement of the essential Lys(K) 833 by Arg(R)). Both share comparable immunologic defects, while 
cardiac protection after aortic constriction was lost only in p110γ-/- mice (Crackower et al., 2002; Patrucco et 
al., 2004), which suggests a kinase independent function of PI3Kγ as a scaffold protein. As for class IA 
targeting, down-modulated adapter protein levels, e.g. p101 and p84, were reported in p110γ-/- neutrophils 
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(Suire et al., 2005). As p110γ does neither compete with class IA PI3Ks for activated receptors, which was 
proposed for class IA (Okkenhaug and Vanhaesebroeck, 2003), nor any of the adapters associate with class 
IA catalytic subunits, one can assume that despite modulated adapter protein levels neither receptor- nor 
adapter-availability to other PI3Ks is affected. More recently elimination of the p101 adapter subunit was 
reported (Suire et al., 2006), while the PIK3r6 gene was not targeted yet.  
 
 
2.6.3 Pharmacological Targeting 
 
The discovery of first generation PI3K inhibitors (Arcaro and Wymann, 1993; Vlahos et al., 1994) and 
especially the understanding of their molecular action (Wymann et al., 1996; Walker et al., 2000) allowed the 
development of many 2nd generation compounds, with decreased toxicity, increased stability and specificity 
(Marone et al., 2008). These pharmacological tools in combination with gene-targeted mice emphasized 
PI3Kγ and PI3Kδ as excellent targets in human immune disease related animal models (Tab.2). That all 
inhibitors are based on their competition with ATP for binding to the catalytic core, however risks that other 
lipid- or protein kinases are inhibited, due to structural homologies in their catalytic domains. Thus 
alternative therapeutic approaches, e.g. by allosteric inhibition or disruption of required interactions of PI3Kγ 
with other proteins, could minimize adverse effects. Therefore a detailed knowledge of how e.g. PI3Kγ is  
activated is required
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Table 2: Reported roles of PI3K isoforms in murine disease model 
 
           PI3K isoforms 
Disease Murine Model α β  γ δ  Effects of PI3K inhibition (GT= gene targeting; PH= pharmacological treatment) 
Inflammation 
    Pancreatitis •acute cerulein induced 
  pancreatitis 
•CDE diet  
 
PI3Kγ deficient mice are more resistant to cerulein induced acute pancreatitis, with reduced acinar 
cell injury/necrosis, diminished neutrophil infiltration and increased acinar cell apoptosis. The non-
invasive CDE (choline-deficient, ethionine supplemented) diet model confirmed positive effects of 
PI3Kγ ablation. Thus PI3Kγ deficient mice showed reduced mortality after CDE diet (GT; (Lupia et 
al., 2004) 
    Peritonitis •septic (E.coli injection) 
and aseptic (Thiol-
glycollate) peritonitis 
 
PI3Kγ deficient mice challenged with peritoneal injection of either thiolglycollate or bacteria (E.coli 
or S. aureus) showed strongly reduced leukocyte infiltration and bacteria clearance (GT; (Hirsch et 
al., 2000)). Selective loss of gastrointestinal mast cells in “PI3K deficient” mice (by deletion of p85α) 
show reduced bacteria clearance in septic peritonitis. This was however not attributed to a specific 
catalytic subunit (p110α, β or δ; GT; (Fukao et al., 2002b)) 
Airway Inflammation, Allergy, Asthma, Anaphylaxis 
    Allergy, 
Anaphylaxis 
• passive cutaneous or 
systemic anaphylaxis 
(PCA or PSA) 
 
 
PI3Kγ null mice are protected from IgE/antigen driven PSA, due to interruption of a paracrine/ 
autocrine adenosine feedback loop. In accordance adenosine induced vascular permeability was 
decreased (GT; (Laffargue et al., 2002)). PI3Kδ targeted mice are protected from PCA, due to a 
blocked FcεR I signaling in mast cells (GT, PH; (Ali et al., 2004)). However “class IA deficient” mice 
(p85α null mice) were not resistant to PSA and showed anaphylactic shock induced death as wild 
type mice (GT; (Fukao et al., 2002b)) 
    Asthma, Airway 
inflammation 
•intra-nasal KC, MIP-2 
• Ovalbumin induced 
allergic asthma 
•  Metacholine induced 
hyperresponsivness 
 
Neutrophil numbers in BAL fluids post intra-nasal chemokine administration are strongly reduced in 
PI3Kγ deficient mice (GT; (Thomas et al., 2005)). In LPS induced airway inflammation PI3Kγ and 
PI3Kδ are required for neutrophil extravasation, however PI3Kγ appears to be dominant in 
neutrophils, while PI3Kδ could have functions in the endothelium (GT, (Puri et al., 2004)). 
Pharmacological inhibition of PI3Kδ reduces leukocyte infiltration (mainly eosinophils) into 
ovalbumin challenged lungs, mucus production and levels of inflammatory cytokine as well as 
expression of cell adhesion molecules (PH; (Lee et al., 2006b), (Lee et al., 2006a)). Genetic 
targeting of PI3Kδ suppresses type 2 cytokine response and is required for Th2 mediated airway 
inflammation (GT; (Nashed et al., 2007)) 
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Disease Murine Model α β  γ δ  Effects of PI3K inhibition (GT= gene targeting; PH= pharmacological treatment) 
Autoimmune disease 
    Rheumatic 
arthritis (RA) 
 • Collagen induced 
arthritis (CIA) 
• passive CIIα 1A 
model (T-, B-cell 
independent) 
 
Both models result in improved histological and clinical scores for RA in PI3Kγ deficient mice or 
mice treated with PI3Kγ specific inhibitor AS-605240. Mild disease progression is characterized by 
reduced paw swelling, impaired neutrophil infiltration and cartilage erosion (GT, PH; (Camps et al., 
2005)). Pharmacological inhibition of PI3Kγ improved the disease state even after the onset of RA, 
indicating therapeutic relevance. 
    Systemic lupus 
erythematosous,   
Glomerolu-
nephritis  
• MPR-lpr mice 
• Class1A PI3K 
mediated SLE (p65PI3K) 
 
MPR mice carrying homozygous lymphoproliferation (lpr) mutation develop spontaneous lupus like 
disease. Abrogation of PI3Kγ activity results in reduced CD4+ T-cells reduced autoantibody 
production and thus ameliorates renal failure and improves clinical scores of glomerulonephritis 
(GT, PH; (Barber et al., 2005)). PI3Kγ inactivation protects from SLE like disease induced by 
constitutive activation of PI3K class IA, by the truncated activating p65PI3K (GT, (Barber et al., 
2006)). 
    Crohn’s disease •Inflammatory bowels 
disease  
Genetic targeting of PI3Kδ results in the development of mild inflammatory bowels disease in the 
rectum and cecum, characterized by mucosal hyperplasia, crypt abscesses and leukocyte 
infiltration (GT; (Okkenhaug et al., 2002)) 
    Sjörgen’s 
syndrome 
• r1ΔT/r2n mice (Oak, 
2006)  
T-cell specific targeted PIK3R1 gene products in p85β null mice develop immune cell infiltration 
(mainly CD4+) into lacrimal glands and their destruction. Mice show increased autoantibody levels, 
altered Thelper-cell differentiation and cytokine production (GT; (Oak et al., 2006))  
Others 
    Atherosclerosis • Apolipoprotein E 
(ApoE)-/- mice 
• LDL-receptor -/- mice 
 
ApoE-/- mice develop spontaneous atherosclerotic lesions, LDL-receptor-/- mice after fat rich, 
cholesterol-depleted diet. PI3Kγ inactivation resulted in decreased macrophage activation after pro-
atherosclerotic or acute inflammation stimuli (oxidized LDL, C-peptide, CRP)(GT; (Chang et al., 
2007)). PI3Kγ null mice and PI3Kγ-inhibitor treated wild type mice had reduced atherosclerotic 
lesions, macrophage and T-cell (CD4+) invasion and increased stabilization of formed plaques. 
(GT, PH; (Fougerat et al., 2008)) 
    Thrombosis • ADP induced 
thrombosis  
PI3Kγ null mice are protected from ADP induced thrombosis, as ADP induced platelet aggregation 
is impaired (GT; (Hirsch et al., 2001)) 
No Shading:  No reported effect on disease 
Green:   Isoform inhibition has a positive effect on disease  
Orange: Class IA inhibition has a positive effect on disease, however catalytic isoform has not been further defined 
Red:  Negative effect or cause of disease after isoform inhibition.
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2.6.4 In vivo verified functions of PI3K isoforms in immune cells: 
 
T-cells 
Class IA PI3K signaling in T-cells was studied with all viable gene-targeted mice described above. Neither 
p85α nor p110δ null T-cells showed any defects, whereas p85, 55, and 50α null mice displayed an altered 
Th1:Th2 balance in vivo, however mediated by T cell extrinsic, dentritic cell mediated effects (Fukao et al., 
2002a). Loss of p85β protein in T cells, rather surprising, increased proliferation upon anti-CD3 and IL2 
treatment and reduced cell death in vivo and in vitro (Deane et al., 2004). Interestingly PI3KδKD/KD mice, in 
contrast to PI3Kδ-/- mice, were impaired in proliferation upon TCR cross-linking with anti-CD3 antibodies, so 
were Ca2+ fluxes and phosphorylation of PKB impaired in vitro. Co-stimulation with IL-2 or CD28, however, 
eliminated proliferative defects (Okkenhaug et al., 2002). Inactive PI3Kδ impaired also proper differentiation 
into effector T cells, memory T cells, and Th1 and Th2 helper cells while T cell populations were normal in 
the periphery (Okkenhaug et al., 2006). Elimination of all class IA regulatory subunits in T cells and 
thymocytes could however only partially confirm the PI3KδKD/KD phenotype, as their normal development and 
differentiation challenges the requirement of class IA PI3K in T cell development (Deane et al., 2007).  
PI3Kγ deletion perturbs T cell development, reducing double positive cells and altering the CD4+: CD8+ 
single positive ratio. Peripheral T cell proliferation and cytokine production in response to TCR/CD28 co-
stimulation (Sasaki et al., 2000; Alcazar et al., 2007; Rodriguez-Borlado et al., 2003) is negatively affected, 
too. Defects in chemokine induced T cell migration are present, but not as prominent as in neutrophils or 
macrophages defective for PI3Kγ signaling (Reif et al., 2004).  
Similar and mild defects in T cell development were observed by inactivation of either PI3Kδ or 
PI3Kγ.  Combined inactivation of both isoforms, however, led to complete block of thymocyte development. 
Thus signaling through one isoforms could compensate for loss of the other, or partial PI3K activity could be 
sufficient for T cell development (Webb et al., 2005).  
 
B cells 
B cells a highly dependent on class IA PI3K downstream the B cell receptor (BCR). Deletion of PIK3r1 gene 
products (p85α, p55α, p50α), or manipulated p110δ impairs BCR signaling, while defects in p85β or PI3Kγ 
deleted B cells were absent (Suzuki et al., 1999; Okkenhaug et al., 2002; Jou et al., 2002). Mice with 
disrupted or defective PI3Kδ or p85α have profoundly reduced total number of mature B cells, due to 
blocked transition from pro-B cell to the pre B cell stage during development. Proliferation upon anti-IgM 
treatment was completely compromised, while anti-CD40 or LPS treatment resulted in partial proliferation 
defects. So was the T cell-dependent and -independent antibody production defective in PI3Kδ or PIK3r1 
targeted B cells.  
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Neutrophils and macrophages 
Neutrophils and macrophages are required for immediate clearance of bacterial pathogens and cause acute 
and chronic inflammatory processes. Therefore they are dependent on their ability to migrate towards sites 
of inflammation along shallow chemotractant gradients, including blood vessel extravasation, degranulation, 
phagocytosis, superoxide production and chemokine release. Neutrophilic migration and superoxide 
production post chemokine stimulation are strongly impaired by elimination of PI3Kγ activity by either gene 
targeting (Hirsch et al., 2000) or isoform specific inhibition of PI3Kγ in vitro and in murine disease models 
such as chemokine induced neutrophilia in airway inflammation (Thomas et al., 2005) or septic peritonitis 
(Hirsch et al., 2000; Camps et al., 2005). 
Although none of the above-mentioned neutrophil-intrinsic functions require PI3Kδ, in vivo its cooperative 
activity with PI3Kγ was required for LTB4-induced extravasation of neutrophils (Puri et al., 2004). Since then, 
approaches using combinations of isoform specific inhibition and gene targeting proposed a biphasic 
process for chemokine driven neutrophil extravasation and ROS production in TNFα primed human 
neutrophils: in an early phase PI3Kγ is indispensable, which is prerequisite for the second phase, in which 
PI3Kδ is involved (Liu et al., 2007; Condliffe et al., 2005). 
 
 
2.6.5 Class I PI3K in mast cells: 
 
2.6.5.1 PI3K signaling in mast cell development 
 
Class IA PI3Ks are commonly critical signal transducers in growth factor receptor signaling (Fig. 3). In mast 
cells c-KIT is substantial for survival, proliferation and differentiation. Inhibitory experiments with wortmannin 
supported the involvement of PI3K in SCF mediated survival, proliferation, adhesion of BMMC (Serve et al., 
1995). Both, mice with kinase inactive PI3Kδ and mice with deleted p85α, confirmed the vital function of 
class IA PI3K and in particular of PI3Kδ downstream c-KIT in vivo. Thus reduced mast cell numbers and a 
complete lack of mast cells in the peritoneum and the gastrointestinal tract were reported for either of the 
gene-targeted mice (Ali et al., 2004; Fukao et al., 2002b). In line doubling times of cultured PI3KδKD/KD 
BMMC are prolonged (Ali et al., 2004).  
 
2.6.5.2 PI3K signaling in mast cell migration 
 
Mast cell precursors have to evade the circulation in order to become tissue resident. As outlined before the 
sequential steps in this process were suggested to be SCF/c-Kit mediated (Lorentz et al., 2002; Nilsson et 
al., 1994; Boyce, 2003). In line with the role of class IA PI3K downstream c-Kit, mice with inactivated p110δ 
or deleted p85α show tissue specific reductions in mast cell numbers. Further BMMC of either of the mice 
were defective to migrate in response to SCF stimulation. Thus the tissue specific loss of mast cells is most 
likely a convoluted result of decreased survival and impaired migration towards SCF gradients for initial 
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mast cell distribution to tissues, provided that SCF gradients between the circulation and tissues exist (Ali et 
al., 2004; Fukao et al., 2002b). During the development of allergic disease IgE is secreted from B cells in 
inflamed tissues. Thus IgE gradients can be expected (Cameron et al., 1998; Smurthwaite et al., 2001). 
Under allergic conditions the chemotactic capacity of IgE can thus locally enhance mast cell numbers. 
Interestingly migration towards IgE is PI3Kγ dependent in vitro (Kitaura et al., 2005) and in vivo, while PI3Kδ 
was dispensable (Collmann et al., in preparation). Moreover IgE-mediated BMMC migration is amplified in a 
PI3Kγ dependent autocrine and paracrine feedback signaling of GPCR agonists, which are gradually 
distributed from the inflamed tissue (Kitaura et al., 2005).  
 
 
2.6.6 PI3K signaling in mast cell degranulation 
 
Mast cell activation via the FcεRI 
The FcεRI is a multidomain receptor, with four membrane spanning subunits: the α-subunit for extracellular 
ligand binding, a tetra-spanning β-subunit and the dimeric, di-sulfide linked γ-subunit for signal transduction 
and amplification, due to the ITAM motifs present in cytoplasmic tails the β- and γ-subunits. FcεRI mediated 
signal transduction requires sensitization by bound IgE, which in a monomeric form positively modulates 
receptor expression (Hsu and MacGlashan, 1996; Yamaguchi et al., 1997) and cell survival (Asai et al., 
2001; Kalesnikoff et al., 2001) but also lymphokine synthesis and release (Gonzalez-Espinosa et al., 2003).  
When IgE-decorated FcεRI is however cross-linked by polyvalent antigens (Ag-IgE-FcεRI; Kinet, 1999) 
signal transduction is transiently enhanced, leading to an immediate release of secretory granules, followed 
by a late phase response, through the release of de novo synthesized inflammatory mediators, such as 
prostaglandins (PGE2, PGD2), leukotrienes (LTB4, LTC4), cytokines and chemokines (Tab.1). Both phases 
thereby contribute to the typical, location dependent, allergic indications.  
Mechanistically, Ag-IgE-FcεRI complexes re-localize to lipid raft compartments (Holowka and Baird, 2001), 
which was suggested to induce close proximity to the Lyn tyrosine kinase of the src family. Lyn 
phosphorylates the β and γ chain located ITAM motifs, further recruiting and activating Lyn itself as well as 
the PTK Syk. Fyn is a second src family kinase to be activated by cross-linked Ag-IgE-FcεRI complexes, but 
independent of Lyn activity (Parravicini et al., 2002).  
Lyn and Fyn subsequently induce an inconceivable signaling network through a tyrosine phosphorylation 
cascade and the assembly of signalosome complexes, consisting of trans-membrane, membrane-
associated and cytosolic adapters, as well as signal transduction enzymes (Kalesnikoff and Galli, 2008). In 
the end various physiologic responses are induced, amongst others, Ca2+ mobilization which is required for 
degranulation (Blank and Rivera, 2004). Simplified, the Lyn-Syk axis hereby acquires LAT and NTAL as 
signaling platform, which is phosphorylated at multiple tyrosine residues to attract cytosolic adapters, such 
as SLP76, Grb2 or Gads, the Rac-GEF Vav and Rac itself. PLCγ is additionally recruited and the whole 
signalosome orchestrates Ca2+ mobilization, due to positive modulation of PLCγ activity. 
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Fyn is also implicated in the Ca2+ response, however through affecting a different set of molecular targets as 
Lyn. The association of Fyn to the β-chain ITAMs of the FcεRI is required initially (Parravicini et al., 2002). 
Being activated, Fyn phosphorylates the “signaling platform” Gab2 to recruit class IA PI3K and SHP-2.   
There is a lot of evidence for the requirement of PI3K activity downstream FcεRI aggregation, as both the 
Lyn-Syk-LAT and Fyn-Gab2-PI3K pathways include multiple proteins that associate with PI3K and can thus 
integrate class IA PI3K activity. The gatekeeper role of SHIP in mast cell degranulation (Huber et al., 1998) 
further supports PI3K activity downstream of FcεRI aggregation.  
Mast cells from Gab2 deficient mice are blocked in the transmission of signals from FcεRI to PI3K, and have 
thus tremendous reduction of PI3K activity, reduction in Ca2+ fluxes and show diminished degranulation, 
which translates into protection from anaphylaxis in Gab2 deficient mice (Gu et al., 2001). The reduced PI3K 
activity and thus the inactive Btk might be causal for diminished Ca2+ fluxes. Although the regulatory subunit 
p85 associates with Gab2 in BMMC lysates these data do not define the class IA PI3K isoform, which is 
associated. Comparable defects were observed in PI3KδKD/KD mice and BMMC (Ali et al., 2004) with 
complete inhibition of signaling to PKB/Akt, a 30-50% inhibition of granule and cytokine release in BMMC 
and partial protection from passive cutaneous anaphylaxis (PCA) in mice, which challenged the previously 
reported role of PI3Kγ in systemic anaphylaxis (Laffargue et al., 2002). This indicates that Gab2 could be 
associated with PI3Kδ activity. Similar to PI3KδKD/KD mice, Gab2 deficient mice have a tissue specific loss of 
mast cells, and BMMC of both genotypes are defective in SCF-mediated signaling (Nishida et al., 2002; Ali 
et al., 2004). 
Confusing herein is however that mice and mast cells lacking all class IA PI3K activity, through deletion of 
p85α or p85, p55 and p50α, were fully functional in IgE/Ag induced degranulation and passive systemic 
anaphylaxis was as severe as in wild type controls (Fukao et al., 2002b ;Lu-Kuo et al., 2000).  
PI3Kγ deficient mice are resistant to passive systemic anaphylaxis (PSA) after IgE/antigen challenge, 
highlighting this isoform in vivo. Reduced IgE/Ag dependent granule exocytosis in BMMC supplemented to 
observed protection in vivo (Laffargue et al., 2002). Mechanistically PI3Kγ is however not to directly engaged 
downstream of FcεRI.  In accordance with the model of PI3Kγ activation here PI3Kγ was involved in a GPCR 
dependent autocrine/paracrine positive feedback loop, which is essential for full-scale mast cell activation 
(Laffargue et al., 2002). Thereby increased PtdIns(3,4,5)P3 levels overshoot a threshold, for which SHIP 
activity can not compensate anymore (Fig. 9). The feedback was shown to involve adenosine, as adenosine 
deaminase treatment blocked signal amplification. Similar effects were observed with pertussis toxin 
treatment, thus signaling through the Gαi coupled A3 adenosine receptor. Interestingly increased adenosine 
levels were reported in brocho-alveolar lavage fluids from asthmatic patients, and those showed increased 
sensitivity to inhaled adenosine compared to healthy controls (Fozard, 2003). Extrapolation of murine 
models to human disease like asthma or allergy could thus be possible. The contradictions on which PI3K is 
involved in mast cell activation led to a side-by-side analysis of PI3Kδ and PI3Kγ inhibition 
(pharmacologically and genetically; Ali et al., 2008). First this study could not confirm the complete block of 
IgE/Ag signaling in PI3Kδ inhibited BMMC, as it was reported before. In contrast PI3Kγ inactivation impaired 
IgE/Ag mediated signaling to phosphorylation of PKB/Akt to a great extent. 
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Fig. 8: Simplified network of activating signaling events downstream of FcεRI cross-linking by IgE/antigen 
complexes: Aggregated FcεRI requires Lyn or Fyn kinases for initial phosphorylation of its ITAM motifs, which are 
then bound by more Lyn or Fyn molecules as well as by the tyrosine kinase Syk. The associated and in turn activated 
kinases phosphorylate adapter proteins, like Gab2, LAT and NTAL, for further recruitment of pY binding adapter 
proteins or enzymes. Class IA PI3Ks (p110cIA complexed with p85) are associated to the signaling complexes, 
mainly via p85’s SH2 domains binding to the pYxxM motifs on Gab2, but also by additional or co-operative protein 
interactions, e.g. with GTP loaded Ras or direct association with Lyn (not shown). PI3Ks can here directly activate 
phospholipase Cγ (PLCγ) or by PtdIns(4,5)P2 phosphorylation, which increases Btk membrane translocation and its 
activation through phosphorylation by Lyn and auto-phosphorylation. Btk then activates PLCγ, which hydrolyses 
PI(4,5)P2 to Diacylglycerol (DAG) and Inositol(1,4,5)P3 (IP3). DAG directly activates protein kinase C (PKC) in 
synergy with Ca2+, mobilized from the ER (via IP3 regulated Ca2+ channels) and the coupling to extracellular Ca2+ 
currents via stromal interaction molecule1 (Stim1) activity, to increase Ca2+ levels (not shown) and to drive 
degranulation. PtdIns(3,4,5)P3 also recruits PDK1  and PKB to the membrane thus activating PKB, which indirectly 
induces gene transcription and degranulation (via IKK [IκB kinase] complex phosphorylation and subsequent 
SNAP23 [synaptosomal associated protein, 23 kDA] phosphorylation). Some indirect interconnections are indicated 
by dashed lines, others are not shown to increase clarity, e.g. the positive effect of PI3K activity on GEFs, as Vav, or 
Sos, and consequently Ras and Rac GTPases. SLP: SH2 domain containing leukocyte protein of 76kDa; Grb2: 
Growth factor receptor bound protein 2; JNK: Janus kinase; CaM: Calmodulin; NFAT: Nuclear factor of activated T-
cells; MAPK: Mitogen activated protein kinase pathway; PLA2: Phospolipase A2, References see main text) 
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Fig. 9: Inhibitory events in FcεRI signaling and the PI3Kγ  dependent bypass driving hyperreagibility: 
Left: Antigen cross-linking leads to the activating events shown in Fig. 8 (indicated with the dashed line here for class 
IA PI3K). It however also integrates (red arrow) inhibitory immune receptors (in red; FcγRIIB), containing ITIMs, into 
the signaling complex, and other inhibitory receptors (gp41b, MAFA [mast cell function associated antigen]) are close 
to the FcεRI as well, which drives phosphorylation of their ITIMs by Lyn. Phosphorylated ITIMs recruit protein tyrosine 
phosphatases (SH2 containing tyrosine phosphatase 1 and 2 [SHP1, 2], which de-phosphorylate Syk and ITAMs 
(thus inactivating the PTK cascade), and/or the SH2 domain containing inositol-5-phosphatase 1 and 2 (SHIP), which 
convert PtdIns(3,4,5)P3 to PtdIns(3,4)P2, leading to the redistribution of essential signaling components (e.g. Btk) to 
the cytosol. Thus signaling is finely balanced. Note: there are alternative routes for down-modulation of FcεRI 
signaling such as endocytosis and degradation of FcεRI and Syk by interaction with Cbl and subsequent 
ubiquitination (not shown). Right: PI3Kγ mediated autocrine/paracrine feedback loop (green arrow) provides an 
additional PtdIns(3,4,5)P3 source, which overshoots SHIP’s capacity to regulate PI3K activity, leading to imbalanced 
signaling, hyperreactivity of mast cells and maximal degranulation. Here, especially adenosine, with increased levels 
in inflamed and hypoxic tissue is very effective in driving this signal amplification. Notably the requirement of PI3Kγ 
adapters is undefined herein. 
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The inhibition of either PI3Kδ or PI3Kγ  yielded in equal reductions of granule exocytosis from BMMC. From 
this it is difficult to construe how then inhibition of PI3Kδ, but not of PI3Kγ, protected mice from PCA, as 
reported here. 
Accepting this observation, an explanation could be provided by indirect effects on mast cells in their natural 
context, rather than by a direct effect in IgE/antigen mediated mast cell activation. Notably both isoform 
equally contributed to IgE/antigen dependent mast cell degranulation in vitro. Thus impaired c-Kit and IL-3 
signaling could reduce the concentration of tissue resident mast cells, which was reported for non-IgE 
treated mice (Ali et al., 2004), but which was thus far not assessed after local tissue sensitization with IgE. 
Moreover PI3Kδ inhibited mast cells are certainly impaired the signal transduction of co-stimulatory 
effectors, such as SCF (Hundley et al., 2004), and apart from this PI3Kδ inhibition deprives signaling from 
cytokine and growth factor sources, changing the overall state of the cells. 
 Recent work in our laboratory (Collmann et al., in preparation) reevaluated the functional requirement of 
PI3Kδ, compared to PI3Kγ, in FcεRI mediated mast cell activation: in short our results showed that the role 
of PI3Kδ diminishes to its vital function in mast cell differentiation, while signaling from aggregated FcεRI to 
activation of PKB/Akt and to granule exocytosis were unaffected in PI3KδKD/KD BMMC or PI3Kδ inhibitor 
treated wild type mast cells. Moreover, genetic and pharmaceutical inhibition of PI3Kδ was neither effective 
to protect mice from PCA, nor to prevent mast cell precursor recruitment to sites of IgE injection or to sites of 
TNFα simulated inflammation in vivo. In contrast all the physiological processes, and their simulative in vitro 
experiments, were impaired by genetic of pharmaceutical PI3Kγ targeting.  
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3 Aims 
 
As outlined above PI3Kγ is an excellent target for treatment of allergic disease. First inhibition of PI3Kγ 
protected mice from mast cell degranulation after allergic challenge and thus reduced allergic symptoms, 
even when the PI3Kγ inhibitor was acutely administered. Second PI3Kγ inhibition prior sensitizing tissue with 
IgE prevented mast cell recruitment to the site of IgE injection (Collmann et al., in preparation). Thus 
prolonged administration of PI3Kγ inhibitors could be beneficial in reducing disease progression, due to 
reduced mast cell numbers in tissues leading to decreased release of inflammatory mediators. Similarly the 
physiologic importance of PI3Kγ signaling was also very well documented in other haematopoietic cells, e.g. 
neutrophils, macrophages (Hirsch et al., 2000).  
In recent years many promising compounds for PI3Kγ inhibition were tested in human disease related 
animal models (Tab. 2). All inhibitors act here by competing with ATP for binding to the catalytic core. 
Consequently there is still a risk to inhibit other lipid- or protein kinases, due to structural homologies in their 
catalytic domains.  
Thus alternative therapeutic approaches, e.g. by allosteric inhibition or disruption of required interactions of 
PI3Kγ with other proteins, could minimize adverse effects. Therefore a detailed knowledge of how PI3Kγ is 
activated is required. But even the physiologic requirement of the only known PI3Kγ adapter subunit p101 
was disputed until Suire et al. (Suire et al., 2006) could show that p101 was required for PI3Kγ mediated 
neutrophil migration. An adapter independent PI3Kγ-mediated migration could however not be excluded. 
Our work and work of others identified a second adapter subunit of PI3Kγ, dubbed p84 or p87PIKAP (Suire et 
al., 2005; Voigt et al., 2006), which further complicated interpretation of p101’s function in neutrophils, as 
cross-compensatory effects of both adapters could not be excluded. 
 
1st we thus aimed to define a clean system with physiologic relevance in which to analyze the role of p84- if 
PI3Kγ adapters are required at all. Expression analysis presented mast cells as most appropriate to study 
the function of p84. 
 
2nd by developing a mast cell complementation system we aimed to show and could show that PI3Kγ activity 
completely depends on the presence of p84 in mast cells. 
 
3rd we aimed to analyze if the two adapters have non-overlapping functions, although in vitro data did not 
suggest so.  
Distinct functions of either of the two adapter:p110γ complexes would add additional complexity to 
PI3Kγ signaling, but would certainly be highly interesting for therapeutic aspects. Indeed we were able to 
define a non-redundant function of either of the adapter:p110γ complexes. 
 
4th we approached to explain the distinct signal capacities of both of the adapter:p110γ complexes.  
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C E L L B I O L O G Y
PI3Kg Adaptor Subunits Define Coupling to
Degranulation and Cell Motility by Distinct
PtdIns(3,4,5)P3 Pools in Mast Cells
Thomas Bohnacker,1 Romina Marone,1* Emilie Collmann,1* Ronan Calvez,1†
Emilio Hirsch,2 Matthias P. Wymann1‡
(Published 9 June 2009; Volume 2 Issue 74 ra27)
Phosphoinositide 3-kinase g (PI3Kg) plays a major role in chronic inflammation and allergy. It is a hetero-
dimer of a catalytic p110g subunit and an adaptor protein, either p101 or the p101 homolog p84 (p87PIKAP). It
is unclear whether both PI3Kg complexes specifically modulate responses such as chemotaxis and de-
granulation. In mast cells, the p84:p110g complex synergizes with immunoglobulin E (IgE)– and antigen-
clustered FcɛRI receptor signaling and is required to achieve maximal degranulation. During this process,
PI3Kg is activated by ligands of heterotrimeric guanine nucleotide–binding protein (G protein)–coupled
receptors (GPCRs), in particular adenosine receptors, through autocrine and paracrine pathways. Here,
we show that p110g needs p84 to relay signals from GPCRs to formation of phosphatidylinositol 3,4,5-
trisphosphate [PtdIns(3,4,5)P3], phosphorylation of Akt, migration of cells, and synergistic adenosine-
enforced degranulation. Furthermore, the absence of adaptor subunits could not be compensated for by
increased p110g abundance. Differentiated, p110g null cells also lost adaptor proteins. Complementation
of p110g null mast cells with p101 and p110g restored the activation of Akt and cell migration, but failed to
support degranulation. Lack of degranulation was attributed to a change in the spatiotemporal localiza-
tion of PI3Kg-derived PtdIns(3,4,5)P3; although both p84:p110g and p101:p110g complexes initially depos-
ited PtdIns(3,4,5)P3 at the plasma membrane, p101:p110g–derived PtdIns(3,4,5)P3 was rapidly endocytosed
to motile, microtubule-associated vesicles. In addition, p84:p110g, but not p101:p110g signaling was sen-
sitive to disruption of lipid rafts. Our results demonstrate a nonredundant function for the p101 and p84
PI3Kg adaptor proteins and show that distinct pools of PtdIns(3,4,5)P3 at the plasma membrane can elicit
specific cell responses.
INTRODUCTION
Phosphoinositide 3-kinases (PI3Ks) are implicated in cancer (1–4) and in-
flammation (5, 6), and their net activity can modulate the transition from
normal cell functions to the progress of disease. Regulatory subunits trans-
locate the 110-kD catalytic subunits—consisting of class IA PI3K members
p110a, b, and d and class IB p110g—to their substrate phosphatidylinositol
4,5-bisphosphate [PtdIns(4,5)P2] at the plasma membrane. For class IA
PI3Ks, it is well documented that both Src homology 2 (SH2) domains of
p85-like regulatory subunits (encoded by PIK3R1, PIK3R2, and PIK3R3)
direct the PI3Kcomplexes to phosphorylatedTyr-X-X-Metmotifs on recep-
tor protein tyrosine kinases or their substrates (5, 7) and that interactions
between p85 and p110 regulate enzyme activity (8, 9). In spite of this knowl-
edge, the physiological consequences of genetic ablation of regulatory p85
subunits have often been surprising.Whereas targeting of p85a (by deletion
of exon 1 of PIK3R1) attenuated the function of PI3K downstream of the B
cell receptor as expected (10–12), loss of p85a or p85b increased insulin
signaling (13–15). Due to the multilevel complexity of the PI3K network,
however, a full description of the physiological roles of the regulatory sub-
units of PI3Ks is far from being complete.
The sole member of the class IB family, p110g (encoded by PIK3CG)
operates downstream of heterotrimeric guanine nucleotide–binding protein
(G protein)–coupled receptors (GPCRs) (5, 16) and is activated by bg sub-
units of G proteins (Gbg) in vitro (17, 18). The catalytic subunit p110g forms
heterodimers with either of the adaptor subunits p101 (encoded by PIK3R5)
(18) and a p101 homolog, p84 (also called p87PIKAP, encoded by PIK3R6)
(19, 20). N- and C-terminal sites of p110g bind to Gbg subunits directly (21),
but p101 and p84 are required for efficient Gbg-stimulated phosphorylation of
PtdIns(4,5)P2 invitro (19, 22, 23). The physiological importance of p101was
demonstrated convincingly in p101 null mice, in which GPCR ligands failed
to trigger neutrophil chemotactic responses, whereas the induction of neutro-
phil NADPH oxidase was not affected (24), even though both responses are
dependent on PI3Kg (16). The p101 and p84 adaptor subunits perform equally
well in vitro (19), but a physiological role for p84 is yet to be defined. It is
still unclear whether p84 and p101 have overlapping or nonredundant func-
tions in vivo.
We have therefore addressed the requirement and actions of PI3Kg adaptor
proteins in the physiologic context of mast cell activation, which provides a
superb model system in which to study the function of PI3Kg. In mouse mast
cells, PI3Kg signals downstream ofA3 adenosine receptors (A3ARs) and drives
cell migration (25), as well as synergistically enhancing IgE- and antigen-
mediated degranulation in vitro and IgE- and antigen-induced passive systemic
anaphylaxis in vivo (26). In this context, adenosine signaling throughGPCRs is
well known for activating mast cells in atopic, but not normal, patients (27, 28).
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The clustering of FceRI receptors through antigen-IgE complexes trig-
gers a protein tyrosine kinase cascade that leads to the phosphorylation of
immunoreceptor tyrosine–based activation motifs (ITAMs) on FceRI recep-
tor chains, multiple tyrosines on linker of activated T cells (LAT), non–T cell
activation linker [(NTAL), also known as linker for activation of B cells
(LAB), also known as LAT2] (29), and Tyr-X-X-Metmotifs on growth factor
receptor–bound protein 2 (Grb2)–associated binding protein 2 (Gab2) (30).
Class IA PI3Ks, and in particular p110d (31), thus produce a first wave of
phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3] as a consequence
of the clustering of FceRI receptors. This signal is, however, quenched by the
action of the SH2 domain–containing inositol 5′-phosphatase (SHIP), which
degrades PtdIns(3,4,5)P3 to PtdIns(3,4)P2 (32). In this context, GPCR-
triggered activity of PI3Kg delivers a superimposed pulse of PtdIns(3,4,5)P3,
which is integrated with the FceRI protein tyrosine cascade and produces a
full-scale activation and degranulation response. Its exclusive dependence
onPI3Kgmakes this an attractivemodel inwhich to unravel the functions of
the PI3Kg adaptor proteins.
Here, we show that differentiated hematopoietic cells that lack the p110g
catalytic subunit also lose their PI3Kg adaptor proteins, which was exploited
to producemast cells devoid of both p110g andp84.Complementation assays
showed that p110g could not operate without its adaptor proteins. Moreover,
p101 and p84 had nonredundant functions in a physiological context and
produced distinct pools of PtdIns(3,4,5)P3 with different fates, sensitivities
to depletion of cholesterol, and capacities to promote release of mast cell
granules. PI3Kg adaptor subunits thus controlled spatiotemporal signaling
of p110g catalytic subunits to yield diverse physiologic outputs. Because
PI3Kg is an important component in chronic inflammation and allergy, a
full understanding of its mechanism of activation might open previously
unknown avenues of context- and tissue-specific targeting of PI3Kg. Spatial
organization might also apply to mammalian p85 class IA PI3K adaptor
proteins, which have physiologically poorly explored interaction domains,
such as the SH3 and breakpoint cluster region homology (BH) domains (7).
RESULTS
Mast cells: a model in which to study the functions of
PI3Kg adaptor proteins
To evaluate and compare the tissue distribution of p84:p110g and p101:
p110g complexes, wemeasured the abundance of messenger RNAs (mRNAs)
for mouse p110g, p84, and p101 by quantitative polymerase chain reaction
(qPCR) assays. mRNAs for p110g, p84, and p101 were detected at high
abundance in murine hematopoetic tissues and cells (Fig. 1A and fig. S1),
corresponding to the reported role of PI3Kg in the recruitment of leukocytes
(16) and full-scale activation of mast cells (26). In all tissues investigated,
p110gmRNA correlated with the presence of that of at least one of the adap-
tor subunits, supporting the importance of the regulators to the function of
PI3Kg. The mRNA for p101 was prominently expressed in bone marrow
(BM), thymus, spleen, and lymph nodes but was at low abundance in BM-
derived mast cells (BMMCs) (see Fig. 1C for protein abundance) and mast
cell lines of mouse (MC/9), rat (RBL-2H3), and human (HMC-1) origin. In
contrast, the abundance of p84 mRNAwas high in mast cells (Fig. 1, A and
B). Similarly, we examined the abundance of PI3Kg subunit proteins in
hematopoietic cells derived from wild-type (WT) mice, p110g null mice
(KO) (16, 33), or genetically targeted mice with catalytically inactive
p110g (KR, which contains a Lys833→Arg mutation) (34). In BM samples,
the abundance of p84 protein was not affected by manipulations of the
p110g locus (Fig. 1D). However, the abundance of p84 was lower in differ-
entiated cells such as mast cells, macrophages, splenocytes, and neutrophils
from KO mice than from WT mice, whereas the abundance of p84 was
normal in cells from KR mice (Fig. 1D and fig. S2). This implies that the
stability of p84was dependent on the presence of p110g but not on its kinase
activity. That other, yet unexplored mechanisms control the abundance of
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Fig. 1. Tissue distribution of p110g and its adaptor subunits. (A) Relative
copy numbers of mRNAs for p110g, p84, and p101 were assessed by
qPCR in the indicated murine tissues (for additional tissues, see fig. S1),
as well as in BMMCs and a mouse mast cell line (MC/9). Data shown
represent mean ± SEM of more than three experiments. All values are
normalized to the copy number of p84 mRNA in BM. (B) p84, p101,
p110g, and GAPDH (internal standard) mRNAs were amplified from the
RBL-2H3 and HMC-1 mast cell lines and the indicated rat and human
cells and tissues by RT-PCR, separated by agarose gel electrophoresis,
and visualized with ethidium bromide. (C) p101 protein is undetectable
in murine BMMCs. Total lysates of murine BMMCs and J774 cells were
subjected to SDS-PAGE and the indicated proteins were detected by
Western blotting. (D) p84 protein is stabilized in the presence of p110g.
Bone marrow (BM), macrophages (MØ), splenocytes (Spleno), neutrophils
(NØ), and mast cells (BMMC) fromWT mice (WT), mice deficient in p110g
(KO), or mice with a catalytically inactivated p110g (Lys833→Arg mutation;
KR) were probed for the presence of p110g and p84 proteins by Western
blotting. Blots in (B) to (D) are representative of more than three experi-
ments each.
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PI3Kg adaptor proteins is illustrated by the stability of p84 in BM samples
from KO mice and the lower abundance of p84 mRNA in KO BMMCs
compared to that in WT BMMCs (fig. S2C).
Because BMMCs from KO mice lack both adaptor and catalytic sub-
units, we used them for complementation assays and functional studies.
We first explored the physiological output of the p84:p110g complex and
then tested whether exogenous p101 could substitute for p84. Both adaptor
proteins interact with p110g and Gbg subunits in vitro, although p101 sen-
sitizes PI3Kg for activation byGbg subunits at even lower concentrations of
Gbg subunits (19).
Combinations of WTor catalytically inactive (KR) p110g proteins with
either green fluorescent protein (GFP)–tagged p84 (GFP-p84) or p101
(GFP-p101) were introduced into KO BMMCs by nucleofection. Com-
plementation ofWT p110gwith GFP-p84 or GFP-p101 restored adenosine
receptor signaling, as detected by the presence of phosphorylated Akt, but
the isolated introduction of p110g did not (Fig. 2A).Under these conditions,
introduction of p110g with or without GFP-p84 or GFP-p101 did not in-
crease the abundance of endogenous p84 (fig. S3). As for WT BMMCs
(26), adenosine-mediated phosphorylation of Akt in KOBMMCs reconsti-
tutedwith either p110-adaptor complexwas prevented by the PI3K inhibitor
wortmannin (Fig. 2B) and by pretreatment with pertussis toxin (PTX) (fig.
S4). The A3AR-specific agonist IB-MECA and agonists targeting all aden-
osine receptors (adenosine and NECA) stimulated phosphorylation of Akt
to a similar extent independently of the PI3Kg adaptor protein used, indicat-
ing that PI3Kg adaptors did not alter adenosine receptor signaling (fig. S4).
A role for PI3Kg in GPCR-induced chemotaxis has been established in
various cell types (16, 24, 35, 36). Mast cells migrate toward adenosine
through activation of A3AR in a PI3Kg-dependent, PTX-sensitive manner
(25). When reconstituted with p110g only, BMMCs derived from KOmice
were unable to migrate toward adenosine, whereas reconstitution with WT
p110g and either hemagglutinin (HA)-tagged p84 (HA-p84) or p101 (HA-
p101) resulted in the cells having an increasedmigratory capacity (Fig. 2C).
Neither the presence of the individual adaptor proteins nor reconstitution
with either adaptor protein and catalytically inactive p110g (KR) restored
Fig. 2. Adenosine-induced phosphorylation of Akt and cell migration is
restored in KO BMMCs by reconstitution with p110g and either p84 or
p101. KO BMMCs were transfected with plasmids encoding functional
p110g (WT) and either GFP-tagged p84 (GFP-p84) or p101 (GFP-p101).
One day later, cells were starved in IL-3–free medium containing 2%
FCS for 3 hours and stimulated with 2 mM adenosine for 3 min. (A) Phos-
phorylation of Akt at Ser473 was determined by analysis of Western blots
of cell lysates with an anti–Akt-pSer473. The abundance of p110g was
assessed with an anti-p110g, whereas GFP-p84 and GFP-p101 were de-
tected and their relative abundance was compared with an anti-GFP.
One representative experiment of three is shown. (B) Stimulations per-
formed as in (A) were tested for their sensitivity to 30 min of pre-
incubation with 500 nM wortmannin (Wm). Phosphorylation of Thr308 of
Akt was assessed in parallel with the appropriate antibody. (C) KO
BMMCs were reconstituted with WT or KR p110g and either HA-p84 or
HA-p101 as indicated, as well as with GFP to select for transfected cells.
Migration of GFP-positive BMMCs was assayed in Transwell chambers
for 6 hours in the absence (top) or presence of 1 mM adenosine (bottom)
in the lower well. Subsequently, GFP-positive cells were quantified. Data
shown are the mean number ± SEM of migrated GFP-positive cells from
n = 3 to 9 experiments. (D) Comparison of activation of Akt and migration
of reconstituted KO BMMCs. KO BMMCs were transfected with plasmids
encoding GFP, p110g, and either HA-p84 or HA-p101 (as indicated, with
variable DNA concentrations), whereas WT BMMCs were transfected
with a plasmid encoding GFP as a control. Experiments to measure
adenosine-stimulated Akt activity and cell migration were performed as
described for (A) and (C), respectively. In parallel, the abundance of
p110g protein was determined by Western blotting. Cell responses
(phosphorylation of Thr308 of Akt and cell migration) of complemented
KO BMMCs are expressed as the fold difference to those of WT BMMCS
and were correlated with the fold difference in the abundance of p110g
protein compared to that of WT BMMCs. Data shown are from n = 3
experiments, with two to three different DNA inputs in each experiment.
Migration events were corrected by subtracting the number of migrating
unstimulated cells to determine the number of cells that migrated in re-
sponse to adenosine.
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mast cell migration, showing that a functional p110g:adaptor complex is
required to sustain motility (Fig. 2C). This is underlined by the extent of
adenosine-dependent phosphorylation of Thr308 of Akt and the efficiency
of cell migration both being proportional to the amount of PI3Kg complex
present, whereas even when the abundance of p110g was greater than six-
fold higher than that of the endogenous protein in WT cells, the lack of
adaptor proteins could not be compensated for (Fig. 2D).
Nonredundant functions of PI3Kg adaptor proteins
To investigate adaptor-dependent PI3Kg signaling in the degranulation of
mast cells, we adapted a flow cytometric assay first described byDemo et al.
(37), which is based on the degranulation-induced, extracellular exposure of
phosphatidylserine on the cell surface and the subsequent staining of cells
with annexin V. Many groups (37–40) have established a direct correlation
between the extent of release of b-hexosaminidase and the extent of annexin
V binding in various contexts. With WT and KO BMMCs, we confirmed
that the assay sensitively detected IgE- and antigen-mediated degranulation
and we distinguished this from a full-scale response that involved costimu-
lation of cells with adenosine (Fig. 3, A and B). In agreement with previous
b-hexosaminidase assays, the stimulation of WT BMMCs with IgE and a
low concentration of antigen resulted in little degranulation,whichwas even
less so for KO BMMCs. As expected, adenosine-triggered hyperactivation
of mast cells was completely abrogated in the absence of PI3Kg (Fig. 3B).
With the annexin V staining assay, we could separately analyze transfected
and nontransfected cells through the detection of GFP or GFP fusion pro-
teins by flow cytometry. GFP-negative cells served as an internal standard.
When KO BMMCs were transfected with plasmids that encoded GFP-p84
and p110g, responsiveness to adenosine was restored to that of WT BMMCs,
and only the GFP–p84:p110g complex could enhance degranulation after
costimulation with adenosine. As was observed for phosphorylation of Akt
and cell migration, the individual subunits GFP-p84 and p110g, or the cat-
alytically inactive p110g-adaptor complex, failed to reconstitute adenosine-
dependent degranulation ofmast cells (Fig. 3C). These results underline that
p110g was incapable of signaling or contributing to degranulation in the
absence of an adaptor subunit.
As shown above, p84 was indispensable for adenosine receptor–mediated
PI3Kg signaling that led to enhancement of IgE- and antigen-mediated de-
granulation (Fig. 3C). KO BMMCs reconstituted with GFP-p101 and WT
p110g, however, did not produce an adenosine-dependent increase in de-
granulation above that observed in response to IgE and antigen, whereas
cells reconstituted with GFP-p84 and p110g exhibited maximal degranula-
tion (Fig. 4A). The abundance of p110g, p84, and p101 proteins were also
quantified. When the abundance of p110g was normalized to that of the
p84:p110g complex, it was found that reconstitution of cells with p110g
alone resulted in a fivefold lower abundance of p110g protein than that in
cells reconstituted with both p110g and p84. The p101 protein stabilized
p110g somewhat better than p84 did (Fig. 4B). There was no significant
difference in the abundance of GFP-p84 and GFP-p101 (Fig. 4D), and both
GFP-tagged adaptor proteins were localized to the cytosol (Fig. 4E). Because
p101 translocates to the nucleus in the absence of p110g (41), we assumed that
cytosolicGFP-p101was tightly bound to p110g andwas thus in a functional
state. This is also in agreement with mediation of adenosine-induced acti-
vation of Akt andmigration by the p101:p110g complex. Similar results were
obtained in experiments with cells reconstituted with GFP-fused p110g and
HA-tagged adaptor subunits (Fig. 4A). Consistent with the previous experi-
ments, KOBMMCs reconstituted with HA-p84:GFP-p110g complexes ex-
hibited adenosine-dependent degranulation, whereas those reconstituted with
HA-p101:GFP-p110g complexes did not. In the latter experiments, fusion
of GFP to the N terminus of p110g stabilized the kinase when expressed
alone, so that its abundance approached that observed in the presence of
its adaptor proteins (Fig. 4C). Despite this increased abundance, GFP-p110g
alone was incapable of rescuing adenosine signaling in KO BMMCs.
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Fig. 3. Mast cell hyperreactivity requires p84. (A and B) Mast cell degran-
ulation was assessed by annexin V staining and flow cytometry. WT and
KO BMMCs were exposed overnight to anti-DNP IgE (100 ng/ml). (A) Left:
Cells were stained with annexin V after loading with IgE (red), additional
stimulation with DNP-HSA (1 ng/ml; Ag) for 20 min (green), or with DNP-
HSA (1 ng/ml) and 2 mM adenosine for 20 min (black). Right: Adenosine-
dependent activation is represented by the difference in histograms from
[IgE+Ag+Ade] and [IgE+Ag] stimulations, given as Events(3) – Events(2).
(B) Top: Quantification of the experiments shown in (A). Degranulation was
calculated from events within region M2 after stimulation with IgE+Ag or
IgE+Ag+Ade, as indicated. Data shown are the mean ± SEM of n = 4
experiments with two populations of BMMCs and are expressed as the
percentage of annexin V–positive cells in the M2 gate (Degranulation,
% of annexin V staining). Bottom: For comparison, b-hexosaminidase
(b-hex.) release assays were performed under identical conditions. Data
shown are the mean ± SEM of n = 3 experiments. (C) Restoration of
adenosine-enforced degranulation in transfected KO BMMCs. KO BMMCs
were transfected with expression plasmids for GFP or GFP-p84 in combi-
nation with p110g (WT or KR). The adenosine-dependent component of
degranulation in the reconstituted BMMCs is shown (DDegranulation; see
Materials and Methods). Here, % of annexin V staining represents the
difference [Events(3) – Events(2)] as explained for (A). Data shown are
the mean ± SEM for n > 3 experiments. The dotted line sets P < 0.015
for comparison with p110g:GFP-p84. The bar labeled with GFP– denotes
the degranulation of GFP-negative, electroporated, but nontransfected
KO BMMCs, which served as an internal control. The setting of regions
(GFP+, M2, etc.) is explained in detail in fig. S5.
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Differences in p84- and p101-mediated
localization of PtdIns(3,4,5)P3
PI3Kg-derived PtdIns(3,4,5)P3 was visualized with the PtdIns(3,4,5)P3-
specific pleckstrin homology (PH) domain of Bruton’s protein tyrosine
kinase (Btk) (42) fused toGFP (PHBtk-GFP). Although adenosine-triggered
phosphorylation of Akt occurred with both types of PI3Kg complex, the
localization of PHBtk-GFP was distinguishable depending on the adaptor
protein used. Whereas adenosine caused the transient translocation of
PHBtk-GFP from the cytosol to the plasma membrane in cells containing
HA–p84:p110g complexes, in adenosine-treated BMMCs that contained
HA–p101:p110g complexes, PHBtk-GFP displayed a vesicular distribution
below the plasma membrane at later time points (Fig. 5A and movies m1
and m2). These endocytosed vesicles were separated from the plasma mem-
brane and did not contain PtdIns(4,5)P2, as visualized with a red fluorescent
probe made from the PH domain of phospholipase C d (PHPLCd-RFP) (Fig.
5B). Whereas the PHPLCd-RFP probe was constitutively localized at the
plasma membrane, the membrane docking of PHBtk-GFP required stimula-
tion of the cells with adenosine, an active PI3Kg complex, and an intact
PHBtk domain, because the Arg
28→Cys (R28C) mutation of PHBtk blocked
its translocation (Fig. 5, A and B). Therefore, PtdIns(3,4,5)P3 was indeed
present in the p101-dependent, internalized vesicles, whereas PtdIns(4,5)P2
was excluded.
To test a correlation between the occurrence of intracellular PtdIns(3,4,5)P3
and the abundance of p101, we performed an analysis of a population of
cells to assess the extent of plasma membrane (rim) or internal, vesicular
staining for PtdIns(3,4,5)P3 (Fig. 6A). Within 20 s of stimulation with aden-
osine, cells that contained HA–p84:p110g complexes displayed translocated
PHBtk-GFP at the plasmamembrane and attenuated rim staining could be de-
tected until 2 min later. Cells that contained HA–p101:p110g complexes
showed rim staining at early time points (<15 s), but intracellular speckles
of PtdIns(3,4,5)P3 also became visible. By 120 s after the addition of adeno-
sine, most p101-containing cells displayed speckles, whereas p84-containing
cells did not.
Live-cell microscopy was applied as an alternative method to monitor
the relocalization of PtdIns(3,4,5)P3. In single cells that contained HA–p84:
p110g complexes, translocation of PHBtk-GFP to the plasmamembranewas
maximal at 40 to 50 s after the addition of adenosine andwasmaintained for
less than 2 min after stimulation before moving from the rim region to the
cytosol. In BMMCs that contained HA–p101:p110g complexes, the inten-
sity of fluorescence at the rim showed similar dynamics, but diminished be-
cause of endocytosis of PtdIns(3,4,5)P3 (Fig. 6, B andC, fig. S6, andmovies
m3 and m4). Quantification of this process illustrated that PtdIns(3,4,5)P3
was produced at the plasma membrane by both PI3Kg complexes at the
same rate, and that the pace of degradation of PtdIns(3,4,5)P3 within the
plasma membrane was comparable to the removal of PtdIns(3,4,5)P3 by
endocytosis (Fig. 6C). Costimulation of mast cells with IgE-antigen and
adenosine dramatically prolonged and accentuated the localization of
PHBtk-GFP to the plasma membrane in cells containing p84:p110g and
delayed the onset of translocation and p101:p110g-mediated endocytosis
of PHBtk-GFP to >2 min after stimulation with adenosine (Fig. 6, D and
E, and movies m5 and m6). The prolonged retention times of PHBtk-GFP
at the plasma membrane might reflect a spatial synergy between p84- and
class IA–derived PI3K activities.
Cytosolic, PtdIns(3,4,5)P3-containing vesicles were mobile, and endo-
cytosis of PtdIns(3,4,5)P3 was followed by fast transcellular movements in a
fraction of the speckles (fig. S6; see alternative analysis exemplified with
movie m4). The curvature of the transport trajectories and the often peri-
nuclear destination of the speckles suggested that a subset of the speckles
was associated with microtubules. Indeed, pretreatment of BMMCs that
contained HA–p101:p110g with the microtubule disruptor nocodazole
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Fig. 4. The p101 adaptor protein does not compensate for p84 in degran-
ulation responses. (A) Left: KO BMMCs were transfected with plasmids
encoding p110g in combination with plasmids encoding GFP (√), GFP-
p84, or GFP-p101. Degranulation was measured after stimulation of cells
with IgE and antigen with or without adenosine as in Fig. 3C. Data shown
are the mean ± SEM for n > 5 experiments with P < 0.0004 for p84 com-
pared to p101. “Neg.” denotes the degranulation of GFP-negative, electro-
porated, but nontransfected KO BMMCs. Right: Experiments were performed
as in the left panel but with GFP fused to p110g instead of the adaptor pro-
teins. (B to D) Quantification of restored p110g and adaptor subunits on an
Odyssey infrared-detection system. The abundance of p110g is shown nor-
malized to that of p110g when coexpressed with p84. Data shown are the
mean ± SEM of n = 3 experiments. (B) Quantification of data from the left
panel of (A). (C) Quantification of data from the right panel of (A). (D) Quan-
tification of the abundance of GFP-p84 and GFP-p101 proteins normal-
ized to that of GFP-p84. Data shown are the mean ± SEM from n = 2
experiments. (E) Cellular localization of GFP-p84 and GFP-p101 in KO
BMMCs reconstituted with either fusion protein and p110g. Images are
deconvoluted. N, nucleus.
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attenuated the mobility of PtdIns(3,4,5)P3-containing speckles, but not the
initial endocytosis to a submembrane localization (fig. S6B and movies m8
and m9).
Disruption of cholesterol-rich domains affects the
signaling of p84:p110g, but not of p101-containing PI3Kg
PI3Kg complexes consisting of p101 were capable of driving a subset of
cellular responses even though PtdIns(3,4,5)P3 was endocytosed. The only
response not promoted by p101 was degranulation, which requires the
integration of signals derived from costimulation with IgE and antigen. Be-
cause cross-linked FceRI receptors accumulate and signal in cholesterol-
rich, plasma membrane microdomains called lipid rafts (43–45), we set
out to test the sensitivities of both types of PI3Kg complex to methyl-b-
cyclodextrin (MbCD), a compound that depletes cholesterol from mem-
branes. Tomonitor the process, we stained cells with fluorescently labeled
cholera toxin subunit b (CTb), a marker of lipid rafts. In untreated cells,
CTb showed a punctuate pattern, which was disrupted on exposure to
MbCD (Fig. 7A). Of note, pretreatmentwithMbCDselectively attenuated
adenosine signaling mediated by p84:p110g in WT BMMCs (Fig. 7A) or
by p84:p110g in reconstituted KO BMMCs (Fig. 7, B and C). In contrast,
p101:p110g–mediated or interleukin-3 (IL-3)–stimulated phosphoryl-
ation of Akt was unaffected by disruption of lipid rafts (Fig. 7, B and C).
The above data add to the evidence that suggests that the PI3Kg adaptors
p84 and p101 serve a nonredundant function and can specifically diverge
PI3Kg signals downstream of GPCRs. Altogether, our results are com-
patible with a model in which both p110g complexes integrate upstream
signals fromGPCRs and PTX-sensitive heterotrimericGproteins, but differ
in downstream processing toward a localized signal output.
Cells with endogenous p101 internalize PtdIns(3,4,5)P3
Having shown the nonredundant role of PI3Kg adaptor subunits in mast
cells inwhich p84 is the predominant adaptor protein, we investigated trans-
location of PHBtk-GFP in the J774 macrophage cell line, in which p101 is the
predominant PI3Kg adaptor protein (Fig. 1C and fig. S8C). It can therefore
Fig. 5. Adaptor-specific, spatio-
temporal differences in the lo-
calization of PtdIns(3,4,5)P3. KO
BMMCs were transfected with
plasmids encoding p110g (WT
or KR) with or without plasmids
encoding HA-p87 or HA-p101,
as well as PHBtk-GFP to monitor
PtdIns(3,4,5)P3 production. Twenty-
four hours after transfection, cells
were depleted of IL-3 and serum-
starved for 3 hours before stimula-
tion with 2 mM adenosine. (A) At
0 s (control) and120s (adenosine,
Ade) after stimulation with adeno-
sine, cells were fixed in 4% p-
formaldehyde and prepared for
microscopy. The localization of
PtdIns(3,4,5)P3 was visualized
with PHBtk-GFP. For adenosine-
stimulated cells containing p84:
p110g or p101:p110g complexes,
deconvoluted, high-resolution z
stacks can be found in movies m1
and m2, respectively. (B) p101:
p110g–driven internalization is spe-
cific to PtdIns(3,4,5)P3-binding PH
domains. KO BMMCswere recon-
stituted with p101:p110g and the
indicated fluorescently labeled lipid-
binding probes. Stimulation with
adenosine (2 mM) was stopped
after 15 and 120 s and the local-
izations of the lipid probes were
visualized. Only portions of cells
are shown. Left: PHBtk-GFP (Btk)
and PHPLCd-RFP (PLCd) were co-
expressed. Middle: Merged pic-
ture of PtdIns(3,4,5)P3-bound (green) and PtdIns(4,5)P2-bound (red) PH domains after 120 s of stimulation with adenosine. Right: Cells were also
transfected with either PHBtk-GFP (Btk) or a lipid-binding defective mutant PHBtk(R28C)-GFP (BtkR28C). z stacks were acquired, and images were sub-
sequently deconvoluted.
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be assumed that the major output of PI3Kg in these cells is derived from
p101:p110g complexes. J774 cells could be stimulated with either C5a or
C3a to phosphorylate Akt (fig. S8A). C5a and C3a signaling to Akt was
PI3Kg dependent, because the PI3Kg-specific inhibitor AS252424 efficiently
blocked phosphorylation of Akt, whereas TGX-221, which targets PI3Kb,
was ineffective at blocking phosphorylation of Akt (fig. S8A). In J774 cells
transfected with a plasmid encoding PHBtk-GFP, stimulation with C5a and
C3a led to the association of the PtdIns(3,4,5)P3 probe with the plasma
membrane at early time points (<15 s), but at >45 s, PHBtk-GFP was in-
ternalized, as had been observed in adenosine-stimulated KO BMMCs re-
constituted with p101:p110g complexes. Internalization of PtdIns(3,4,5)P3
thus occurs in cells with endogenous p101:p110g complexes and might
be a pathway alternative to that of the lipid phosphatases to remove
PtdIns(3,4,5)P3 from the plasma membrane (fig. S8B).
DISCUSSION
PI3Kg is the major PI3K isoform that operates downstream of GPCRs,
such as receptors for chemokines, N-formyl-Met-Leu-Phe, complement
fragments (16, 33, 46), and murine A3AR (26), in hematopoietic cells.
GPCRs mediate the activation of PI3Kg through the release of Gbg sub-
units from heterotrimeric G proteins (18, 21, 47). Biochemical and over-
Fig. 6. Time course of the localiza-
tion of PtdIns(3,4,5)P3 visualized
with PHBtk-GFP after stimulation
with adenosine. (A) Performed as
a population analysis: The local-
ization of the probe was differen-
tiated between membrane staining
(rim) and speckles. Quantification
ofn=3experimentswasperformed
blindly and the results are expressed
as a percentage of the total number
of transfected cells. (B) Selected
time points of live-cell imaging ex-
periments in adenosine-stimulated
KOBMMCs reconstitutedwith p110g
and either p84 or p101 (see also
moviesm3 andm4). (C) Quantifica-
tion of plasmamembrane–localized
PHBtk-GFP calculated from live-cell
imaging experiments. a.u., arbitrary
units, every fifth frame is marked
with a symbol. Cells were stimu-
lated with 5 mM adenosine. Data
shown are the mean ± SEM for
n = 6 experiments. Inset is an
image that illustrates the region
defined as plasma membrane–
localized PHBtk-GFP located be-
tween the outer circle and the
inner circle, for a sample of trans-
fected cells containing p84:p110g
(left) or p101:p110g (right) com-
plexes. (D) Selected time points
of live-cell imaging experiments
in KO BMMCs reconstituted with
p110g and either p84 or p101.
Cells were loaded overnight with
anti-DNP IgE (100 ng/ml), washed,
and stimulated with DNP-HSA
(5 ng/ml; Ag) and 5 mM adenosine
for the indicated times. Data shown
represent excerpts from movies
m5 and m6. (E) Quantification of
membrane-bound PtdIns(3,4,5)P3
in IgE+Ag+adenosine–stimulated cells. Data shown are the mean ± SEM of nine experiments for cells containing p84:p110g complexes, and of seven
experiments for cells containingp101:p110g complexes, andwereanalyzedas in (C). The lowconcentration of antigenusedheredidnot trigger translocation
of PHBtk-GFP in the absence of adenosine (see fig. S7).
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expression studies in nonhematopoietic cells have shown that p101 aug-
ments the translocation of PI3Kg (41) and the Gbg-dependent turnover
of PtdIns(4,5)P2 (18, 22), but the necessity for a PI3Kg adaptor protein
in physiological processes has remained disputed until recently (24).
Studies of the expression profiles of PI3Kg across multiple tissues show
that mRNAs encoding p110g, p84, and p101 are highly expressed in hema-
topoietic tissues.Whereas the abundance of p101mRNAwas high in tissues
and cells that contain lymphocytes [thymus, spleen, and peripheral blood
lymphocytes (PBLs)], we could not detect p84 mRNA in PBLs, and the
abundance of p84 protein was low in splenocytes. Both adaptor proteins
were found in neutrophils and monocytes or macrophages, whereas only
p84 was found in mast cells. Overall, p101:p110g complexes dominate
the lymphoid lineage, whereas p84 is found in myeloid cells with varying
penetrance.When p110gwas eliminated by gene targeting, p84 protein was
destabilized in differentiated cells. Similar reductions were observed for
p101 in neutrophils isolated from BM of p110g null mice (19). Because
catalytically inactive p110g (KR) was sufficient to maintain p84 protein
in BMMCs, the lipid kinase activity of p110g is apparently not required
for the stabilization of adaptor proteins.
In mast cells lacking functional p110g, adenosinewas incapable of activat-
ing Akt or of triggering the translocation of a probe of PtdIns(3,4,5)P3
(PHBtk-GFP) to the plasmamembrane. In this setting, the combination of adap-
tor protein with active p110g was required to restore the responsiveness of KO
BMMCs to adenosine. These results show conclusively that p110gmust inter-
act with adaptor protein to generate PtdIns(3,4,5)P3 downstream of GPCRs.
To date, functional comparisons of p101 and p84 in cells that normally ex-
press p110g have not been performed; in vitro studies have, however, convinc-
ingly shown that p101 and p84 activate p110g by the same basic mechanism
(19, 22, 23). In mast cells, PI3Kg controls physiological responses in vitro and
in vivo (26), and both the loss of adaptor protein in p110g null cells and the
inability of monomeric p110g to rescue GPCR signaling exclude the interfer-
ence of cross-compensatory effects of the PI3Kg adaptors in this model.
With the above biochemical studies in mind, it was a surprise that the
coexpression of p101 with p110g did not reconstitute adenosine-dependent
degranulation in IgE- and antigen-primed KOBMMCs. The analysis of the
abundance of p110g, p84, and p101 proteins, as well as of their cellular lo-
calization, suggested that both types of PI3Kg complexes were in a position
to signal, but that only p84:p110g did so successfully. In contrast to de-
granulation, both p84 and p101 could be combined with p110g to reconsti-
tute adenosine-induced cell motility of KO BMMCs, whereas p110g alone
was insufficient. It is thus evident that GPCRs can link to the chemotactic
machinery through both adaptor isoforms. Important roles for p110g (16, 48)
and p101 (24) in the chemotaxis of neutrophils have been described previ-
ously. That migration ofmast cellswas proportional to the amount of PI3Kg
complex present strongly suggests that the loss of migratory capacity in
p101 null neutrophils (24) is due to a reduction in the extent of PI3Kg
signaling rather than to an exclusive link between p101 and cell motility.
The selective promotion of degranulation by p84 suggests that the two
adaptor proteins selectively redirect PI3Kg downstream signaling into
separate response patterns. Such selectivity is unlikely achieved through
the deployment or interference of different adenosine receptor types, be-
cause an A3AR-specific ligand (IB-MECA) and ligands that stimulate all
four adenosine receptors (adenosine, NECA) caused phosphorylation of
Akt to an equivalent extent in conjunction with both types of PI3Kg
complexes. The observation that PtdIns(3,4,5)P3 remained at the plasma
membrane when it originated from the activity of p84:p110g, but was en-
docytosed when its source was the p101:p110g complex, strongly indicates
that the two PI3K complexes produce two distinct PtdIns(3,4,5)P3 pools at
the plasma membrane. That p84:p110g could signal in lipid microdomains
was also supported by its sensitivity to disruption of cholesterol-rich do-
mains by MbCD, whereas adenosine-mediated signaling through p101:
p110g to activation of Akt resisted cholesterol depletion. Cross-linking of
FceRI concentrates the activated receptor in lipid rafts (43, 44), and one
could thus speculate that p84:p110g locally enhances the abundance of
PtdIns(3,4,5)P3 in the vicinity of clustered FceRI receptors and the asso-
ciated protein tyrosine kinase cascade. This would imply that degranulation
is under the control of a system that integrates the status of the protein tyro-
sine kinase cascade output with local concentrations of PtdIns(3,4,5)P3 and
relays downstream signals only when the two inputs occur coincidently.
Moreover, for efficient degranulation to occur, high threshold concentra-
tions of PtdIns(3,4,5)P3 have to be reached (26), which could be achieved
through the selective targeting of p84:p110g complexes. Such a localized
but high-amplitude signal emerging from PI3Kg could thus overrun the
gatekeeper function of the 5′-lipid phosphatase SHIP (32, 49), which con-
tinuously attenuates the low-level signal of PtdIns(3,4,5)P3 produced by
p85-associated class IA PI3K under conditions of low concentrations of
antigen. If PtdIns(3,4,5)P3 is localized outside of these areas, as assumed
here for p101:p110g–derived PtdIns(3,4,5)P3, it has a different route of deg-
radation and can be endocytosed.
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Fig. 7. The function of p84:p110g, but not p101:p110g, is sensitive to dis-
ruption of lipid rafts. (A) Left: WT BMMCs were starved in IL-3–free medium
containing 2% FCS for 3 hours with or without 30 min of pretreatment with
5 mM MbCD at 37°C, and then stimulated with 2 mM adenosine or 10 nM
IB-MECA for 2 min. Phosphorylation of Akt was determined by Western
blotting analysis with an anti-pSer473. Right: Precooled WT BMMCs were
incubated at 4°C for 30min with Alexa555-conjugated choleratoxin b-subunit
(CTb) with or without MbCD. Deconvoluted images were acquired after fixa-
tion and sedimentation of cells. (B) p110g and GFP fusions of p84 or p101
were expressed in KO BMMCs as indicated (indicators refer to Ade and
IL-3 stimulations). Cells were starved as in (A) before phosphorylation of
Akt was detected after stimulation with adenosine (Ade) or IL-3 (20 ng/ml
for 2 min). One representative experiment of four is shown. (C) Quantifi-
cation of adenosine-triggered phosphorylation of Akt fromexperiments as
shown in (B). Data shown are the mean ± SEM of n = 4 experiments.
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Binding of p101 to p110g has been reported to reduce the basal catalytic
activity of PI3Kg (50), and the adaptor proteins can thus be considered as
inhibitors and stabilizers of cytosolic PI3Kg complexes. Here, we showed
that these complexes seem to be fully activated only in the correct context
and cellular localization. Due to technical limitations, it cannot be con-
cluded presently whether the main action of the adaptors is to restrict access
of PI3Kg to certain sites and responses or to direct PI3Kg to specific cellular
docking sites. The whole process shows similarity to the activation of class
IA PI3Ks, in which p85-like regulators block the activity of the catalytic
p110 subunit as long as they do not interact with phosphorylated tyrosines
on growth factor receptors (9, 51).
The processes in mast cells presented here illustrate that the p84:p110g
and p101:p110g complexes serve nonredundant but also overlapping func-
tions. In allergy, only the p84:p110g complex cooperates with IgE- and
antigen-dependent signaling in mast cell activation. Our elucidation of
adaptor-specific PI3Kg signaling has a potential therapeutic value, because
loss of PI3Kg function not only attenuates chronic inflammation and allergy,
but also modulates cardiovascular parameters (34, 52). Although inhibition
of PI3Kg has been regarded as cardioprotective, such convolution might
complicate chronic pharmaceutical targeting of PI3Kg in inflammatory dis-
eases. Based on our results, tissue selective targeting of PI3Kg bymodulation
of the function of adaptor molecules might become possible in the future.
MATERIALS AND METHODS
Cloning of p84, plasmids, and antisera
Murine p84 complementary DNA (cDNA) was obtained from murine 32D
cells by reverse transcription PCR (RT-PCR) (for details and primers see
Supplementary Materials). Human full-length p84 cDNA was amplified
from neutrophils with Pwo polymerase (Roche Diagnostics, Mannheim,
Germany) (accession data for p84:Musmusculus, AY753194;Homo sapiens,
AY753192; UniProt: PI3R6_Human; GenBank:PIK3R6). The p101 coding
sequence (18) and p84 were transferred to pcDNA3, pcDNA-HA, and
pEGFP vectors for expression. Plasmids for the expression of p110g were
previously described (53). The PH domain of Btk fused to GFP (pEGFP-
PHBtk, donated by T. Balla) was used as a sensor of PtdIns(3,4,5)P3. The
cDNAof the PH domain of PLCdwas subcloned into pTagRFP-N1. Antisera
against murine p84 fragment (Met1 to Glu162) were raised in rabbits and
goats and antisera against human p101 fragment (Pro575 to Pro880) were
raised in rabbits. Protein fragments were expressed as (His)6 fusion proteins
from bacterial pQE vectors (Qiagen, Hilden) and purified on Ni2+-NTA
beads (Qiagen) according to the manufacturer’s instructions.
Cell culture, isolation, and differentiation
To isolate, derive, and culture BMMCs from C57BL/6J mice and mice
without functional PI3Kg [KO1 (16), KO2 (33), and KR (34)], cells from
fresh BMwere resuspended in complete Iscove’s modified Dulbecco’s me-
dium (IMDM) with 10% heat-inactivated fetal calf serum (HIFCS), 2 mM
L-glutamine (Gln), 1% penicillin-streptomycin solution (PEST), 50 mM
b-mercaptoethanol (b-ME), and recombinantmurine IL-3 (2ng/ml; Peprotech,
Rocky Hill, NJ) and cultured at 37°C and 5% CO2 for 4 days. Subsequently,
BMMCswere dilutedweekly to 0.5× 106 cells/mlwith amixture of 80% fresh,
complete IMDMand20% recycledmedium,with IL-3 added every secondday
(26).Nonadherent cellsweremonitored for thepresenceofFceRI[withaphyco-
erythrin (PE)-conjugated hamster antibody to mouse FceRIa; clone MAR-1,
eBioscience, San Diego, CA] and c-kit (rat IgG2B anti-mouse CD117/c-kit;
clone 3c1, ImmunoKontact, Bioggo, Switzerland) by fluorescence-activated cell
sorting (FACS) analysis. BM-derivedmacrophageswere differentiated in bacte-
rial dishes (Greiner bio-one,Kremsmünster,Austria) at 1×106cells/ml inRPMI
1640 (Sigma) supplemented with HIFCS/Gln/PEST/b-ME and 20% L-929
cell-conditioned medium. Nonadherent cells were collected 5 days later
for experiments (54). Neutrophils and splenocytes were isolated as de-
scribed (16). The murine macrophage cell line J774 and the rat mast cell
line RBL2H3 were cultured in complete DMEM (HIFCS, Gln, PEST),
the human mast cell line HMC-1 was cultured in IMDM containing
HIFCS/Gln/PEST/ b-ME, and the human monocytic cell line THP-1 was
cultured in complete RPMI 1640 (HIFCS/Gln/PEST/b-ME).
Transfections
BMMCs were transfected with the Amaxa Nucleofector according to the
manufacturer’s protocol (Amaxa). BMMCs (7 × 106 to 10 × 106) were re-
suspended in 100 ml of nucleofection solution T (Amaxa) to which was
added 10 to 15 mg of plasmid DNA (in 15 ml of 10 mM tris and 1 mM
EDTA, pH 8.0). Immediately after electroporation, cells were cultured in
5 ml of complete IMDM at 37°C and 5%CO2 for 5 hours. After a medium
change with complete IMDM, transfected cell populations were cultured
for 24 hours, after which they were sensitized with mouse anti-DNP IgE
(100 ng/ml; mAB SPE-7, Sigma-Aldrich) for degranulation experiments.
Stimulations occurred 24 hours after transfection.
Stimulation of BMMCs with adenosine
Twenty-one hours after transfection, BMMCswere collected by centrifuga-
tion (160g for 3 min), washed, and starved in IL-3–free medium containing
2% fetal calf serum (FCS) for 3 hours (0.5 × 106 to 1 × 106 cells/ml), and
were then stimulated with 2 mM adenosine for the indicated time (at 37°C,
5%CO2). ForWestern blotting analysis, stimulation of cells was stopped on
ice, the cells were collected by centrifugation (16,000g for 1 min at 4°C),
washed in 1× phosphate-buffered saline (PBS) and lysed at 1 × 107 cells/ml
in 2× sample buffer [125 mM Tris-HCl (pH 6.8), 4% SDS, 10% b-ME,
20%glycerol, bromphenol blue]. Proteinswere denatured at 95°C for 7min,
and then subjected to SDS–polyacrylamide gel electrophoresis (PAGE) and
Western blotting. For microscopy experiments, stimulation was stopped by
the addition of an equal volume of ice-cold 10% p-formaldehyde in PBS.
Wortmannin (500 nM), PTX (100 ng/ml, Sigma), MbCD (5 mM, Sigma),
AS252424 (1 mM,Merck-Serono, Geneva), and TGX-221 (1 mM, Cayman
Pharma,Neratovice)were added to cells 30min before stimulation,whereas
nocodazole (1 mM, Sigma) was added 3 hours before stimulation.
Western blotting analysis
Proteins were separated by SDS-PAGE and transferred byWestern blotting
to Immobilon PVDF membranes (Millipore). Mouse monoclonal antibody
(mAb) to p110g (clone H1, Alexis), rabbit mAbs to pSer473-PKB/Akt and
to pThr308-PKB/Akt (both from Cell Signaling Technology, Danvers, MA),
mouse mAbs to GFP (Roche Diagnostics) and to HA (HA.11, Babco), and
the antisera mentioned above were used to detect proteins in the PI3Kg
pathway. Mouse mAb to vinculin was produced from the hybridoma clone
VII-F9 (a gift of V. Kotelianski). Secondary antibodies such as horseradish
peroxidase (HRP)–conjugated rabbit antibody to mouse IgG and goat anti-
body to rabbit IgG (Sigma, St. Louis, MO) were visualized by enhanced
chemiluminescence (Millipore).
Quantitative Western blotting
After SDS-PAGE, proteins were transferred to Immobilon FL membranes
(Millipore) and blocked with Odyssey blocking buffer (LI-COR Bio-
sciences, NE), followed by incubation with primary antibodies in the same
buffer.Matched secondary antibodieswere goat anti-rabbit IgG-IRDye 800
(Rockland, Gilbertsville, PA) and goat anti-mouse IgG-Alexa Fluor 680
(Molecular Probes, Eugene, OR). Membrane-bound fluorescence was
detected on the Odyssey Infrared Imaging System (LI-COR Biosciences).
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Isolation of total RNA, RT-PCR, and qPCR
RNA was isolated from TRIzol-lysed tissues as described by Invitrogen.
cDNAwas generatedwith 2 mgof total RNAwithM-MLV reverse transcrip-
tase (RT buffer and protocol, Invitrogen) and RNAsin (Promega) and stored
at –80°C until ready for use. An ABPrism 7000 (Applied Biosystems, Foster
City, CA) and SYBR GREEN PCR Master Mix (Applied Biosystems) was
used for qPCR analysis of p84, p110g, and p101 mRNAs. GAPDH mRNA
served as an internal standard to generate calibration curves in which the cycle
numbers at the crossing point (CP) were given by
CP ¼ b þ a logð½cDNA%Þ
where b was 15.136 and a was –3.2877. Variations in total cDNA content
were compensated for with the GAPDH CP values for a given tissue:
CPtissue corrected ¼ CPtissue − ðCPGAPDH tissue − CPGAPDH external standardÞ
The relative copy number (Rc#) was then calculated as:
Rc# ¼ 10ð4:872 − 0:30354'CPsample correctedÞ
The efficiency E of PCR was 2.01 or 101%. The above calculation was
cross-checked with calibration curves established with linearized plasmids
for p110g and p84. Deviations from theGAPDH-based calculationswere in
the range of 1.1- to 1.3-fold. cDNA of rat or human origin was amplified by
conventional PCR by Taq Polymerase (New England Biolabs, Ipswich,
MA) in aT3Thermocycler (Biometra, Göttingen,Germany). PCRproducts
were separated in 2% agarose gels and visualized with ethidium bromide in
a Geneflash imaging system for gel documentation (Syngene, Cambridge,
UK). Primers are listed in the Supplementary Materials.
Fluorescence microscopy
After stimulation, cells were fixed by the addition of an equal volume of
ice-cold 10% p-formaldehyde in PBS. For staining of F-actin, cells were
permeabilized in PBS, 1% BSA, 0.1% Triton X-100 and incubated with
rhodamine-phalloidin (Molecular Probes) (55). Alexa555-conjugated chol-
era toxin staining (Invitrogen) was performed according to the supplier’s
instructions. Subsequently, cells were spun onto microscopy slides (at 100g)
and mounted in Mowiol (Plüss-Stauffer). Images were acquired on an
Axiovert 200 M microscope (Zeiss) fitted with a Plan-Achromat 100×/1.4
oil objective and an Orca ER II camera (Hamamatsu) with OpenLab
software (Improvision). High-resolution images were generated from 0.2 mM
image z stacks, which were then deconvoluted with Volocity 4.0 software.
Live-cell microscopy
Transfected cells (0.5 × 106 to 1.0 × 106/ml, in 0.5 ml) were plated in
IMDM containing 2% HIFCS, L-Gln, PEST, 50 mM b-ME on poly-Lys–
coated (Sigma-Aldrich) coverslips for 3 hours in live-microscopy chambers
(Life Imaging Services, Basel, Switzerland). Live imaging was performed
on a Zeiss Axiovert 35 microscope (with a 100× plan-Neofluar 1.30/oil ob-
jective), equipped with Micromax heating (to 37°C) and a Princeton
Instruments camera system (Trenton, NJ), or on an Axiovert 200 Mmicro-
scope (Zeiss) fitted with a Plan-Achromat 63×/1.4 oil objective and anOrca
ER II camera (Hamamatsu), equipped with a microscope temperature con-
trol system (Life Imaging Services). For stimulations, 0.5 ml of modified
Tyrode’s buffer (137mMNaCl, 2.7mMKCl, 1.8mMCaCl2, 1mMMgCl2,
5.6 mM glucose, 20 mM Hepes, pH 7.4) containing 5 mM adenosine or
5 mM adenosine and DNP-HSA [10 ng/ml; where cells were presensi-
tized with anti-DNP IgE (100 ng/ml) overnight] were added carefully to
avoid displacement of cells. To monitor the translocation of GFP-PHBtk,
images were acquired every 2 s over the indicated time with either Meta-
morph 4.01 software (Axiovert 35 microscope) or OpenLab software
(Axiovert 200 M microscope). Movies were assembled with Volocity 4.0
software. Plasmamembrane–localized PHBtk-GFPwas determined bymea-
suring the integrated fluorescent intensities of two circular regions of interest
(ROIs) with ImageJ software. The first ROI (ROIout) included the whole cell,
whereas the secondROI (ROIin),which had a reduced radius,was set such that
plasmamembrane staining was excluded. The sizes and locations of the ROIs
were constant in all frames. Plasma membrane–localized PHBtk-GFP was
calculated as (ROIout – ROIin)/ROIout for each acquired frame. Division
by ROIout in this formula corrects for sample bleaching, because values
(in arbitrary units) of all frames were normalized to the first (unstimulated)
frame and plotted over time. Intensity surface plots were calculated with
ImageJ software.
Single cell–based degranulation assay
BMMCs were incubated in complete IMDM with mouse anti-DNP IgE
(100 ng/ml) overnight and then stimulated with DNP-HSA (1 ng/ml;
Sigma-Aldrich) with or without 2 mM adenosine for 20 min at 37°C.
Cells were then washed in PBS, transferred to annexin V–binding buffer
(10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) and stained with
Cy5-conjugated annexin V (BD Biosciences) for 15 min on ice. FACS
analysis was performed on a FACSCalibur with CellQuest software (BD
Biosciences). FACSeventswere gated according to cell size, GFP-positive
and GFP-negative cells, and annexin V–Cy5 staining as a measure of de-
granulation [see Demo et al. (37) and Martin et al. (56) for assay valida-
tion]. It must be noted that the correlation between annexin V staining and
degranulation required validation for each of the stimuli and conditions
used (57). For experiments with transfected KO BMMCs, degranulation
was calculated for GFP-positive and GFP-negative cells separately, as GFP-
negative cells define basal degranulation of KO BMMCs. For reconstituted
cells, adenosine-induced degranulation was expressed as the difference in
the percentage of total cells in M2 (annexin V–positive) after stimulation
with IgE and antigen either with (IgE+Ag+Ade) or without (IgE+Ag) aden-
osine (DDegranulation, % of annexin V staining). The borders of the M2
gate were set to discriminate the synergistic action of adenosine from stim-
ulation with IgE and antigen and from apoptotic cells after nucleofection,
which were also stained with propidium iodide (PI). See fig. S5 for more
information.
Release of b-hexosaminidase
The release of histamine-containing granuleswas quantified by the determi-
nation of b-hexosaminidase in the cell supernatants with a method slightly
modified from that of Laffargue et. al. (26). BMMCs were incubated with
anti-DNP IgE (100 ng/ml) overnight and resuspended in modified Tyrode’s
buffer at 0.5 × 106 to 1.0× 106 cells/ml at 37°C and 5%CO2.Degranulation
was induced with DNP-HSA (1 ng/ml) with or without 2 mMadenosine for
20min at 37°C and 5%CO2. The reactionwas stopped and b-hexosaminidase
activity was measured with p-nitrophenyl-N-acetyl-b-D-glucosaminide
(Sigma). Results are given as the percentage of total Triton X-100–releasable
b-hexosaminidase.
Cell migration assays
Migration of transfected BMMCs was assayed in 24-well Transwell Sup-
ports (Corning) with 5.0-mm pore polycarbonate membranes for 6 hours.
Before the experiment, Transwell membranes were coated with fibronectin
(1 mg/ml) in PBS at 4°C overnight, blockedwith 4%BSA in PBS for 1 hour
at 37°C, and equilibrated in migration medium (IMDM supplemented with
L-Gln, PEST, 1%BSA, 50 µM b-ME, and 20mMHepes, pH 7.4) for 30 min
at 37°C. Transfected BMMCs were washed twice in migration medium.
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Cell suspensions (0.5× 106 cells in 200 ml) were applied to the upper compart-
ment of the Transwell inserts already containing migration medium supple-
mented with or without 1 mM adenosine in the lower well. Fluorescent cells
that reached the lower well were quantified with the fluorescent microscope.
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Fig. S1. Tissue distribution of p110g and its adaptor subunits (additional tissues).
Fig. S2. p84 is stabilized by p110g in mast cells.
Fig. S3. Restoration of p110g does not affect the abundance of endogenous p84 protein.
Fig. S4. Adenosine receptor ligands and PI3Kg signaling leads to phosphorylation of Akt.
Fig. S5. Illustration of the gating procedures used in single-cell degranulation assays.
Fig. S6. p101:p110g–dependent endocytosis of PtdIns(3,4,5)P3 is associated with micro-
tubules.
Fig. S7. Quantification of PHBtk-GFP probes at the plasma membrane after low-level stim-
ulation of BMMCs with IgE and antigen.
Fig. S8. Activation of Akt and localization of PtdIns(3,4,5)P3 in J774 cells.
Table S1. Sequences of primers used for cloning, antigen production, qPCR, and RT-PCR.
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Supplementary Text 
 
Quantification of p84 and p110γ protein in WT and KO BMMCs and bone marrow 
We observed a dramatic loss in p84 protein in hematopoitetic cells derived from p110γ null (KO) mice. To 
determine the amount of residual p84 protein in these cells, we quantified the abundance of p84 and p110γ 
protein on an infrared fluorescence imaging system (Odyssey, LI-COR). Quantification revealed a residual 
amount of p84 in BMMCs derived from two p110γ null mouse strains generated by different gene targeting 
strategies [fig. S2; for KO1 see (Hirsch et al., 2000), for KO2 see (Sasaki et al., 2000)] that was <20% of that in 
WT BMMCs. The abundance of p84 protein in bone marrow isolated from these mice was identical to that of 
bone marrow from WT mice. 
 
Exogenous p110γ does not alter the abundance of endogenous p84 protein in KO BMMCs 
Because p110γ stabilizes p84 in differentiated hematopoietic cells (Fig. 1D), one could speculate that 
endogenous p84 protein is stabilized by exogenous p110γ in KO BMMCs. Hence, we determined the 
abundance of endogenous p84 protein in KO BMMCs 24 hours after transfection with a plasmid encoding 
p110γ (time point of stimulation). Neither the expression of p110γ alone, nor of p110γ in combination with its 
adaptor proteins yielded significant alterations to the reduced abundance of endogenous p84 protein, as 
compared to mock-transfected KO BMMCs (fig. S3). Thus, possible confounding effects of increased p84 
abundance on cellular functions can be excluded, which is further supported by the inability of exogenous 
p110γ to restore adenosine-dependent signaling in transfected KO BMMCs. 
 
 
Materials and Methods 
 
Culture, transfection, and stimulation of J774 cells 
The murine macrophage cell line J774 (kindly provided by J. Pieters, Basel) was cultured in complete DMEM 
(HIFCS, Gln, PEST). For passaging, cells were washed with complete DMEM, detached with a cell lifter 
(Corning), and seeded on fresh cell culture dishes (at a 1:5 dilution). For nucleofection, J774 cells (1x106) 
were resuspended in 100 µl of nucleofection solution V (Amaxa), to which was added 1 to 2 µg of the 
appropriate plasmid DNA. After electroporation, cells were seeded in complete DMEM onto 12-mm coverslips, 
after which cell attachment medium was changed to eliminate the transfection solution. For stimulation, J774 
cells were serum-starved in DMEM (Gln, PEST) for 3 hours. Wortmannin (500 nM), AS252424 (1 µM), or 
TGX-221 (1 µM) were added 30 minutes prior to stimulation with 10 nM C5a (R&D systems, Minneapolis) or 
50 nM C3a (a kind gift of C. Dahinden, Bern). For fluorescence microscopy, stimulation was stopped by the 
addition of an equal volume of ice-cold 10% p-formaldehyde in PBS. For Western blotting analysis, cells were 
washed with ice-cold PBS on ice, followed by lysis in 20 mM Tris-HCl, 138 mM NaCl, 2.7 mM KCl, 5% 
glycerol, 1 mM CaCl2, 1 mM MgCl2, 1% NP-40, 20 µM Leupeptin, 18 µM pepstatin, 1 mM sodium-ortho-
vanadate, and 2 mM NaF. Equal amounts of protein (measured with BioRad Protein assay) were denatured 
and subjected to SDS-PAGE and Western blotting. 
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Fig. S1. Tissue distribution of p110γ and its adaptor subunits (additional tissues). Relative mRNA copy 
numbers for p110γ and adapters in the indicated mouse tissues, BMMCs, and the MC/9 mouse mast cell 
line  were assessed by qPCR (n>3, mean ± SEM). Values were normalized to the copy numbers of p84 
mRNA in bone marrow. 
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Fig. S2. p84 is stabilized by p110γ in mast cells. (A) p110γ and p84 proteins were separated on SDS-PAGE 
and detected with fluorescent secondary antibodies. (B) Quantification of signals was performed on an 
Odyssey Infrared Imaging device in samples from individual BMMC populations and total bone marrow 
(BM). Tissue was isolated and differentiated from WT mice and from two independent p110γ null mouse 
strains [KO1 (Hirsch et al., 2000) and KO2 (Sasaki et al., 2000)]. Values are normalized to those of WT 
samples (n = 2, mean ± SEM). (C) p84 mRNA was quantified (as described for fig. S1) in BMMCs and BM 
isolated from mice with the indicated genotypes. 
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Fig. S3. Restoration of p110γ does not affect the abundance of endogenous p84 protein. Top Functional 
p110γ (WT) and GFP-tagged p84 or p101 were expressed in KO BMMCs (as indicated), whereas WT 
BMMCs were mock transfected. Twenty-four hours post-nucleofection, total lysates were subjected to SDS-
PAGE and Western blotting analysis with the indicated antibodies (right labels). Bottom Quantification of the 
abundance of endogenous p84 protein arranged as in upper panel, depicted as percentage relative to the 
abundance of endogenous p84 in WT cells (n = 3, mean ± SEM). Statistics among KO BMMCs are not 
significantly different. 
 
 
 
Fig. S4. Adenosine receptor ligands and PI3Kγ signaling lead to the phosphorylation of Akt. KO BMMCs 
were transfected with plasmids encoding functional p110γ (WT) and GFP-tagged p84 or p101. After 
starvation in IL-3-free medium containing 2% FCS for 3 hours (24 hours post-nucleofection), phosphorylation 
of Akt was determined with anti-pSer473 antibodies. (A) Stimulation of BMMCs occurred with 2 µM 
adenosine for 3 minutes with or without pertussis toxin pretreatment (PTX, 100 ng/ml, for 30 min.). (B) 
BMMCs were stimulated as indicated with either adenosine (A, 2 µM), a stable, broad spectrum adenosine 
receptor agonist (N, NECA, 1 µM), or an A3AR-specific agonist (I, IB-MECA, 10 nM) for 3 minutes before 
the extent of phosphorylation of Akt was detected as described earlier. 
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Fig. S5. Illustration of the gating procedures used in single-cell degranulation assays. KO BMMCs were 
transfected with the indicated expression plasmids for GFP, GFP-p84, and p110γ, and later stimulated with 
IgE+Ag or IgE+Ag+adenosine as described in the legend for Fig. 3. (A) GFP+ cells were selected as shown, 
and monitored for binding of Cy5-conjugated Annexin V. The M2 region was defined to include annexin V+ 
cells, but to exclude dead cells (see B). Histograms obtained after stimulation of cells with 
IgE+Ag+adenosine or with IgE+Ag were subtracted from each other to display the adenosine-dependent 
part of degranulation response, which is given by [Events(3) – Events(2)]. (B) To avoid the false positive 
detection of dead cells in the annexin V-Cy5 channel, region M2 was limited to the right side so as to 
exclude cells staining positive for propidium iodide (PI). 
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Fig. S6. p101:p110γ-dependent endocytosis of PtdIns(3,4,5)P3 is associated with microtubules. KO BMMCs 
were reconstituted with p101:p110γ and PHBTK-GFP to monitor the production of PtdIns(3,4,5)P3. One day 
after nucleofection, cells were IL-3-starved for 3 hours prior to stimulation with 5 µM adenosine (t = 0). (A) 
Top left Selected time points of live-cell imaging experiments in KO BMMCs reconstituted with p101:p110γ 
(taken from movie m4) are aligned with plots of the surface intensity of GFP-PHBtk. (Bottom left; see also 
movies m4 and m7). Top right The trajectory of a cytosolic PtdIns(3,4,5)P3-GFP-PHBtk speckle is indicated. 
Arrows point to a motile speckle in a KO BMMC reconstituted with p101:p110γ. (B) Selected time points of 
live-cell imaging experiments (top) in a KO BMMC reconstituted with p101:p110γ after pretreatment with 
nocodazole (1 µM for 3 hours; see movies m8 and m9). Bottom Intensity surface plots as in (A). 
 
 
 
Fig. S7. Quantification of PHBtk-GFP probes at the plasma membrane after low-level stimulation of BMMCs 
with IgE and antigen. Cells were loaded with IgE overnight and stimulated with 5 ng/ml DNP-HSA (Ag) only. 
Analysis and conditions as described in the legend for Fig. 6 (n=>8, mean ± SEM). 
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Fig. S8.Activation of Akt and localization of PtdIns(3,4,5)P3 in J774 cells. (A) J774 cells were starved in 
serum-free DMEM for 3 hours and stimulated with 10 nM C5a (left) or 50 nM C3a (right) for 3 minutes, after 
a 30-minute pretreatment with or without wortmannin (Wm, 500 nM), AS252424 (AS, 1 µM) or TGX-221 
(Tgx, 1 µM). Total cell lysates were subjected to SDS-PAGE followed by Western blotting. Phosphorylation 
of Akt was determined with an anti-pSer473 antibody. (B) J774 cells were transfected with a plasmid 
encoding PHBTK-GFP and one day later were stimulated with either 50 nM C3a (top) or 10 nM C5a (bottom). 
Cells were fixed in 4% p-formaldehyde after stimulation at the indicated times and mounted for analysis by 
fluorescence microscopy. (C) Transcripts for p84, p101, p110γ and GAPDH (internal standard) were 
amplified in J774 cells by RT-PCR with 3 different concentrations of mRNA input (a.u., arbitrary units). 
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Movie descriptions (movies can be found on the provided CD-ROM) 
 
Movie m1 (m1.p84_z_stack) 
A stack of deconvoluted images of a KO BMMC reconstituted with WT p110γ and HA-p84 was taken 2 
minutes after stimulation with 2 µM adenosine, and runs through adjacent focal planes to visualize the 
distribution of PHBTK-GFP (green) and subcortical F-actin stained with rhodamine-phalloidin (red). 
 
Movie m2 (m2.p101_z_stack) 
KO BMMCs were complemented with WT p110γ and HA-p101. Subsequently experiments were performed 
exactly as for movie m1. 
 
Movie m3 (m3.p84_ade.mov) 
Time-lapse video microscopy was used to visualize PtdIns(3,4,5)P3 in KO BMMCs reconstituted with p84 and 
p110γ. Images were acquired immediately after stimulation with adenosine over 360 frames (1 frame / 2 s). 
The movie runs at 15 frames / s. 
 
Movie m4 (m4.p101_ade.mov) 
Live-cell video microscopy for visualization of PtdIns(3,4,5)P3 with PHBTK-GFP in KO BMMCs reconstituted 
with p101 and p110γ. Images were acquired immediately after stimulation with adenosine over 360 frames (1 
frame/ 2 s). The movie runs at 15 frames / s. 
 
Movie m5 (m5.p84_DNP_ade.mov) 
Live-cell video microscopy for visualization of PtdIns(3,4,5)P3 with PHBTK-GFP in KO BMMC reconstituted with 
p84 and p110γ. Cells were sensitized overnight with 100 ng/ml anti-DNP IgE. Images were acquired 
immediately after stimulation with DNP-HSA + adenosine over 400 frames (1 frame/ 2 s). The movie runs at 
15 frames / s. 
 
Movie m6 (m6.p101_DNP_ade.mov) 
Live-cell video microscopy for visualization of PtdIns(3,4,5)P3 with PHBTK-GFP in KO BMMC complemented 
with p101 and p110γ. Cells were sensitized overnight with 100 ng/ml anti-DNP IgE. Images were acquired 
immediately after DNP-HSA and adenosine were added (1 frame/ 2 s; 400 frames). The movie runs at 15 
frames / s. 
 
Movie m7 (m7.p101_ade_SIP.mov) 
Surface intensity plots (SIPs) of the cells monitored in movie m4. Intensity of GFP-PHBtk is shown. The 
intensity scale matches the one in fig. S5. 
 
Movie m8 (m8.p101_ade_NOC.mov) 
Live-cell video microscopy for visualization of PtdIns(3,4,5)P3 with PHBTK-GFP in KO BMMC reconstituted with 
p101 and p110γ. Cells were treated with the microtubule disruptor nocodazole (1 µM for 3h) prior to 
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stimulation with adenosine. Images were acquired immediately after adenosine stimulation over 360 frames (1 
frame/ 2 s). The movie runs at 15 frames / s. 
 
Movie m9 (m9.p101_ade_NOC_SIP.mov) 
Surface intensity plots of the cells monitored in movie m8. Intensity of GFP-PHBtk is shown. Intensity scale 
used is the same as that in fig. S5. 
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Table S1. Sequences of primers used for cloning, antigen production, qPCR and RT-PCR. 
Gene* Accession-
No. 
Primer sequence 5’ to 3’ $ Usage % 
Mm_GAPDH NM_0010019
78 
F: CTGCACCACCAACTGCTTAG 
R: AGATCCAC GACGGACACATT 
qPCR, 
RT-PCR 
Mm_p84 AY753194 F: ATAGAGCAGGTGGCTAGCGA 
R: CGGAGGAAGAGTACCAGTTC 
qPCR 
Mm_p101 NM_177320 F: AAGCCCTGGGAAACTCCACA 
R: TCAGCGCAATGCCTGTCCAT 
qPCR 
Mm_ p110γ NM_020272 F: CCCTGGTGATCGAGAAATGC 
R: AGGCACAGGTCCAGAGATTC 
qPCR 
F: ATAGAGCAGGTGGCTAGCGA 
R: TGCTTTCATACCATGGGTCGACTC 
RT-PCR Mm_p84 AY753194 
F: TCGGGATCCAAGATGGAGAGCTCAGATGTGGAGCTG 
R: GAGGGTACCTGCCTCAGGGTCCACGAACAGAAACAC 
His6 -antigen 
Mm_p101 NM_177320 F: TACAGATTATTTACAGCAAGGGAGCC 
R: ACACTTCACACCTGACCACACTC 
RT-PCR 
Mm_ p110γ NM_020272 F: CCAGCTGGTACAGGCTGTGAAATT 
R: TGCATTTCTCGATCACCAGGGTAC 
RT-PCR 
Hs_GAPDH NM_002046 F: CTGCACCACCAACTGCTTAG 
R: AGGTCCACCACTGACACGTT 
RT-PCR 
F: CAGACACCAGAGACCTGCATGC 
R: CCTCCAAGTCAGCACTGAGGC 
RT-PCR Hs_p84 AY753192 
F: CGACTAAGCTTCCATGGAGAGCTCAGATGTGGAGCTG 
R: CCATGCGGCCGCTCACTGGACAATACCAGAGAATGTG 
Cloning 
Hs_p101 NM_014308 F: CTTCATCACTGGGGAGAAGACG 
R: GAGACCTCACATCTGACTACACTC 
RT-PCR 
Hs_ p110γ? NM_002649 F: GTGATGATCTGCGCCAAGACATG 
R: GGAAGTCAGGGGTTAGCACAAATGG 
RT-PCR 
Rn_GAPDH Not available F: CTGCACCACCAACTGCTTAG 
R: CCTGCTTCACCACCTTCTTG 
RT-PCR 
Rn_p84 Not available F: CTGTCACACAGGTGCTCTGAACAG 
R: GTCTGGCCTAAATCCTTGTAGATCC 
RT-PCR 
Rn_p101 Not available F: CCCACTGTGACCTTCCTAAACTGC 
R: CCTGTCAATCTCCAAGTCCTCCTC 
RT-PCR 
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Rn_p110γ? Not available F: CTGATTGGCTACGACGTCACTGAC 
R: GGGACTTCTTCTTGGCCATCTTGG 
RT-PCR 
*Mm, mus musculus; Hs, homo sapiens; Rn, rattus norvegicus; $F, forward primer; R, reverse primer. %see 
also main text. 
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5 General discussion and conclusions 
 
PI3Ks transduce extracellular signaling immediately downstream of growth factor, cytokine and chemokine 
receptors. Hereby they control a plethora of cellular responses, by which the homeostasis of the organism is 
maintained. Consequently modulated PI3K signaling was connected to various diseases such as cancer 
development and progression, inflammatory disease, allergy and asthma (Marone et al., 2008). As outlined 
above, the impressive development of PI3K specific inhibitors yielded many highly effective compounds, of 
which some are already in clinical trials.  All compounds prevent ATP binding to the catalytic core of PI3K. 
Although inhibiting the kinase activity directly is currently very successful, it however risks the inhibition of 
structurally related kinases or similar domains. Thus alternative approaches such as allosteric inhibition or 
disruption of essential protein interactions with PI3Kγ should not be neglected. Therefore a detailed 
knowledge of how PI3Kγ is activated is required. 
 
 
5.1 The p84 adapter increases complexity of PI3Kγ  signaling 
 
Until recently p101 was the only PI3Kγ adapter subunit (Stephens et al., 1997; Suire et al., 2005). The 
existence of one adapter only should have minimized complications for analyzing its physiologic role, due to 
the lack of cross-compensatory effects. Nevertheless controversial in vitro data were available on whether 
p101 was dispensable for PI3Kγ activity or not. The reduced chemotaxis of p101 null neutrophils towards low 
concentration of GPCR agonists contributed only partially to assess the physiologic role of p101, as high 
agonist concentrations were still able to induce half maximal migration and PtdIns(3,4,5)P3 production in 
absence of p101 (Suire et al., 2006). Thus p110γ may partially promote migration without p101. Similarly the 
p110γ mediated neutrophilic oxidative burst, elicited by the same stimuli, was p101 independent (Suire et al., 
2006), and p110γ might thus be able to signal independent of an adapter subunit. The discovery of p84 as an 
additional p110γ adapter protein provides however also the possibility that p84 compensated for the deleted 
p101 in migration and was required to transduce signaling to the oxidative burst, which was unfortunately not 
addressed. Thus a clean, but physiologic relevant system, in which cross-compensatory effects of either of 
the adapters can be excluded, is fundamental for defining physiologic adapter functions.  
In this report we show that BMMC from p110γ null mice qualify as such a system, in that these do not express 
p110γ, p101 and only little p84, with completely abrogated adenosine signaling. In wild type mast cells 
adenosine signaling, which is PI3Kγ  mediated, is essential for mast cell migration and degranulation (Kitaura 
et al., 2005; Laffargue et al., 2002). Thus p110γ null BMMC were exploited in complementation experiments to 
identify the components required for adenosine induced PI3K signaling. The complementation studies 
provided the first clear-cut demonstration, that p110γ, even at high abundance, is incapable to transduce 
GPCR stimuli to PtdIns(3,4,5)P3 production, phosphorylation of PKB, mast cell migration. The abundance of 
either p84 or p101 together with p110γ was required for PI3Kγ signaling.  
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5.2 p84 - the sole PI3Kγ  adapter in allergic responses: 
 
Expression analysis of p110γ, p101 and p84 developed p84 as the unique PI3Kγ adapter subunit abundant in 
mast cells. In line with the above mentioned complementation studies we also determined p84 to be essential 
in adenosine enhanced mast cell degranulation. Integrating the gained knowledge, that PI3Kγ mediated mast 
cell migration and degranulation are strictly dependent on the abundance of p84, with the fundamental role of 
PI3Kγ activity in mast cell recruitment to and their activation in inflamed tissue (Collmann et al., in preparation) 
highlights p84 as an important component in allergic responses. Thus efforts should be undertaken to 
understand how p84 and p110γ interact, and how to disrupt the p84:p110γ complex, which could open 
alternative avenues for therapeutic approaches. A specific disruption of the p84:p110γ complex could 
specifically inhibit mast cells, due to its the predominant expression of p84 in those, while other immune cells 
might be unaffected. Alternatively modulating the localization of the membrane targeted p84:p110γ complex 
could be an additional attempt, as our data ishow that the p84:p110γ complex produces PtdIns(3,4,5)P3  in 
membrane micro-domains, which was essential for adenosine enhanced degranulation. Thus it is likely that 
p84:p110γ is in proximity to the FcεRI input, which is lipid raft dependent, and locally enhances 
PtdIns(3,4,5)P3  In contrast p101:p110γ complexes, which were not sensitive to the lipid composition were 
also not able enhance degranulation. However it has to be noted, that currently too little is known on how p84 
and p110γ interact and which are the driving forces. Thus many molecular details have identified before 
rationalizing such a strategy 
 
 
5.3 Molecular basis of adapter specific PI3Kγ  functions 
 
In the present study we demonstrated that p110γ signaling in mast cells is strictly dependent on its adapters. 
Under physiologic conditions p84 is dominant here, as p101 protein was not detectable in mast cell lysates. 
Nevertheless replacement of p84 by p101 still led to functional PI3Kγ complexes, which were capable to 
produce PtdIns(3,4,5)P3, promote phosphorylation of PKB and even mast cell migration. The p101:p110γ 
complex was however unable to restore adenosine enhanced mast cell degranulation.  
It is of major interest to elucidate the molecular basis of this first non-redundant function of both PI3Kγ 
complexes, and maybe also of additional nor-redundant functions which are yet undefined. The little 
information on the structure of both adaptors cannot provide an explanation, and their in vitro performance 
was similar (Suire et al., 2005). However it must be noted, that in comparative studies of p84 and p101, the 
adapter dependent increased sensitivity of p110γ to Gβγ subunits included only one combination of Gβγ 
(Gβ1γ2) subunits (Suire et al., 2005; Voigt et al., 2006), while at least p101 increases p110γ activity towards 
other combinations of Gβγ subunits, too (Kerchner et al., 2004). Similarly, over-expression studies only 
applied the fMLP receptor system in non-relevant cell types to assess PtdIns(3,4,5)P3 production, but without 
emphasis on physiologic responses (Voigt et al., 2006). Future studies should thus address, whether 
preferential combinations of Gβγ or GPCR exist for both of the complexes especially in cell types harbouring 
                                                                                                                                                             Discussion 
 
                                                                                                                                                                           73  
        
both adapters. Given that Gβγ specificity could be determined, this may allow an immediate prediction, which 
PI3Kγ complex transduces signals from which GPCR.  
Alike above, in our system both PI3Kγ complexes served the same type of adenosine receptor, and both 
integrated signaling from Gαi-coupled receptors. It is thus unlikely that the cause of non-redundant functions is 
upstream PI3Kγ in our system. Differential PtdIns(3,4,5)P3 localizations and the differential sensitivity to 
cholesterol depletion of either of the PI3Kγ complexes rather suggested that the adapters facilitate the 
differential localization of p110γ to distinct plasma membrane micro-domains. Biochemical confirmation is 
required, e.g. by density- gradient centrifugation techniques, which might however fail due to transient and 
non-convalent association of the PI3Kγ complexes to the membrane compartments. An analysis of the 
interactomes of both PI3Kγ complexes could considerably contribute to understand the differential 
PtdIns(3,4,5)P3 localization and degradation pathways, we observed. Thus p84 might interact with a micro-
domain localized protein, while p101 does not. Unknown adapter intrinsic domains could similarly drive the 
differential localization of the two complexes for PtdIns(3,4,5)P3  production. 
 
 
5.4 “Sub-Isoform” specific PI3Kγ  inhibition? 
 
The potential therapeutic value of the disruption of the p84:p110γ complex in allergy was discussed above. 
The non-redundant function of p101:p110γ and p84: p110γ  shown here should be rapidly extended to 
functional studies in immune cells harbouring both complexes, with the attempt to isolate more adapter 
specific functions. Such a possible adapter specific response could be the neutrophilic oxidative burst 
(discussed above). Defining more adapter specific PI3Kγ functions in combination with the selective inhibition 
of either of the complexes could provide sub-isoform specific targeting. Hereby inhibition might be achieved 
by complex disruption but could also be mediated by inhibiting proper localization of the complexes. 
 
5.5 PI3Kγ  is p84:p110γ  or p101:p110γ  - and Class IA PI3Ks? 
All class I PI3Ks are heterodimeric complexes of a catalytic and a regulatory subunit. Fifteen combinations are 
possible for class IA, two for class IB. Nevertheless they are often referred to as PI3Kα, β, δ or PI3Kγ, which 
only accounts for the catalytic subunit but not for the regulatory one. We however defined non-redundant 
functions of p84:p110γ or p101:p110γ and to me its seems necessary to clearly distinguish the complexes in 
the future.  
For p110δ and class IA regulatory subunits studies in gene targeted mice unraveled some isoform specific 
functions in immune cells, which is indeed important knowledge to pharmacologically modulate (patho-) 
physiologic responses.  Whether the effects are due to intrinsic functions of the specific subunit or whether it 
is “only” the total loss of class IA PI3K activity was however often unclear. Complementation experiments as 
performed here could establish isoform specific functions, namely if an “equivalent” subunit cannot rescue the 
defects of the targeted one.  
Moreover the molar ratios of the 5 regulatory subunits and 3 catalytic subunits of class IA have to be 
determined for each cell type in the future, in order to define real isoform specific functions. Thus it can 
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currently not be excluded, that the “isoform specific” defects are only based on the predominant expression of 
the targeted subunits, which results in a total block of class IA PI3K signaling. Thus it is highly interesting, that 
male PI3KδKD/KD mice are fertile (Ali et al., 2004), although SCF/c-Kit signaling is essential for 
spermatogenesis, while SCF/c-Kit signaling is blocked in mast cells. Male PI3KβKR/KR mice show however 
defects in spermatogenesis (Elisa Ciraolo, in preparation), while extrapolated from Ali et al. 2004, p110β is 
negligible in SCF/c-Kit signaling in mast cells.   
Adapter specific signaling of the p85 family members were also addressed in knock-out approaches, but not 
combined with functional restoration. However already the fact that spliced the forms of p85α  (p55 and 
p50α ) and p55γ do neither contain the SH3 domains nor the BH domain present in p85 α and p85β, suggest 
that there might differential modes of activation or different localizations, as we have observed it for the class 
IB complexes, e.g. by specific protein-protein interactions.  
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7 Appendix 
 
7.1 Protocols: 
 
7.1.1 Mast Cell Protocols 
 
Sterile conditions are obligatory, with exception of bone isolation and post stimulation of BMMC (which do not 
re-enter the incubator). Common tissue culture equipment is not separately listed, e.g. lamina flow, 
incubators, centrifuges, tissue culture flasks in materials. 
 
Isolation of BMMC from the bone marrow 
Material: 
- Various knock-out and wild-type mice, 
- Sterile scissors and tweezers, 
- Sterile 50 ml Falcon tubes, 
- Sterile 1.5 ml Eppendorf tubes, 
- Sterile, punctured 0.5 ml Eppendorf tubes:  
 Prepare 0.5 ml Eppendorf tubes by puncturing a hole at the bottom with flame heated sterile tweezers 
 or a G21 syringe needle. Cut off the caps. Put these small tubes  into intact 1.5 ml sterile Eppendorf 
 tubes. 
- Sterile tissue culture flask, 
- Complete IMDM = IMDMc  (add to 500 ml Iscove’s Modified Dulbecco’s Medium, + 50 ml  10% heat-
 inactivated FCS [Amimed],  5 ml 200mM L-Gln [Sigma, G7513], 
+ 5 ml Penicillin-Streptomycin 10k U-µg/ml [Sigma, N°109],+ 0.5 ml 50mM β-mercaptoethanol. Store 
at 4°C. 
- Murine Interleukin-3 (m-IL3; from Peprotech, CatNo. 213-13). The Stock solution is 10 µg/ml m-IL3 in 
 PBS/BSA 0.1%. Store sterile at -20°C. 
- Optional: stem cell factor (SCF; from Peprotech, CatNo. 250-03, 5 ng/ml final).  
- Note: human IL-3 and SCF do not promote murine mast cell growth. 
Procedure: 
- To disinfect, spray CO2-euthanized mice externally with 70% ethanol 
- Excise the femurs and clean them with a scalpel. Remove all soft tissue. 
- Immerse the thigh bones in 10 ml sterile IMDMc in a 50 ml Falcon tube, keep on ice. 
  Transfer to sterile bench from here! 
- Pour the femurs and IMDMc into a Petri dish. Cut the heads of the femurs and place into the 
 punctured 0.5 ml Eppendorf tubes. 
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- Clean the centrifuge with 70% EtOH. Centrifuge for eppendorf tubes 30 seconds at 5000 rpm and 
 then 2 min at 2000 rpm. 
- Resuspend the pellet in the 1.5 ml Eppendorf tube with 1 ml IMDMc. Transfer the  cells to 20 ml 
 IMDMc  (heated to 37°C) 
- Supplemented cell suspension with 2ng/ml m-IL3 and (optional: 5 ng/ml m-SCF) and cultivate at 
 37°C, 5% CO2.  
 
 
Bone Marrow-derived Mast Cell Culture 
Material: 
- see Isolation of BMMC from bone  
Procedure:  
- Isolate bone marrow as described above. 
 - Incubate 3-5 days at 37°C, 5% CO2 to allow macrophages and fibroblasts to adhere.  
 Note: watch density, if too dense change flask after 2-3 days. 
- Collect non-adherent cells in a 50 ml Falcon tube and centrifuge,  3 min at 900 rpm (approx. 160  g). 
- Remove and keep the supernatant. 
- Resuspend cells in fresh IMDMc and count them. 
- Resuspend the cells at 0.5 x 106 cells/ml in a mixture of 20 % old and 80% fresh  medium 
 supplemented with 2 ng/ml m-IL3, and cultivate at 37°C, 5% CO2. 
- Supply fresh m-IL3 every 2-3 days; passage cells weekly when they reach about 1-2x 106 
 cells/ml and dilute to 0.5x106 cells/ml (keeping 20% of old medium).  
 Lazy way: grow cells to 2.0 x 106 cells/ml (8 ml), add 32 ml fresh medium supplemented with 2 ng/ml 
 m-IL3. Readd IL-3 every 2-3 days. This gives a  passaging cycle of about 9 days.  
  
 The cells show a mast cell-like phenotype after 4-8 weeks. Test for FceRI and c-kit expression. 
 
 
FACS Analysis of FceRI and c-kit Expression 
Additional Material, Antibodies: 
- Hamster anti-mouse FceRI : R-PE-labeled, 0.2 mg/ml (=stock; from eBioscience, CatNr. 12-5898-83, 
lot #E011195; directed against FceRIa chain, clone MAR-1). 
- Rat anti-mouse CD117/c-kit: R-PE-labelled, 0.1 mg/ml (=stock), ImmunoKontact, lot #212-AB-407V, 
rat IgG2b. 
R-Phycoerythrin (R-PE): excitation 488 nm, emission 575 nm  
- 2.4G2 FcγRII exo, Rat IgG1, Karl Matter, Geneva. 
- FACS tubes 
- PBS supplemented with 3% FCS 
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Procedure: 
- Resuspend the bone marrow cells of 2 femurs in 20 ml of IMDMc; during mast cell differentiation 
repeat experiment after 2 and 4 weeks of cell cultivation. Take 3x1 ml of each cell population and 
transfer to FACS tubes. 
- Centrifuge (400g, 3 min.). 
- Aspirate medium and resuspend in 100 µl PBS supplemented with 3% FCS and 1:100 diluted 2.4G2 
FcγRII exo and incubate for 15 min. 
- Add to tube 1-3 of each population 
 1) Nothing (unstained control) 
2) 0.5 µl R-PE-labeled anti-mouse FcεRI (from 0.2 mg/ml stock), 
3) 0.5 µl R-PE-labeled anti-mouse CD117/c-kit (from 0.1mg/ml stock, 
 incubate for 25 minutes on ice in the dark. 
-  Analyze immediately by FACS. Acquisition was performed with FACS Calibur or Cantor II (BD). 
 
 
BMMC transfection 
Materials: 
- BMMC, especially of p110γ null genotype 
- 10-15 µg plasimd DNA (total), isolated with Genelute high performance endotoxin-free Maxi-Prep  KIT 
 (Sigma, #NA 0410), DNA concentration adjusted to 0.5 or 1.0 mg/ml in 1xTE buffer 
- Nucleofector device II (Amaxa) 
- Cell Line Nucleofector Kit T (Amaxa, # VCA-1002) 
- Complete IMDM (Sigma, I3390; HIFCS, Gln, PEST, 50 µM β-mercaptoethanol),  supplemented with 
 2ng/ml recombinant murine IL3 (Peprotech, #213-13) 
- 25 cm2 cell culture flasks (BDTM Falcon) 
Important ! 
- Prepare everything before cells are re-suspended in solution T. Solution T is somewhat toxic to the 
 cells. 
- Everything is performed sterile under the laminar flow, except the nucleofection.  During 
 nucleofection, cuvettes are covered with the caps provided in the kit. 
Procedure: 
- Pipette 10-15µg plasmid DNA into 1.5 ml Eppendorf tubes, adjust the total DNA content to equal 
 amounts were necessary (using base vector without expression  insert).  
- Add 7 ml prewarmed complete IMDM supplemented with 2 ng/ml IL-3, to 25cm2 cell culture flasks and 
 label appropriately. 
- Keep 10 ml complete IMDM, containing IL-3, in a 15 or 50 ml Falcon tube to flush the cuvettes and 
 collect the cell suspension post nucleofection 
- Unwrap nucleofection-cuvettes and plastic pasteur pipettes provided in the cell line nucleofector kit (1 
 cuvette and 1 pipette for each nucleofection reaction) 
- Turn on the nucleofector device and choose program X_001 
-  Count BMMC (CASY-Cell Counter, Analyser System, Model TT; Schärfe System, program 01). 
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- Collect the required amount (8-12x106/ nucleofection) of BMMC by centrifugation  (900 rpm, 3-5 min.) 
- Aspirate supernatant of the cells, and add 100µl solution T per nucleofection reaction to the cells, mix 
 by pipetting.  
 
 From here work as quick as possible 
- Distribute 100µl of cell suspension to each of the DNA-containing Eppendorf tubes  
- Mix DNA and cell suspension and transfer to the nucleofection cuvette. Cap the  cuvette. 
- Place cuvette into the nucleofection device, press ok- nucleofection starts! 
- Post nucleofection flush the cuvette with complete IMDM using the provided plastic pasteur pipette. 
 Aspirate the cell suspension with the same pipette and  transfer to the prepared tissue culture flasks, 
 containing the growth medium. 
- Repeat for all the other nucleofection reactions  
- Incubate the flasks at 37°C, 5% CO2 
- 5 hours post nucleofection, warm complete IMDM, and transfer the samples to 15 ml Falocn tubes 
- Centrifuge cells, 900 rpm, 3-5 min 
- In the meanwhile, label new tissue culture flasks 
- Post centrifugation aspirate the supernatant, add 7ml complete IMDM to each falcon tube and transfer 
 cell suspension to the tissue culture flasks. Add IL-3 (2ng/ml final) and incubate overnight (37°C, 5% 
 CO2)For degranulation experiments add additionally 100 ng/ml IgE anit DNP (SPE-7 clone, Sigma, 
 #D8406)  
 
 
Annexin V binding as measure for MC degranulation 
Material: 
- Non transfected, or transfected BMMC, include GFP or GFP-fusion proteins, for  gating of transfected 
 cells 
- Phosphate buffered saline (PBS) 
- Annexin binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) 
- Annexin-Cy5 (BD Pharmingen, Cat. No. 559934) 
- Optional: propidiume iodide (PI), Sigma P4170, our stock is 2.5 mg/ml 
- FACS tubes 
- IgE anti DNP, stock solution (SPE-7 clone, Sigma, #D8406) 
- DNP-HSA (Sigma, #A-6661) in PBS (stock solution 1 mg/ml) 
- Adenosine (Sigma, # 01890) in H2O (stock solution 10 mM) 
- Complete IMDM (Sigma, I3390; HIFCS, Gln, PEST, 50 µM β-mercaptoethanol), supplemented with 
 2ng/ml recombinant murine IL3 (Peprotech, #213-13) 
- 24-well tissue culture plates (BD FalconTM), do not use our 12-well plates! 
Procedure: 
- The day before the degranulation assay, and the day of transfection for- complementation assays 
 respectively, add 100 ng/ml (final) IgE anti DNP, to sensitize BMMC (in complete IMDM with IL-3, cell 
 concentration 0.5-1.0x 106/ml) 
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- At the day of the degranulation experiment prepare dilutions of 1 µM DNP-HSA with or without the 
 addition of 2 mM adenosine  final concentrations will be 1 ng/ml DNP-HSA and 2 µM adenosine in 
 PBS. 
- Count cells and if required adjust concentration to 0.5- 1.0 x 106/ml with IMDMC 
- Label 24-well plate and pipette 1 µl PBS or stimuli to the wells. 
 Work quick to avoid evaporation of the PBS or stimuli 
- Mix cell suspensions by pipetting up and down and distribute 1 ml (for each sample) of the cell 
 suspension to the 24 well plate. 
- Incubate for 20 min. at 37°C, 5% CO2, in the meanwhile label FACS tubes  
- Post incubation mix each sample (pipetting up and down) and transfer each sample to one of the 
 FACS tubes 
- Sediment cells by centrifugation (400g, 5 min.) 
- Aspirate supernatant and wash with 1xPBS 
- Sediment cells once more, during sedimentation prepare 1x AnnexinV binding buffer with 1:100 
 dilution of AnnexinV-Cy5 (each samples requires 100 µl), optional: add 1:100 Propidium Iodide 
 solution (PI) 
- Aspirate PBS and resuspend cells in 100µl AnnexinV binding buffer, containing  AnnexinV-Cy5 
- Incubate for 15 min. on ice in the dark 
- Perform FACS analysis using FacsCalibur (Becton Dickinson) and Cell Quest pro software. Settings 
 were as followed (only an approximation for new experiments, please include controls of single 
 stained samples to adjust settings if you do a new set of experiments): 
 
 FSC: E00 1.0 
 SSC: 399 1.0 lin 
 FL-1: 420 log  (GFP detection) 
 FL-4: 522 log  (Cy5 detection) 
 If co stained with PI: 
 FL-3: 396 log  (PI detection) 
 Compensation required: 
 FL-4% -FL3%: 22%  (Cy5 and PI signal separation) 
 FL-3%-FL4%: 6% 
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7.1.2 Microscopy: 
 
Preparation of mounting solution: 
Material: 
-  50 mM Tris-HCl, pH7.5-8.0 
- Mowiol (Plüss-Staufer, Oftringen, Hoechst 4-88/cmB339161) 
- Glycerol (Fluka, 49770) 
- n-Propylgallat (Sigma, P3130) 
Procedure: 
- Stir 5 g Mowiol in 20 ml Tris-HCl buffer (0.05M, pH7.5-8.0) on a magnet stirrer (30-40°C, 16h). 
- Add 10 ml 100% Glycerol and stir 16 h. 
- Spin 10 min. at 1500 rpm at room temperature. 
- Add 10 mg/ ml n-propylgallat as anti-fading agent. 
- Aliquot the Mowiol solution 
- Spin aliquots to remove air bubbles, store at -20°C.  
- Thaw the aliquot at least 30 min. before usage at 37°C 
 
 
Preparation of 10% para-formaldehyde in PBS (10% PFA/PBS): 
Material: 
- Weigh 100 g PFA to 400 ml water. 
- Boil in a waterbath under the extractor hood 
- Shake from time to time. 
- Add cautiously drops of 5N NaOH to completely dissolve the PFA (PFA is not soluble at that pH 
 without NaOH). 
- After complete solution of the PFA add 100 ml 10x PBS. 
- Fill up to 1 liter with water. 
- Solution can be further diluted to 4% PFA/PBS. Store at 4°C 
 
 
Preparation of adherent cells: 
Material 
- PBS 
-  4% para-formaldehyde in PBS pH = 8.0 
- Mounting solution, Mowiol, see above 
- Hoechst 33342 (Molecular Probes, H-1399), cell permeable 
-  12- well, or 24- well plate 
- 18 mm or 12 mm diameter coverslips 
- Microscopy slides 
- ddH2O 
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Procedure: 
- Grow (transfected) cells on sterile coverslips in a 12 well or 24-well plate. 
- Perform your experiment of interest.  
- a) if the experiment is time-dependent, add an equal volume of 10% PFA/PBS to the sample directly 
 to stop the reaction 
 b) otherwise wash cells twice with PBS, aspirate PBS, add ice cold 4% PFA in PBS. 
- Incubate on ice for 30 min. 
- Wash with PBS.  
- Optional nuclear staining: add PBS with 1:1000 Hoechst 33342 (stock solution 1 mM in ddH2O), 
 incubate (15 min., 4°C, in the dark).  
 
Preparation of the microscopy slides: 
- Put one drop of mounting solution onto a microscopy slide  
- Take the coverslip with fine forceps and wash with H2O, quickly. 
- Soak residual liquid from the edge of the coverslip with a fine paper towel.  
- Place coverslip upside down onto the drop of mounting solution on the  microscopy slide.  
- Dry for min. 30 min. at room temperature in the dark. 
- Then store at 4°C in the dark. 
 
 
Preparation of suspension cells 
Material: 
- (Transfected) suspension cells (e.g. BMMC) 
- 10% PFA/PBS 
- Mounting solution 
- Fine forceps  
- Coverslips 
- Microscopy slides 
- Cytospin device 
- Cytospin filter cards for cyto-centrifugation (Thermo, 3424) 
- Cytospin microtube 0.75 ml, with 0.5 mm bottom hole (Thermo, 1153) 
- PBS containing 1-2% BSA (BSA reduces shear forces and protects from cell rupture)  
Procedure: 
- Perform your experiment of interest 
- Fix cells by addition of 1:2.5 volume of 10% PFA/PBS 
- Incubate 30 min.  
- Transfer samples to eppendorf tubes 
- Sediment cells (400 g, 3 min.) 
- Permeabilize the cells for additional intracellular stainings! Procedures see  below   
- Wash cells twice with 1 ml PBS/1-2% BSA 
- Collect cells (400 g, 3 min.) 
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- Aspirate supernatant 
 
Cytospin: 
- Resuspend cells in 150 µl PBS/1-2% BSA for cytospin 
- Assemble cytospin device 
- Transfer cell suspension to the cytospin microtube 
- Spin cytospin devices in a centrifuge equipped with a swing out rotor, with a buck for multi-well plates 
 (100g, 1min.) 
- Disassemble cytospin device carefully. 
- Overlay cells with a drop of mounting solution 
- Place coverslip on top of the mounting solution 
- Dry for several hours at room temperature in the dark. 
 
Staining of intracellular components: 
- Post fixation, permeabilize the cells with PBS with 0.1% saponine, 1-2% BSA (or 5% goat serum for 
 antibody staining) (15 min., room temperature) 
- Pellet cells (400 g, 3 min.) 
- Resuspend cells in a small volume (100-200 µl) of PBS/1-2% BSA (or 5% goat  serum)  
- For F-actin staining add rhodamine labeled phalloidin 1:1000  (Molecular Probes, R415), for staining 
 of microtubuli add 1:5 anti tubulin antibody (see antibody table  below), slightly shaking on a rotary 
 wheel or a thermoblock. 
- For F-actin staining proceed with washing steps in PBS/1-2% BSA, followed by cytospin. 
- For microtubuli staining proceed with washing in PBS/5% goat serum, shake slightly for 5 min. 
- Pellet cells (400g, 3 min.), aspirate supernatant, repeat washing step 
- Aspirate supernatant. 
- Resuspend cell in 100-200 µl PBS/5% goat serum 
- Incubate (1h, dark, shaking) with 2nd antibody (1:100 goat anti rat, Alexa546)  
- Wash 3x with PBS/1-2%BSA, with 5 min. washing intervals 
- Prepare for cytospin afterwards. 
 
 
Staining with Alexa555- labeled Choleratoxin 
Materials: 
- BMMC 
- Vybrant Lipid Raft Labeling Kits  (Alexa Fluor 555) (Invitrogen, V-34404) 
- 10% PFA/PBS 
- Cytospin device 
- Mounting solution 
- Coverslips 
- Microscopy slides 
Procedure: 
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- Collect BMMC by sedimentation (900g, 3 min.). Aspirate supernatant. 
- Resuspend cells in complete IMDM (0.5-1.0x 106 cells/ ml). Place on ice. 
- BMMC were labeled according to the manufacturer’s instructions, 
 see http://probes.invitrogen.com/media/pis/mp34403.pdf. 
- Afterwards prepare cells for cytospin (see above). 
- Note: incubation at 4°C “freezes” the original membrane structure,  incubation at 37°C 
 increases endocytosis. The additional incubation with the provided antibodies could induce 
 artificial aggregation of the choleratoxin subunits.  
 
 
Live microscopy 
Material: 
- 5N NaOH 
- 5N HCl 
- Poly-L-Lysine coated coverslips (12 mm diameter) 
- transfected BMMC 
- IMDM (PEST, Gln 2% FCS, without IL-3) 
- 6-slot holder for Ludin chambers (Life Imaging Services [LIS], 10622 
- Ludin chamber type III (LIS, 10920) 
- Reconfiguration tool for Ludin chambers (LIS, 10910) 
- 1 ml syringe, with 21Gx2” needle 
- Modified Tyrode’s Buffer (MT buffer; 137 mM NaCl, 2.7 mM KCl, 1.8 mM  CaCl2, 1 mM MgCl2, 5.6 mM 
 glucose, 20 mM HEPES, pH 7.4) 
- Stimulant (e.g. adenosine, DNP-HSA) 
- Temperature conditioned microscope equipped with “The Cube+ Box temperature control system”, 
 LIS) 
- Silicon tube for perfusion (Fine Bore Polyethylene Tubing 0.76mm ID, Portex, 800/100/240) 
- Silicon grease 
Procedure: 
- The day before the experiment: 
- BMMC transfection (see above) 
- Place coverslips into 24-well plate 
- Add 1 ml 5N NaOH to the coverslips, leave for 2 hours. 
- Aspirate 5N NaOH and wash once with ddH2O, aspirate 
- Add 1 ml 5N HCl for 2 hours. 
- Aspirate 5N HCl and wash with ddH2O, aspirate 
- Add 1 ml ddH2O with 1:10 dilution of poly-L-Lysine solution, 0.1% (Sigma, 8920),  leave overnight 
- At the day of the experiment: 
- Grease the O-ring seals of the Ludin chambers 
- Assemble the Ludin chambers including the poly-L-Lysine coated coverslips using the configuration 
 tool. Assure yourself that the assembly is leak-proof (by filling with water for a while).  
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- Heat IMDM (PEST, Gln 2% FCS, without IL-3) and MT-buffer  
- While preparing the samples UV-irradiate the Ludin chambers, then wash once with IMDM (PEST, 
 Gln 2% FCS, without IL-3)  
- Collect cells by centrifugation (900 rpm., 3 min.), aspirate supernatant 
- Wash once in IMDM (PEST, Gln 2% FCS, without IL-3) and collect cells. 
- Aspirate the supernatant and resuspend in IMDM (PEST, Gln 2% FCS, without IL-3) at 0.5-1.0x 106 
 cells/ml, leave for 3h at 37°C, 5% CO2. 
- 1 hour before the experiment warm polystyrene box (for transport) and the syringe with the attached 
 needle and tubing to 37°C, thaw stimuli. Switch on temperature  control of the microscope.
 Start computer, OpenLab Software and set up time-lapse microscopy automation. 
- Prepare stimuli 2x concentrated in 1 ml MT buffer (no IMDM/ 2%FCS due to possible instability of 
 adenosine) and aspirate to the syringe. 
- Place Ludin chamber into polystyrene box and connect the syringe-tubing system to the perfusion 
 line. 
- Close polystyrene box 
- Carefully (avoid floating of the cells!) transfer samples to the microscope and fit Ludin chamber into 
 the 6-slot holder for Ludin chambers. 
- Once the microscope is set up and the acquisition automation is running, very carefully inject 500 µl 
 stimuli/MT solution (final concentration is then 1x). 
 
7.1.3 Molecular Biology 
 
RNA isolation 
Materials: 
- Various tissues and cells 
- Trizol (Invitrogen, 15596-026) or Tri-Reagent (Sigma, T9424) 
- Chloroform (Fluka, 25690) 
- Isopropanol 
- 75% (v/v) Ethanol 
- RNAse free water 
- Filter tips 
Procedure: 
- Clean bench and pipettes carefully, wear gloves and lab coat to avoid contamination with RNAse. 
- RNA isolation was performed according to the manufacturer’s instruction, 
 details see: http://tools.invitrogen.com/content/sfs/manuals/15596018%20pps%20Tri
 zol%20Reagent%20061207.pdf 
- Measure RNA concentration in a spectrophotometer.  
- Use 2 µg total RNA for cDNA synthesis 
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cDNA synthesis: 
Materials: 
- RNA 
- Oligo-(dT)15 primer (0.5 µg/µl; Microsynth) 
- DTT (supplied with M-MLV RTase)  
- 5x RT buffer (supplied with M-MLV RTase) 
- 10 mM dNTPs (Invitrogen, 10297-018) 
- RNAsin (Promega, N2111) 
- M-MLV RTase (Invitrogen, 28025-013) 
 
Procedure (one reaction): 
- For primer annealing mix 2 µg RNA and 8 µl oligo(dT)15  
- Fill up to 23µl final volume 
- Incubate for 10 min. at 70°C 
- In the meanwhile mix 4 µl 0.1M DTT, 8 µl 5xRT buffer, 2 µl 10 mM dNTPs, 1 µl RNAsin and 2 µl M-
 MLV RTase. 
- Place annealing reaction on ice (2 min.) 
- Add 4 µl 0.1M DTT, 8 µl 5xRT buffer, 2 µl 10 mM dNTPs, 1 µl RNAsin and 2 µl M- MLV RTase to the 
 annealing reaction. 
- Incubate at 37°C, 90 min. 
- Heat to 95°C for 10 min.  
-  store at -20°C until used for PCR. 
 
 
Plasmid DNA amplification and isolation: 
Materials: 
- LB-media (5 g NaCl (LB Miller = 10 g NaCl), 5 g yeast extract; 10 g bacto-tryptone, 5 ml of NaOH 1M, 
 add 1 liter with H2O (autoclave) 
- LB-agar (LB media + 12.5 g Agar [DIFCO, 281230]), autoclave. 
- For antibiotic selection add 100 µg/ml Ampicilline or 25µg/ml Kanamycin to the LB media or LB-agar 
- Chemically competent bacteria (usually E.coli XL-1 Blue strain) 
- Template plasmid DNA or ligation reaction 
- TE- buffer (10 mM Tris-HCl, pH 7,6; 1mM EDTA, pH 8.0) 
 
1. Preparation of chemically competent cells (CaCl2 method) 
Procedure: 
- Take bacteria from -80°C stock by scratching the frozen tube content with a sterile tip and  
 plate on LB agar solid media overnight at 37°C. 
- Pick single colony and inoculate a 100 ml LB-Miller, grow overnight (shaking in 37oC, 300  
 rpm) 
- Inoculate 1 liter LB-Miller with the overnight culture, inoculation 1:100. 
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- Grow in shaker (37oC, ca. 300 rpm) until OD600= 0.6. Then put the flask on ice. Wait 20 min until 
 culture is really cold. Pre-cool CaCl2 solutions on ice! 
- From now keep at 4oC (coldroom)  
- Transfer bacteria to the centrifuge bottles and spin in the pre-cooled centrifuge about  20 min. 
 3000 rpm at 4oC. 
- Discard the supernatant, resuspend the pellet in 500 ml ice-cold CaCl2 (1/2 of initial volume). Mix 
 strongly initially, then gently. 
- Leave the bacteria for few hours at 4oC, mix gently occasionally. Cool down solution of CaCl2/10-15% 
 glycerol on ice.  
- Spin 15 min at 4oC, 3000 rpm, discard the supernatant and resuspend very gently in 100 ml of pre-
 cooled CaCl2/10-15% glycerol. 
- Immediately aliquot the bacteria in 500 µl portions to Eppendorf  tubes and freeze in liquid N2 
 immediately. 
- Store tubes at -80oC. 
 
2. Transformation of competent bacteria 
Procedure 
- Thaw tube with bacterial suspension on ice. 
- Aliquot bacterial suspension to 100 µl portions in pre-cooled tubes. Add DNA (plasmid [100 ng] or 
 ligation [up to15 µl]). 
- Mix and incubate for 30 min. on ice  
- Heat shock for 45- 90s at 42°C. Place tube on ice. 
- Add 900 µl of SOC media and shake for (1 hour, 37°C) 
- Collect cells by centrifugation (1 min. 3000g) 
- Remove 800 µl supernatant, resuspend cells in the remaining 200 µl.  
- Plate suspension on LB agar plate with the respective antibiotic (for plasmid selection). When the fluid 
 is absorbed, incubate plate up side down overnight at 37°C. 
 
3. Plasmid amplification and purification: 
Material: 
- Transformed E. coli 
- LB media, LB agar, supplemented with antibiotics 
- Endofree plasmid maxi kit (Qiagen, 12362) or Genelute high performance endotoxin-free (Sigma, NA 
 0410) or Genelute Plasmid Miniprep kit (Sigma, PLN-350) 
- TE-buffer 
- Isopropanol 
- 70% Ethanol 
Procedure: 
- Pick colonies form the transformed E.coli plates, streak back up on LB agar and inoculate LB media, 
 both supplemented with the selective antibiotic. 
- Growth conditions and plasmid isolation were performed according to the manufacturer’s instructions. 
- Plasmid DNA was eluted with 1xTE buffer 
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- The concentration and purity of the plasmid was measured in a  spectrophotometer 
- (Optional: ethanol precipitation, according to the manufacturer’s instructions, to  increase plasmid 
 concentration and purity) 
- Adjust plasmid DNA to 0.5 or 1.0 µg/µl in 1x TE 
 
 
Agarose gel-electrophoresis 
Material: 
- Agarose, standard (Eurobio, 018054) 
- 1x TAE buffer (40 mM Tris-acetate pH 8.0, 1mM EDTA) 
- ethidium bromide 
- Loading buffer (0.4% bromphenol, 0.4% xylene cyanol FF, 50% glycerol) 
- Lambda marker, l HindIII/EcoRI (Labforce, 1695/1),  
- pBR322 DNA/AluI Marker (Fermentas, SM0121) 
-  GenElute Gel Extraction Kit (Sigma, NA1111) 
Procedure: 
- Prepare 1-2% agarose gels. 
- Melt agarose in TAE (40 mM Tris-acetate pH 8.0, 1mM EDTA)  
- Add 0.3 µg/ml ethidium bromide.  
- Pour liquid agarose on glass plates 
- Place the combs and wait until agarose has solidified. 
- Mix DNA samples (PCR reactions, restriction digests) with 0.1 volume loading buffer and load on the 
 gel together with a DNA marker 
- Separate DNA by electrophoresis (constant current 70 V) 
- Visualize DNA under UV-light. 
- For preparative electrophoresis excise DNA fragments of interest and purify with  GenElute 
 Gel Extraction Kit according to the instructions 
- Run another gel for purified fragments to approximate the DNA amount, if used for ligation 
 
 
Restriction endonuclease digests 
Materials: 
- PCR product or plasmid DNA 1-5µl 
- Reaction buffers (2µl, NEB, type depends on restriction enzymes) 
- NEB restriction enzymes (0.5µl)  
- (Optional add 1:100 BSA, supplied with NEB enzymes) 
- ddH2O, up to 20µl final volume. 
Procedure: 
- Mix all required components (see material) 
- Incubate 1h at 37°C, if required incubate additionally at 65°C afterwards  
- Analyse and isolate digest products by agarose gel electrophoresis.  
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Ligation: 
Material: 
- Purified restriction endonuclease digest products (approx. equimolar concentrations, with compatible 
 ends, 0.5- 2µl) 
- 10x T4 Ligase buffer (1.5µl, NEB) 
- T4 DNA Ligase (0.5µl, NEB, 102378) 
- ddH2O, fill up to 15µl final volume 
Procedure: 
- Thaw T4 Ligase buffer on ice. 
- Mix all required components (see material) 
- Incubate for 5 min. on ice, then for 16 h at 16°C or for 1h at room temperature 
- Transform competent E. coli with ligation products. 
 
 
Polymerase Chain Reaction (PCR) 
Material: 
- Template DNA (plasmid DNA [10-100 ng/ml, 1 µl], cDNA [1µl]) 
- 10x PCR reaction buffer (5 µl) 
-  50 mM MgCl2 stock solution (1.5 µl) 
- Taq-DNA Polymerase (NEB, 102373) or Pwo-DNA Polymerase (Roche,  1164495500; 0.5 µl) 
- 10 mM dNTPs (form dNTP set PCR grade, Invitrogen, 10297-018 [2.5 mM of dATP, dCTP, dTTP, 
 dGTP; 1µl])  
- Forward primer (10µM, 1µl) 
- Reverse primer (10µM, 1µl) 
- ddH2O (fill up to final volume of 50 µl) 
- 0.5 ml PCR tubes (Molecular BioProducts, 3430) 
- T3 Thermocycler (Biometra, Göppingen) 
Procedure: 
- Thaw all frozen components on ice, except for DNA-Polymerase 
- Combine all components on ice, except for the DNA Polymerase in 0.5 ml PCR tubes, volumes are 
 given in material for one PCR reaction) 
- Example of a PCR protocol: 
 - Heated lid (105°C) 
 - 95°C for 5 min, add DNA-Polymerase after 4 min (hot start) 
 a) Denaturing:  95°C, 45 s 
 b) Annealing: 62-65°C, 40 s 
 c) Elongation: 72°C, time dependent on size of the PCR product 
 d) Repeat step a)-c) 30 times 
 e) 72°C, 10 min. 
 f) 4°C 
- Prepare PCR samples for agarose gel electrophoresis. 
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7.1.4 Protein methods: 
 
SDS-PAGE Electrophoresis 
Solutions 
- Ultra pure Accu Gel 29:1 (40%), National Diagnostic, EC852 
- Tris-HCl, pH8.8 (1.875 M) 
-            Tris-HCl, pH 6.8 (1.25M) 
- 10% SDS (Sodium Dodecyl Sulfate solution): 
- 10% Ammonium Persulfate solution 
- 10x Electrode Buffer (Tris-Glycine): 
Glycine (144.2 g), Tris (30.3 g), SDS (10 g). Dissolve in 800 ml H2O.  
 1x: Dilute 100 ml of 10xElectrode Buffer with 900 ml distilled water. 
 - Cell lysis buffer (20 mM Tris/HCl, pH 8.0, 138 mM NaCl, 2.7 mM KCl, 5% glycerol), store at -20°C, 
 prior usage finish lysis buffer by addition of (final conc.): 
 -  1% NP 40 or 0.1% Triton-X 100; Protease and phosphatase inhibitors (20 µM Leupetin,18 µM 
 Pepstatin,1 µg/ml Aprotinin, 1 mM PMSF, 20 mM Sodiumfluoride, 1 mM Sodium-ortho-vanadate,1 
 mM DTT) 
 - 5x Loading Buffer: 1.25 M Tris-HCl pH 6.8 (2.5 ml), SDS (1g), 2-Mercaptoethanol (2.5 ml) Glycerol     
 87% (5.8 ml), Bromophenol blue (5 mg), H2O distilled (35 ml) 
-          Staining solution: Coomassie Brillant Blue G250 (0,1%), 50%Methanol, 7%Acetic acid, 43% ddH2O   -
-          Destaining solution: Methanol (20%), Acetic acid (5%), Distilled water (75%) 
-          PBS 
-          Cell lifter (Corning, F21222F) 
Sample preparation: 
 For adherent cells: place cell culture dishes on ice 
- Aspirate medium, wash 2x with cold PBS 
- Add 100-200 µl cell lysis buffer and incubate on ice 
- Scrape cells from the dishes and transfer cell lysates to eppendorf tubes 
- Incubate 15 min. on ice 
- Spin (16000g, 10 min., 4°C) 
- Transfer supernatant to new eppendorf tubes, measure protein concentration with BioRad Protein 
 Assay (BioRad, 500-0006), store at -20°C or -80°C, or proceed by addition 1/5th of 5x loading buffer.
  Heat to 95°C for 7 min. 
- Store at -20°C until usage for SDS-PAGE  
 For BMMC: 
- Collect cells by centrifugation (16000g, 1 min., 4°C). 
- Aspirate supernatant, wash with PBS. 
- Pellet cells by centrifugation (16000g, 1 min., 4°C). 
- Aspirate PBS 
- Dissolve mast cells in 2x Loading Buffer at a concentration of 1.0x 107 cells/ml and vortex. 
- Heat to 95°C for 7 min., Store at -20°C until usage for SDS-PAGE  
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Gel preparation: 
- Clean alumina and glass plates (Hoefer, SE202N-10 and SE202P-10), the spacers and the combs  
- Assemble 10 gel units in the multicasting cassette with a plastic plate in between the single units (do 
 not place the combs at this time) 
- Prepare the resolving gel mixture (see table next page) and fill the multicasting cassette 
-           Overlay each gel unit with 1ml isopropanol. Polymerization takes about 30 min. 
-           Discard the isopropanol, wash gel surface with water and remove residual water with whatman paper 
-            Prepare the stacking gel solution and overlay the resolving gel with the stacking gel solution. Insert             
 combs. 
- After polymerization disassemble the cassette and store each gel in a plastic bag with 1 ml 1xTris, pH   
 8.8 at 4°C until usage. 
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For ten 0.75 mm gels in multicasting cassette 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter settings for one 0.75 mm gel 
- Constant current: 20 mA 
- Set voltage:   250 V 
- Time:   approx. 60 min. 
 Resolving gel (75 ml) Stacking (30 ml) 
 7.5 % 10 % 12% 15 % 20 % 5 % 
Acrylamide Stock - ml 14.1 18.8 22.5 28.1 37.5 4.8 
Distilled water - ml 44.9 40.2 36.5 30.9 21.5 21.6 
TRIS-HCl pH 8.8 - ml 15 15 15 15 15 --- 
TRIS-HCl pH 6.8 - ml --- --- --- --- --- 3 
Degas solution, then add       
10%-SDS -µl 750 750 750 750 750 300 
TEMED -µl 37.5 37.5 37.5 37.5 37.5 30 
10% Amm.Persulfate - µl 250 250 250 250 250 102 
Mix carefully and cast gel       
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Electrophoretic Transfer / Semi-dry blotting 
Material and solution: 
- Transfer buffer (25 mM Tris, 192 mM Glycine, 20% methanol, pH 8.3) 
- Immobilon FL (Millipore, IPFL00010), Immobilon P PVDF (Millipore, IPVH00010) cutted to gel 
 size (9x6.5 cm) 
- For one gel 6x whatman paper (9x6.5 cm) 
- Semidry blotting device 
- Methanol 
Procedure: 
- NOTE: For infrared imaging with Odyssey use Immobilon FL and always use fresh 
 methanol.  Label membrane with a pencil, not with a pen 
- Label and activate membrane in methanol for 1 min. 
- Equilibrate in Transfer buffer. 
- Mount SDS-PAGE/membrane sandwich. 
- Blot proteins to the membrane with constant current of approx. 10 mA per cm2 for 75 min 
 (0.75mm gel) or 120 min. (1.5 mm gel). 
- Disassemble sandwich, incubate in blocking buffer for 30 min.  
- Add 1st antidbody  (see antibody table below for their dilution, blocking buffer, time).  
- Wash 3x 5 min. with TBS, 0.1%Tween  
- Add 2nd antibody (HRP or IR-Dye conjugated, see antibody table for details) for 1 hour 
- Wash 3x 5 min. with TBS, 0.1%Tween 
- Detection: either enhanced chemoluminiscence (ECL) or by infrared detection (Odyssey) 
 
 
Immunoprecipitation: 
- Described for anti PI3Kγ 641 here. Might also be used for other antibodies, but eventually 
 modifications are necessary.   
Materials: 
- GammaBind Plus Sepharose (Amersham; 17-0886-02) 
- Ascites fluid Mm-α-p110γ 641 (ASC Eurogentech) 
 Corresponds to Alexis JBS-ABD-027 (clone 641, Jena Bioscience) 
 www.axxora.com 
- lysis buffer, recipe see SDS-PAGE electrophoresis protocol 
- Wash buffer 1: lysis buffer (20 mM Tris/HCl, pH 8.0, 138 mM NaCl, 2.7 mM KCl, 5% glycerol) 
 + 1% NP40, no protease inhibitors 
- Wash buffer 2: 50mM Tris/Hcl, pH 8.0, 150 mM NaCl, 1% NP40 
- 1x PBS 
- Optional 0.5 M LiCl solution 
- 10- 20 x 106 bone marrow derived mast cells 
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Procedure  
Important: all steps are on ice, in cooled centrifuges or in the cold room 
- Cell lysis  
 - Collect cells by centrifugation (400g, 5 min), aspirate medium, wash with 1x PBS 
 - Collect cells (400g, 5 min) and aspirate PBS,  
 - Lyse cells in 2 ml lysis buffer (15 min, on ice, pipet up and down or vortex once in a while).  
- GammaBind Sepahrose preparation  
 - Transfer 50 µl 50% slurry into 3x 2ml Eppendorf tubes 
 - Wash with lysis buffer (1ml), pellet beads (1000g, 1 min.) 
 - Aspirate lysis buffer. 
 - Repeat washing step. 
- Preclearing of the lysate: 
 - Centrifuge cell lysate (4°C, 15 min., max. speed). 
 - Take 100-200 µl for usage as total lysates. Add to the 100-200µl 20-40 µl 5x 
 concentrated SDS-sample buffer, heat at 95°C for 7 min., then place on ice (Calculate cell 
 concentration for this; around 1x104/ µl is fine). 
 - The remaining cell lysate (1.8-1.9 ml) is transferred to one of the 3 2ml eppendorf tubes, 
 containing the prewashed GammaBind beads. 
 - Rotate the lysate with the beads for 30-45 min. in the cold room to pre-absorb unspecific 
 binding proteins.  
- Immunoprecipitation 
 - Spin precleared sample (1000 g, 1 min.). Transfer ½ of the supernatant into each of the 2 
 other Eppendorf tubes containing pre-washed GammaBind beads. 
 - Add to one tube 2µl of ascites fluid Mm-α-p110γ 641 
 - Add isogenic control antibody to the second tube (for 6.4.1 it is IgG2a).  
 - Rotate samples for 1h in the cold room (4°C). 
 - Wash 2x with 1 ml wash buffer 1 and sediment beads (1000 g, 1 min.),  aspirate 
 supernatants 
  - Wash twice with wash buffer 2 (1000 g, 1 min.) aspirate supernatants  
 - (optional wash once with 0.5 M LiCl solution) 
 - Wash once with 1x PBS. 
 - Add 2x concentrated SDS-sample buffer (adjust volume that you have a final 
 concentration of 0.5x10- 1x105/ µl; include beads volume (50µl) in your calculations). Heat at 
 95°C for 7 min.  
 Samples can then be loaded for SDS-PAGE. 
 
 
 
 
 
 
 
                                                                                                                                                   Appendix                                                                                                                                                                                   
                                                                                                                                                            108  
        
Purification of bacterial recombinant protein with (His)6 tag 
Materials 
- Handbook “The QIAexpressionist”, can be found online:
 http://www1.qiagen.com/literature/handbooks/PDF/Protein/Expression/
 QXP_QIAexpressionist/1024473_QXPHB_0603.pdf 
- pQE vector expression system  
- E. coli host strain M15 
- Ni2+-NTA beads (Qiagen, 30410) 
- Solutions see handbook 
Procedure, details see “The QIAexpressionist” and especially the protocols given below: 
- Expression of (His)6-tagged recombinant proteins (derived from plasmids #915 and #1105) 
 were tested for solubility, using protocol 6 (Handbook “The QIAexpressionist”) 
- Insolubility of the (His)6-tagged recombinant proteins required protocol 10 and 17 (Handbook 
 “The QIAexpressionist”) for purification. 
 
Protein precipitation 
Material 
-  Recombinant protein 
- Trichloroacetic acid (TCA) 20% in H2O  
- Acetone, -20°C 
Procedure: 
- Add an equal volume of 20% TCA to the protein solution 
- Keep on ice, 30 min. 
- Sediment protein precipitate by centrifugation (5 min, 16000 g, 4°C) 
- Wash protein pellet 3x with Acetone 
- Dry pellet and resuspend in denaturation buffer
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7.2 Consumables 
Restriction enzymes were purchased from New England Biolabs (not separately listed). Chemicals 
from Sigma, if not stated different. 
Product Supplier Cat. No. 
2- Mercaptoethanol Sigma M 7522 
AccuGel 40% National Diagnostics EC-852 
Adenosine Sigma 01890 
Agar Technical DIFCO/BD 281230 
Agarose, standard Eurobio 018054 
Albumin bovine, serum fraction V Sigma A7906 
Albumin human Dinitrophenyl (DNP-HSA) Sigma A-6661 
Ammonium persulfate (APS) Bio-RAD 161-0700 
Ampicillin trihydrate Sigma 10045 
Annexin V Cy5 BD bioscience 559934 
Aprotinin Fluka 10820 
AS-605240 Serono non commercial 
C3a Clemens Dahinden non commercial 
C5a human recombinant carrier free R&D systems 2037-c5/CF 
Calciumchlorid dihydrate Merck 1.02382.0500 
Cell Line Nucleofector Kit T Amaxa VCA-1002 
Cell Line Nucleofector Kit V Amaxa VCA-1003 
Chloroform Fluka 25690 
Cytospin filter cards for cytocentrifugation Thermo 3424 
Cytospin Mikrogefässe 0.75 ml mit 0.5 mm 
Bodenöffnung 
Thermo 1153 
Diisopropyl fluorophosphate Sigma D12600-4 
Dimethyl sulfoxide Sigma 154938 
Dithiothreitol Eurobio GAUDTT00-71 
dNTP set PCR grade Invitrogen 10297-018 
ECL Western Blotting Detection Amersham RPN2106 
Endofree plasmid maxi kit Qiagen 12362 
FITC:rat anti-mouse IgE (R35-72) Pharmingen 553415 
GammaBind Plus Sepharose Amersham 17-0886-01 
GenElute Gel Extraction Kit Sigma NA1111 
Genelute high performance endotoxin-free Sigma NA 0410 
GenElute Plasmid Miniprep Sigma PLN-350 
Glucose D(+) Monohydrate Sigma 49159 
Glutathione Sepharose 4B Amersham 17-0756-01 
Guanidine Hydrochloride Fluka 50590 
HEPES Sigma H3375
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HOECHST 33342 Juro supply H-1399 
Hyperfilm ECL Amersham RPN3103 
IB-MECA Sigma I-146 
Immobilon Western substrate reagents Millipore WBKLS0500 
Immobilon-FL Millipore IPFL00010 
Immobilon-P PVDF membrane Millipore IPVH00010 
IPTG Axon Lab 102124 
Iscove's Modified Dulbecco's Medium Sigma I3390 
Jet PEI transfection reagent Polyplus Transfection 101-40 
Kanamycin-sulfat Fluka 60615 
Lambda marker, l HindIII/EcoRI Labforce 1695/1 
Leupeptin Alexis 260-009-M025 
L-Glutamine (200mM) Sigma G7513 
Lithium chloride anhydrous Fluka 62476 
Luria Broth Base life technologies 127-95-027 
LY294002 Calbiochem 440202 
LysoTracker® Red DND-99 Invitrogen L7528 
Magnesium chloride Fluka 63068 
Magnesium sulfate Fluka 63140 
Methyl-beta-cyclodextrin  Sigma C4555 
M-MLV RTase Invitrogen 28025-013 
Mouse monoclonal anti-DNP IgE Sigma D8406 
Murine recombinant SCF Peprotech 250-03 
N,N,N,N'-Tetramethyl-ethylenediamine, TEMED Bio-Rad 161-0800 
NECA, 5’-n-ethylcarboxamidoadenosine Sigma E 2387 
N-formyl-Met-Leu-Phe Sigma F3506 
Ni-NTA Superflow Qaigen 30410 
Nocodazole Sigma M1404 
Oligo(dT)15 primer Microsynth non commercial 
Optiprep Axon Lab 1114542 
p85a/p110a complex Upstate 14-602 
Penicillin-Streptomycin 100x Sigma P0781 
Pepstatin A Fluka 77170 
Percoll Amersham 17-0891-01 
Pertussis Toxin Sigma P7208 
Phycoerythrin (PE) anti-mouse FcεRIα eBioscience 12-5898-83 
p-Nitrophenyl N-Acetyl-β-D-Glucosaminide Sigma N-9376-1G 
poly-L-Lysine solution, 0.1% Sigma P 8920 
Potassium chloride Fluka 60128 
Propidium Iodide Sigma P4170 
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Pwo DNA Polymerase Roche 11644955001 
Rantes CCL5 carrier free, human recombinant R&D systems 278-RN/CF 
rat anti-mouse CD117 (c-kit):PE conjugated ImmunoKontakt 212-AB-407V 
recombinant murine Interleukin-3 PeproTech 213-13 
recombinant murine Stem Cell Factor PeproTech 250-03 
Rhodamine phalloidin Molecular Probes R415 
RNasin Promega N2111 
SERVA Blue R Serva 35051 
siStrike U6Hairpin Cloning system (human)-
hMGFP 
Promega C3550 
Sodium chloride Fluka 71376 
Sodium dihydrogen phosphate Fluka 71500 
Sodium dodecyl sulfate Fluka 71729 
Sodium orthovanadate Sigma S6508 
Super RX film Fuji F57164052 
T4 DNA ligase NEB 102378 
Taq DNA Polymerase NEB 102373 
Taq DNA Polymerase recombinant Invitrogen 10342-020 
TGX-221 Cayman 10007349 
TOPO TA Cloning kit Invitrogen K4575-01 
Trichloroacetic acid Fluka 91230 
Tri-Reagent Sigma T9424 
Triton X-100 Fluka 93420 
Trizma base Fluka 93304 
TRIZOL Reagent Invitrogen 15596-026 
Urea purum p.a., crystallized, ≥99.0% (N)  Fluka 51461 
Vybrant Lipid Raft Labeling Kits  (Alexa Fluor 555) Invitrogen V-34404 
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7.3 Antibodies  
# Detected Protein Supplier/ Cat.-No. Species Usage, additional information 
- Vinculin  Gift of Victor Kotelianski Rouse, mAb, 
clone VII-F9 
1:5000 in 5% skim milk TBST, 1-3 hours RT, overnight 4°C, WB 
** 99 mouse IgG Sigma/ A4416 Goat 1:5000 in 5% skim milk TBST, HRPO-conjugated. WB 
- Tubulin Gift from Romina Marone  Rat 1:5, 2nd antibody goat anti rat-Alexa546 (obtained from Christofori lab) IF 
1 GST Babco/MMS-112R Mouse, mAB  IP, WB 
7 HA-tag Lucernachem/ MMs-101R Mouse, mAb 
clone HA.11 
1:2000 in 5% skim milk TBST, for complemented mast cells(MC) (4°C 
overnight or 1-3 hours, RT); more diluted in other experiments, WB  
45 ACTIVE® MAPK Promega/ V8031 Rabbit , 
polyclonal 
1:5000 in 5% BSA/TBST, WB 
75 Phospho-Akt (Thr308) 
(244F9) 
Cell signaling technology / 
#4056 
Rabbit, mAB 1:500 in 5% BSA TBST for complemented MC, overnight, 4°C, ideally 
increase MC number to 3x105 per slot. For non-transfected cells 2-3 hours 
incubation, RT, 1:1000 works. WB 
78 Phospho-Akt (Ser473) 
(193H12) 
Cell signaling technology / 
#4058 
Rabbit, mAB 1:2000 in 5% BSA TBST for complemented MC, overnight, 4°C, or for 2-3 
hours, RT. WB 
90 PI3Kγ (Russian) Eurogentech, gift from 
R.Wetker  
Mouse, mAB 
ascites 
1:5000 in 5% BSA TBST for complementation experiments, 1 hour RT. In 
other experiments 1:10000 is possible, too. Now commercially available from 
Alexis 804-230-L001, clone H1. WB 
91 PI3Kγ (641) now Alexis JBS-ABD-027 
(clone 641, JenaBioscience) 
Mouse, mAB 
 
1:500 for IP only, no western blotting 
115 (PE) anti-mouse FcεRIα eBioscience/ 12-5898-83 Hamster, 
mAB, MAR-1 
1: 150 in FACS, PE-conjugated 
119 p84, p87 This work/ flask labeled 
Rabbit #1 Antiserum/Max, 
p87 N-term, T. Bohnacker 
Rabbit total 
serum  
1:2000 in 5% skim milk TBST (4°C overnight or 1-3 hours, RT). Antisera 
were raised by Zymed in 2 rabbits (#1, #2). Both detect p84. Used here: 
flask labeled “Rabbit #1 Antiserum/Max, p87 N-term, T. Bohnacker Lot 
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Lot 50802 50802. Part of the serum was absorbed against human serum. 
Recombinant protein originate from plasmid #915 (Met1 to Glu162 of 
murine p84) 
121 goat IgG Jackson ImmunoResearch 
#705-035-147 
Donkey, 
polyclonal 
1:5000 in 5% skim milk TBST, HRPO-conjugated. WB 
122 rabbit IgG Sigma-Aldrich/A 6154 Goat, IgG 1:5000 in 5% skim milk TBST, HRPO-conjugated. WB 
132 GFP (Green Fluorescent 
Protein) 
Roche/ #11814460001 Mouse, mAB  1:1000 in 5% skim milk TBST for detection of GFP fusion proteins in 
complemented overnight. WB 
155 rabbit IgG Rockland(Bioconcept)/ 611-
132-122 
Goat 1:5000 in 5% skim milk TBST, IRDye800- conjugated for quantitative WB 
with Odyssey, usage in the dark, 2-3 hours, RT. 
212 mouse IgG  LICOR Biosciences/926-
32220 
Goat 1:5000 in 5% skim milk TBST, IRDye 680- conjugated for quantitative WB 
with Odyssey, usage in the dark, 2-3 hours, RT. 
216 p101 This work, tube label 
p1105-p101, RB11537, 
date 070704 
Rabbit, total 
serum 
1:1000 in 5% skim milk TBST, 1 hour RT, wash extensively, WB, 
recombinant protein was expressed from plasmid #1105,  
thus the antiserum is against Pro575 to Pro880 of human p101 
# : Inventory ID (Antibody database); ** ID Consumables; WB Western Blot; IF: Immunofluorescence; IP Immunoprecipitation; RT room temperature; TBST 
0.1% Tween/TBS 
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7.4 Plasmids 
# Name Protein Origin Notes 
9 pcDNA3 - Invitrogen www.invitrogen.com,  
64 pSTC-tkGST<pi3kg 
BamHI/PmeI> 
GST-p110γ Previous work  
147 pCDM8-β1 β1 G-protein subunit 
148 pCDM8-γ2 γ2 G-protein subunit 
Garritsen and 
Simonds, JBC 1994, 
269:24418- 
 
378 pDNA3<p110g wt> Hsp110γ Previous work  
530 eGFP_BTKPH wt GFP_PHBtk PtdIns(3,4,5)P3 sensor 
531 eGFP_BTKPH R28C GFP_PHBtk 
Obtained from T. 
Balla PtdIns(3,4,5)P3 binding deficient mutant 
537 pcDNA3 HA<p101> HA-Ssp101 Previous work,   
592 pcDNA3<p110g KR KI> Hsp110γ( kinase inactive)  Previous work  
594 pcDNA3<p110g wt-
CAAX KI> 
Hsp110γ with c-terminal 
CAAX box 
Previous work Constitutively membrane targeted p110γ, due to c-terminal CAAX box 
601 pEGFP-C1 GFP Clontech www.clontech.com 
868 pcDNA3<p101-YFP> Scp101-YFP Obtained from 
P.Voigt 
 
884 pEYFP<Mm_p101β> YFP-Mmp84 Previous work, 
Ronan Calvez 
Introduce Mm_p101β coding sequence (witout polyA signal) in 2 pieces: 
- XhoI/BstEII PCR fragment from TOPO #881 (sequence 100% correct)  
- BstEII/HindIII fragment from #875 
893 pcDNA3-HA<Mm_p87> HA-Mmp84 Previous work, 
Ronan Calvez 
Originally dubbed p101β or p87; excised from #885 (which is original 
p101β cDNA deleted of 3’-UTR and poly-A) in 2 fragments BamHI/BstEII 
(818bp) and BstEII/NotI (1461bp). Inserted into #515 digested 
BamHI/NotI; contains N-terminal HA-tag. 
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912 pEGFP<Mm_p87> GFP-Mmp84  This work Cloned from pEGFP (#601) and #884 pEYFP<Mm_p87>. 
Digested XhoI/ Hind III. 
915 pQE<p87Frag2-1> N-terminus Mmp84 
(Met1 to Glu162) 
This work For recombinant protein expression and antisera production, (His)6 tag for 
purification 
999 pEGFP<Sc_p101> GFP-Scp101 This work Derived from #602, #866. Digestion NdeI/ EcoRI digested. Strategy: 
replacement of YFP (in #866) by a GFP (isolated from #602) 
1000 peGFP<p110g> GFP-Hsp110g This work Originates from # 862 and # 912. Digestion with BamHI, XhoI. Strategy: 
Replacement of p87/84 insert by p110γ ORF 
1105 pQE30<Hs_p101CTl> C-terminus Hsp101 
(Pro575 to Pro880) 
This work For recombinant protein expression and antiserum production, (His)6 tag 
for purification 
1139 pTagRFP-N1 RFP Evrogen http://www.evrogen.com/products/vectors/pTagRFP-N/pTagRFP-N.shtml 
1189 pTagRFP<PH-PLCd> RFP-PHPLCd This work Cloned by excision of the PH-BTK domain from plasmid 1140 (EcoRI/ 
BamHI). Ligation of this backbone with the PH-PLCd ORF obtained from 
plasmid 528 (EcoRI/ BamHI).  
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Abbreviations used in introduction and discussion: 
 
Ag Antigen 
Arg Arginine 
ATP Adenosine Trisphosphate 
Bam32 B cell adaptor molecule of 32 kD 
BCAP B cell activating protein 
BCR B cell receptor 
BH Breackpoint homology 
bLT1 Leukotriene B receptor 
BMMC Bone marrow derived mast cell 
Bmx Tec familiy tyrosine kinase 
Btk Bruton’s tyrosine kinase 
C5a Complement factor 5a 
Ca2+ Calcium ions 
cAMP cyclic Adenosine monophosphate 
Cbl E3 ubiquitin ligase 
c-Kit CD117 cytokine receptor 
CR Complement Receptor 
CSF-1R Colony stimulatingfactor-1 receptor 
Cys Cystein 
CysLT Cysteinyl leukotrienes (receptor) 
DAG Diacylglycerol 
DC Dentritic cell  
DH Dbl homology 
DNA-PK DNA-activated protein kinase 
EAE Experimental autoimmune encephalomyelitis 
ECM Extracellular matrix 
EGFR Epidermal growth factor receptor 
FceRI High affinity receptor for IgE 
fMLP Formyl-Methionyl-Leucyl-Phenylalanine 
Fyn, Lyn, Lck Src familiy kinases 
FYVE Zinc finger domain as present in Fab1, YOTB/ZK632.12, Vac1, and 
EEA1 
g Gram 
Gab Grb2 associted binding protein 
Gads Grb2 related adapter protein 
GAP GTPase activating protein 
Gbg βγ subunits of heterotrimeric G-proteins 
GDP Guanosine bisphosphate  
GEF Guanine- nucleotide exchage factor 
GMCSF, GM-CSF Granulocyte- macrophage colony stimulating factor 
GPCR G-protein coupled receptor 
Grb2 Growth factor receptor-bound protein 2 
GTP Guanosine Trisphosphate 
HGFR Hepatocyte growth factor receptor 
HIV Human immunodeficiency virus 
ICAM Intercellular adhesion molecule 
IgE Immunglobulin E 
IGFR Insulin like growth factor receptor 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IL Interleukin 
Inf  Interferon 
IP3, Soluble inositol (1,4,5)P3 
IR Insulin receptor 
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IRS Insulin receptor substrate 
ITAM Immunreceptor based activation motif 
ITIM Immunreceptor based inhibition motif 
Itk IL2-inducible T-cell kinase 
JAK Janus kinase 
kDa Kilodalton 
kg  Kilogram 
l Liter 
LAT Linker of activated T cells 
LPA Lyophosphatidic acid 
LPS Lipopolysaccharide 
LTB, LTC Leukotriene B, C 
Lys Lysine 
MAPK Mitogen activated protein kinase 
MCP1 Monocyte chemotactic protein-1 
mg Milligram 
MHC  Major histocompatibility complex 
ml Milliliter 
MS Multiplesclerosis 
mTOR Mammalian Target of Rapamycin (TOR) 
ng Nanogram 
NGFR Nerve growth factor receptor 
NK Natural killer 
NRTK Non receptor tyrosine kinase 
NTAL Non-T-cell activation linker 
PCA Passive cutaneous anaphylaxis 
PDGF-R Plateled derived growth factor receptor 
PDK1 3-Phosphoinositide-dependent kinase 1 
PDZ Post synaptic density protein (PSD95), Drosophila disc large tumor 
suppressor (DlgA), and zonula occludens-1 protein (zo-1) 
PGD, PGE Prostaglandin D, E 
PH Pleckstrin homology 
PI Phosphoinositide 
PI3K Phosphatidylinositol 3-Kinase 
PKA Protein kinase A (cAMP dependent) 
PKB/Akt Protein kinase B, V-akt murine thymoma viral oncogene homolog 1 
PKC Protein kinase C 
PKG Protein kinase G (cGMP dependent) 
PLC Phospholipase 
PSA Passive systemic anaphylaxis 
PtdIns Phosphoinositide 
PTEN Phosphatase and tensin homolog on chromosome 10 
PTK Proteintyrosine kinase 
PX Phox homology 
pY Phosphorylated tyroisne 
Rab GTPase 
Ras GTPase 
RBD Ras binding domain 
Rho, Rac, Cdc42 Small GTP of the Rho- family 
ROS Reactive oxygen species 
RTK Receptor tyrosin kinase 
SCF Stem cell factor 
SGK Serum and glucocorticoid-inducible kinase 
SH2 Src homology 2 
SH3 Src homology 3 
Shc Src homology 2 domain-containing adaptor protein 
SHIP SH2 Domain-containing Inositol 5-Phosphatase 
Shp SH2 domain containing proteinphosphatase 
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SLP76 SH2 domain containing leukocyte protein (76kDa) 
Sos Son of sevenless 
Src v-src homologous protein tyrosine kinase 
Syk Spleen tyrosine kinase 
Tapp Tandem-pleckstrin-homology-domain-containing protein 
TCR T cell recepotr 
Tec Tyrosine kinase expressed in hepatocarcinoma 
TGFβ Transforming growth factor 
Th T helper 
TLR Toll-like receptor 
TRIM TCR-interacting molecule 
Vav GEF of the Rho family members 
VCAM Vascular cell adhesion molecule 
VEGF-R Vascular endothelial growth factor receptor 
Vps Vacuolar protein sorting 
YxxM Tyrosine-Xxx-Xxx-Met  motif 
ZAP70 Zeta-chain-associated protein kinase of 70 kDa 
µg microgram 
µl Microliter 
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